

**VEITH** SYMPOSIUM™  
Connecting The **Vascular** Community

**39**<sup>th</sup> Annual

Wednesday – Sunday, November 14-18, 2012

**V**ascular  
**E**ndovascular  
**I**ssues  
**T**echniques  
**H**orizons



Symposium Chairman  
**Frank J. Veith, MD**

Symposium Co-Chairmen  
**Enrico Ascher, MD**  
**Kenneth Ouriel, MD, MBA**  
**Daniel G. Clair, MD**

Sponsored by

 **Cleveland Clinic**

  
**Hilton**

[www.VEITHsymposium.org](http://www.VEITHsymposium.org)

# ACKNOWLEDGMENTS

The Cleveland Clinic Foundation Center for Continuing Education and VEITHsymposium acknowledge educational grants in support of this activity from:





**SYMPOSIUM CHAIRMAN**  
Frank J. Veith, MD

**SYMPOSIUM CO-CHAIRMAN**  
Enrico Ascher, MD  
Kenneth Ouriel, MD, MBA  
Daniel G. Clair, MD

**SCIENTIFIC COMMITTEE**  
Ali F. AbuRahma, MD  
Mark A. Adelman, MD  
Jean-Pierre Becquemin, MD  
Giorgio M. Biasi, MD  
Nicholas J. Cheshire, MD  
Jacob Cynamon, MD  
Peter Gloviczki, MD  
Roger M. Greenhalgh, MD  
Krassi Ivancev, MD, PhD  
Mario Lachat, MD  
Christos D. Liapis, MD  
Evan C. Lipsitz, MD  
Frans L. Moll, MD, PhD  
Juan C. Parodi, MD  
Don Poldermans, MD  
Vicente Riambau, MD, PhD  
Jean-Baptiste Ricco, MD, PhD  
Thomas S. Riles, MD  
Plinio Rossi, MD  
Timur P. Sarac, MD  
Carlo Setacci, MD  
Eric L.G. Verhoeven, MD, PhD

**COMPONENT MEETING LEADERS**  
Jose I. Almeida, MD  
Richard A. Baum, MD, MPA, MBA  
George L. Berdejo, BA, RVT  
Allan L. Brook, MD  
Jacob Cynamon, MD  
Roy K. Greenberg, MD  
Ziv J. Haskal, MD  
Michael R. Jaff, DO  
Lowell S. Kabnick, MD  
Nicos Labropoulos, PhD, RVT  
Bruce Lytle, MD  
Dieter O. Mayer, MD  
Larry A. Scher, MD  
Thomas M. Vesely, MD

**ADMINISTRATIVE COMMITTEE**  
Jacqueline M. Simpson

**THE CENTER FOR CONTINUING EDUCATION**  
William D. Carey, MD  
Steven M. Kawczak, PhD

## CONTENTS

Acknowledgments.....	Inside Front Cover
General Information.....	7
Accreditation.....	9
Faculty Disclosure.....	9
Social Events.....	10
Hotel and Travel.....	10
Agenda.....	11–71
Faculty Listing.....	73–80
Registration.....	81–82
Save the Date.....	Inside Back Cover



# 17<sup>th</sup> European Vascular Course

March 10-12, 2013

Maastricht, The Netherlands

[www.vascular-course.com](http://www.vascular-course.com)

1250 participants

84 invited lectures

42 company presentations

2 high quality textbooks

Vascular International Masterclass

Vascular Access Masterclass

European Venous Masterclass

Interactive Case Discussions

Hands-on courses, EVC e-Learning

*Learning by training*





## Emerging Management Options for Pulmonary Embolism

COURSE LEADER

Michael R. Jaff, DO

## Endovenous Management of Varicose Veins

COURSE LEADERS

Jose I. Almeida, MD, RVT

Lowell S. Kabnick, MD

## Hemodialysis Access

COURSE LEADERS

Larry A. Scher, MD

Thomas M. Vesely, MD

## Management of Proximal Venous Obstruction

COURSE LEADERS

Kenneth Ouriel, MD, MBA

Peter Gloviczki, MD

## WOUNDS

COURSE LEADER

Dieter O. Mayer, MD

## POSTER SESSION

JUDGES

Peter Gloviczki, MD

Ali F. AbuRahma, MD

Ali Amin, MD, RVT

Enrico Ascher, MD

Giorgio M. Biasi, MD

Piergiorgio Cao, MD

Nicholas J.W. Cheshire, MD

Krassi Ivancev, MD, PhD

Christos D. Liapis, MD

Frans L. Moll, MD, PhD

Kenneth Ouriel, MD, MBA

Dieter Raithel, MD, PhD

Vicente Rimbau, MD, PhD

Norman M. Rich, MD

Carlo Setacci, MD

Matt M. Thompson, MD

Eric L.G. Verhoeven, MD, PhD

# SPECIAL NON-CME ACCREDITED ACTIVITY AT VEITHsymposium

## VIDEO SESSION FEATURING COMPLICATIONS AND UNUSUAL CASES

**Wednesday, November 14, 2012 - 5:30 P.M. – 7:45 P.M.**

**Trianon Ballroom, 3rd Floor**

5:30 P.M. Cocktails and Heavy Hors d'oeuvres will be served throughout the evening.

*Moderators: Plinio Rossi, MD  
Carlo Setacci, MD  
Frank J. Veith, MD*

- 5:45 – 5:55** Endovascular Treatment Of An 8-Week-Old Embolic Occlusion Of The Popliteal Trifurcation  
*Nicolas A. Diehm, MD*
- 5:55 – 6:00** Discussion
- 6:00 – 6:10** Pedal Revascularization  
*Thomas Rand, MD*
- 6:10 – 6:15** Discussion
- 6:15 – 6:25** Evolution Of The Proximal Neck And Aneurysm Rupture Post EVAR: Endovascular Options  
*Daniele Gasparini, MD*
- 6:25 – 6:45** Discussion
- 6:45 – 6:55** Unusual Aortic Reinterventions  
*Robert A. Morgan, MD*
- 6:55 – 7:00** Discussion
- 7:00 – 7:10** How To Survive A Potential Catastrophic Complication During EVAR  
*Fabrizio Fanelli, MD*
- 7:10 – 7:15** Discussion
- 7:15 – 7:25** Iatrogenic Arterial Ruptures During Endovascular Procedures  
*Andrej Schmidt, MD*
- 7:25 – 7:30** Discussion
- 7:30 – 7:40** Unexpected Successful Access For BTA Treatment  
*Marco Manzi, MD*
- 7:40 – 7:45** Discussion
- 7:45** Adjourn

# GENERAL INFORMATION

## NEEDS ASSESSMENT

Vascular disease in all of its manifestations is a leading cause of death and disability affecting a large percentage of Americans over the age of 50. There is a critical need for physicians who diagnose, treat and manage patients with vascular disease to receive continuing medical education in this area. The latest pharmacologic, radiologic, surgical and endovascular techniques and technologies will be presented, along with discussions of when these treatments are justified and indicated and when they are not. Updates on clinical trials and opportunities for dialogue with experts in the field provide insight along with the latest data on the results of the various treatment modalities.

There is an enormous gap between actual practice and the current state of knowledge. This gap is filled imperfectly with material in books and published articles. These sources are also often negatively influenced by the biases of authors, reviewers and editors. VEITHsymposium attempts to fill this gap more perfectly and more currently by enlisting speakers with up-to-date information and data, and also those on both sides of controversial issues. In this way, the audience gets a current view of the state-of-the-art in vascular disease management as of the date of the meeting. All important topics are covered.

In addition, by having numerous short (5-6 minutes) talks followed by panel discussions and capturing the entire meeting on the web based library, the meeting will provide an electronic reference source to help vascular specialists in their practice decisions throughout the year. It will also provide the most up-to-date unbiased information possible to help with these decisions.

## FOCUS

The VEITHsymposium provides Vascular Surgeons and other Vascular Specialists with a five-day conference on the most current information about new developments in clinical practice and relevant research. Beginning Wednesday, the symposium offers over 750 fast-paced presentations on what is new and important in the treatment of vascular disease. Important updates and reevaluations, as well as the latest significant advances, changing concepts in diagnosis and management, pressing controversies and new techniques, agents and diagnostic modalities will be presented. Video case presentations will also be included.

## OBJECTIVES

Upon completion of the VEITHsymposium, the participants will, after learning about a wide array of topics, be able to:

- Provide information about the latest technologies, techniques and data from clinical trials for endovascular repair of AAAs and thoracic and abdominal aortic disease
- Provide information about the latest data, techniques and technologies for carotid disease management
- Provide information about the latest developments in pharmacologic agents for the management of vascular disease
- Provide information on the latest state-of-the-art for the treatment of superficial femoral and tibial artery disease
- Provide new information about the treatment of venous disease
- Provide new information about the latest developments in hemodialysis access
- Provide information about new developments in wound care
- Provide updated information about the medical or non-interventional management of vascular disease

# GENERAL INFORMATION

## TARGET AUDIENCE

Vascular Surgeons, Interventional Radiologists, Interventional Cardiologists, Vascular Medicine Specialists and all others interested in the management of vascular disease.

## TRANSLATION LANGUAGES

We will have translation from English to Spanish, Portuguese, Russian and Mandarin Chinese from Thursday to Sunday.

## SIXTH ANNUAL POSTER SESSION

This year, VEITH Symposium in collaboration with the International Society for Vascular Surgery (ISVS) will continue its feature designed to allow vascular surgeons who are ISVS members to present their work at the meeting. Posters selected by a distinguished panel of judges (Drs. Peter Gloviczki, Ali AbuRahma, Ali Amin, Enrico Ascher, Giorgio Biasi, Piergiorgio Cao, Nicholas Cheshire, Krassi Ivancev, Christos Liapis, Frans Moll, Kenneth Ouriel, Dieter Raithel, Vicente Riambau, Norman Rich, Carlo Setacci, Matt Thompson, and Eric Verhoeven) will be available for viewing throughout the meeting in the Rhinelander Gallery, 2nd floor. The formal Poster Session judging will be open to all interested attendees on Friday afternoon from 2:00 p.m. to 4:30 p.m. The distinguished panel of judges will select the 3 best poster presentations for awards on the basis of the poster and 3-minute oral presentations. These awards will be presented on Saturday, November 17, 2012 in the Grand Ballroom East, 3rd floor.

## GENERAL SESSIONS

General Sessions will be held in the Grand Ballroom East and West on the 3rd floor on Thursday, Friday, Saturday and Sunday.

### Wednesday Component Sessions will be held as follows:

Hemodialysis Access

**Location:** Trianon Ballroom, 3rd floor

Emerging Management Options For Pulmonary Embolism

**Location:** Grand Ballroom West, 3rd floor

Management Of Proximal Venous Obstruction

**Location:** Grand Ballroom West, 3rd floor

Endovenous Management Of Varicose Veins

**Location:** Grand Ballroom East, 3rd floor

WOUNDS

**Location:** Gramercy Suites A&B, 2nd floor

Multidisciplinary Acute Stroke Management

**Location:** Murray Hill Suites A&B, 2nd floor

## VIDEO SESSION FEATURING COMPLICATIONS AND UNUSUAL CASES

Wednesday, November 14, 2012 - 5:30 P.M. - 7:45 P.M.

**Location:** Trianon Ballroom, 3rd floor

There are some European interventionalists who are cutting edge leaders in new and better techniques for performing below knee endovascular treatments and carotid artery stenting. Some of these individuals will be included in this Wednesday evening program featuring challenging recorded live cases in these two important areas.

This program will be led by Dr. Plinio Rossi and will start at 5:30 P.M. and go until approximately 7:45 P.M., with ample time for audience discussion and questions. This program will provide a state-of-the-art update on exciting new treatment techniques. Cocktails and heavy hors d'oeuvres will be provided throughout the evening, courtesy of Cook Medical. (This is a non-CME activity.)



# GENERAL INFORMATION

## ACCREDITATION STATEMENT

The Cleveland Clinic Foundation Center for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The Cleveland Clinic Foundation Center for Continuing Education designates this live activity for a maximum of 52 *AMA PRA Category 1 Credits™*. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Participants claiming CME credit from this activity may submit the credit hours to the American Osteopathic Association for Category 2 credit.

## CME CERTIFICATES AND COURSE EVALUATION FORMS

Your CME certificate will be available online at [www.veithsymposium.org](http://www.veithsymposium.org). An e-mail will be sent to all registered attendees immediately following the meeting with a unique password and instructions on how to obtain the certificate and complete a brief, optional course evaluation. Please note that the e-mail will be sent to the e-mail address that was used to register the attendee.

## FACULTY DISCLOSURE

The Cleveland Clinic Foundation Center for Continuing Education has implemented a policy to comply with the current Accreditation Council for Continuing Medical Education Standards for Commercial Support requiring resolution of all faculty conflicts of interest. Faculty declaring a relevant commercial interest will be identified in the activity syllabus.

## ADA STATEMENT

The Cleveland Clinic Foundation Center for Continuing Education complies with the legal requirements of the Americans with Disability Act. If any participant of the VEITHsymposium requires special assistance, please send written request at least one month prior to the activity to [admin@veithsymposium.org](mailto:admin@veithsymposium.org), or by fax to (845) 368-2324.

## ONLINE ACCESS TO ABSTRACTS

All conference attendees will receive instructions on how to access and print out available meeting abstracts prior to the meeting. These abstracts will be available on the program page of the VEITHsymposium web site at [www.veithsymposium.org](http://www.veithsymposium.org). Abstracts will be available on the web site for one full year.

## ONLINE CONFERENCE LIBRARY

The entire program with all the talks, all the slides, all the videos - fully synchronized - and all the panels, will be available in an Online Conference Library, which can be obtained at a nominal cost. For more information on how to obtain the VEITHsymposium Online Library, please call 800-987-9314, ext. 300.

# GENERAL INFORMATION

## SOCIAL EVENTS

*Tickets (Theater, Opera, Symphony, Sports, Etc.)*

Marilyn Rosenblatt, Charge d'Affaires

Phone: (212) 794-2773

E-mail: blattcda@aol.com

## FROM HIGH ABOVE THE WORLD TO 'HIGH' ABOVE NEW YORK

**Thursday, November 15, 2012 - 9:30 A.M. – 3:00 P.M.**

Meet at 9:15 A.M. at the Hospitality Desk, 2nd Floor, New York Hilton.

New York was selected by NASA as the permanent home for the retired Space Shuttle Enterprise.

Join our tour and be among the first to see it at its new exhibit site on the USS Intrepid, as part of the Intrepid Sea, Air and Space Museum. After viewing other exhibits on this historic aircraft carrier, our van (with guide) will take us to the High Line, currently the city's most popular visitor attraction. A lovely meandering elevated park affording unique, spectacular views of the city, this reclaimed railroad trestle called the High Line winds its way high above the Meat Packing District and beyond through one of New York's most exciting neighborhoods, past hotels, new residential buildings, elegant boutiques, shops, markets and restaurants in the streets below.

Then, we'll stop for a memorable lunch at the nearby Tribeca Grill, a true New York City landmark, co-owned by renowned restaurateur Drew Nieporent and legendary actor Robert De Niro.

**Cost: \$125.00** (includes admission, transportation, tour guide and lunch).

**To reserve space** please make your check (U.S. bank only) payable to Charge d' Affaires, Inc. and mail it to Marilyn Rosenblatt, Charge d'Affaires, Inc., 75 East End Avenue, #11L, New York, NY 10028. We regret that we cannot accept payment by credit card.

For more information please call (212) 794-2773 or e-mail blattcda@aol.com.

## HOTEL AND TRAVEL

A block of rooms has been reserved at the conference rate of \$389 plus taxes per night. This rate is available until the block is filled or until October 19, 2012. *Please request the VEITH rate when reserving your accommodations.*

### **Hilton New York (Symposium Site)**

1335 Avenue of the Americas

New York, NY 10019

(212) 586-7000 or

1-800-HILTONS (toll free U.S. only)

### **American Express Business Travel at**

#### **The Cleveland Clinic Foundation**

9500 Euclid Avenue, P83

Cleveland, OH 44195

Phone: (800) 955-6111 (U.S. toll free)

(216) 444-2564 (U.S. and International)

Fax: (216) 444-2500

E-mail: Diane.M.Geneva@aexp.com

## WEDNESDAY, NOVEMBER 14, 2012

**6:30 A.M. General Registration – 2nd Floor Promenade**  
**Faculty Registration – Morgan Suite, 2nd Floor**  
**Continental Breakfast – Sutton Complex, 2nd Floor**

### CONCURRENT WEDNESDAY PROGRAMS

#### SESSIONS 1 & 2

##### **Hemodialysis Access**

7:55 A.M. – 5:00 P.M.

Trianon Ballroom, 3rd Floor

#### SESSION 3

##### **Emerging Management Options For Pulmonary Embolism**

10:00 A.M. – 12:00 P.M.

Grand Ballroom West, 3rd Floor

#### SESSION 4

##### **Management Of Proximal Venous Obstruction**

1:00 P.M. – 3:15 P.M.

Grand Ballroom West, 3rd Floor

#### SESSIONS 5 & 6

##### **Endovenous Management Of Varicose Veins**

8:00 A.M. – 5:15 P.M.

Grand Ballroom East, 3rd Floor

#### SESSIONS 7 & 8

##### **WOUNDS**

9:00 A.M. – 5:20 P.M.

Gramercy Suites A&B, 2nd Floor

#### SESSIONS 9 & 10

##### **Multidisciplinary Acute Stroke Management**

7:55 A.M. – 4:00 P.M.

Murray Hill Suites A&B, 2nd Floor

SESSION 1 (Trianon Ballroom, 3rd Floor)

### HEMODIALYSIS ACCESS – PART 1

**7:55 – 8:00** Welcome And Introduction

*Larry A. Scher, MD*

*Thomas M. Vesely, MD*

**PART 1A: INTERVENTIONAL PROCEDURES FOR  
HEMODIALYSIS ACCESS**

**Moderators: Larry A. Scher, MD**

*Thomas M. Vesely, MD*

**8:00 – 8:08** Where Is The SVC/RA Junction And Why Is It  
Important In The Dialysis Patient

*Jacob Cynamon, MD*

**8:09 – 8:17** Access Survival After Prophylactic Angioplasty

*Timothy A. Pflederer, MD*

**8:18 – 8:26** Stent Grafts For Venous Anastomotic Stenosis

*Thomas M. Vesely, MD*

**8:27 – 8:35** Angioplasty, Stents Or Stent Grafts For Swing-Point  
Or Cephalic Arch Stenosis

*Theodore F. Saad, MD*

- 8:36 – 8:44** Percutaneous Management Of The Non-Maturing Fistula  
*John E. Aruny, MD*
- 8:45 – 8:53** Blood Flow Measurement During Hemodialysis Access Procedures  
*Oleg Leontiev, MD*
- 8:54 – 9:02** Cardiovascular Implantable Device Guidelines In ESRD Patients  
*Haimanot (Monnie) Wasse, MD, MPH*
- 9:03 – 9:11** Endovascular Treatment Of Pacemaker Related Central Venous Stenosis  
*Dheeraj Rajan, MD*
- 9:12 – 9:20** Management Of SVC Syndrome And Complex Central Venous Stenosis  
*Richard J. Gray, MD*
- 9:21 – 9:29** Radiofrequency Recanalization Of Central Venous Stenosis  
*Neal J. Halin, DO*
- 9:30 – 9:50** Panel Discussion
- 9:50 – 10:15** Break – Visit Exhibits and Pavilions (2nd and 3rd Floors)

**PART 1B: HEMODIALYSIS CATHETERS AND NEW TECHNOLOGY**

**Moderators:** *Haimanot (Monnie) Wasse, MD, MPH*  
*Theodore F. Saad, MD*

- 10:15 – 10:23** Uncommon Complications Of Hemodialysis Catheters  
*Kenneth D. Abreo, MD*
- 10:24 – 10:32** Inadvertent Arterial Catheterization During Central Venous Catheter Insertion  
*Tony P. Smith, MD*
- 10:33 – 10:41** Translumbar Hemodialysis Catheters  
*Gregory J. Nadolski, MD*
- 10:42 – 10:50** Balloon-Assisted Technique For The Placement Of The Outflow Segment Of The HeRO Device  
*Hector Ferral, MD*
- 10:51 – 10:59** Subclavian Vein Access: Over The Wire Graft Implantation Techniques With Hybrid Graft Technology  
*Stephen Settle, MD*
- 11:00 – 11:08** Computational Fluid Dynamics Of Hemodialysis Grafts  
*Christof Karmonik, PhD*
- 11:09 – 11:17** Vessel-Select Access System For Percutaneous AV Fistula Creation  
*Jeffrey E. Hull, MD*
- 11:18 – 11:26** Arteriovenous Fistula Creation Using The Optiflow Anastomotic Connector  
*Prabir Roy-Chaudhury, MD, PhD*
- 11:27 – 11:35** Blood Flow As Predictor Of Patency For Hemodialysis Access Procedures  
*Lars Lonn, MD, PhD*
- 11:36 – 11:55** Panel Discussion
- 11:55 – 12:45** Lunch Break – Americas Hall 1, 3rd Floor  
Visit Exhibits and Pavilions (2nd and 3rd Floors)

SESSION 2 (Trianon Ballroom, 3rd Floor)

**HEMODIALYSIS ACCESS – PART 2**

**PART 2A: CLINICAL PRACTICE ISSUES I**

**Moderators:** *Thomas M. Vesely, MD*  
*Joseph N. Shams, MD*

- 12:45 – 12:53** Genetic Causation Of Hemodialysis Access Stenosis  
*Timmy Lee, MD, MSPH*
- 12:54 – 1:02** Mathematical Model Of Brachiocephalic Fistula: New Explanation For Success Of DRIL Procedure In Treating Hand Ischemia  
*William D. Paulson, MD*
- 1:03 – 1:11** The Effect Of Access Blood Flow On Cardiac Function  
*Louise Moist, MD, MSc*
- 1:12 – 1:20** Targeting Catheter Last In Fistula First  
*Joseph A. Vassalotti, MD*
- 1:21 – 1:36** Reducing Hemodialysis Catheters: When Is A Graft Preferred To Fistula?  
*Charmaine Lok, MD*
- 1:37 – 1:45** When Should Peritoneal Dialysis Be Considered?  
*Jack Work, MD*
- 1:46 – 1:59** Panel Discussion

**PART 2B: CLINICAL PRACTICE ISSUES II**

**Moderators:** *Mitchell L. Henry, MD*  
*Eric K. Peden, MD*

- 2:00 – 2:08** Bundling And Revaluing Hemodialysis Access Services  
*Sean P. Roddy, MD*
- 2:09 – 2:17** Accountable Access Care Organization  
*Timothy A. Pflederer, MD*
- 2:18 – 2:26** Fistula Maturation Is Related To Logistics, Communication, Training And Competency  
*Prabir Roy-Chaudhury, MD, PhD*
- 2:27 – 2:35** Training Surgeons To Perform Vascular Access  
*Mitchell L. Henry, MD*
- 2:36 – 2:44** Nursing Assessment And Management Of Access Related Aneurysms And Pseudoaneurysms  
*Brian LaMendola, RN, MBA*
- 2:45 – 2:53** Surgical Management Of Access Related Aneurysms And Pseudoaneurysms  
*Gary A. Gelbfish, MD*
- 2:54 – 3:02** Risk Of Infection After Stent Graft Placement In Hemodialysis Grafts  
*Tony P. Smith, MD*
- 3:03 – 3:25** Panel Discussion
- 3:25 – 3:45** Break - Visit Exhibits and Pavilions (2nd and 3rd Floors)

**PART 2C: SURGICAL ISSUES IN HEMODIALYSIS ACCESS**

**Moderators:** *Marc H. Glickman, MD*  
*A. Frederick Schild, MD*

- 3:45 – 3:53** Can Early Cannulation Grafts Reduce Catheter Dependency?  
*Marc H. Glickman, MD*
- 3:54 – 4:02** Management Of Lower Extremity Steal Syndrome  
*Eric K. Peden, MD*
- 4:03 – 4:11** Endovascular And Surgical Options For Inflow Stenosis In Patients With Dysfunctional AV Access  
*Karl A. Illig, MD*



- 4:12 – 4:20 Options For Vascular Access In The Obese Patient  
*David L. Cull, MD*
- 4:21 – 4:29 Use Of A Bovine Carotid Artery For Hemodialysis Access  
*Eric K. Peden, MD*
- 4:30 – 4:38 Forearm Basilic Vein Transposition  
*Larry A. Scher, MD*
- 4:39 – 5:00 Panel Discussion
- 5:00 Adjourn

SESSION 3 (Grand Ballroom West, 3rd Floor)

## EMERGING MANAGEMENT OPTIONS FOR PULMONARY EMBOLISM

**Moderator:** *Michael R. Jaff, DO*

- 10:00 – 10:02 Introduction To The Session  
*Frank J. Veith, MD*
- 10:03 – 10:08 Welcome And Introduction Of The Topic  
*Michael R. Jaff, DO*
- 10:09 – 10:18 What Must The Vascular Specialist Know About PE  
*Victor F. Tapson, MD*
- 10:19 – 10:28 Intravenous rtPA For Pulmonary Embolism: Does This Work  
*Ido Weinberg, MD, MSc*
- 10:29 – 10:38 Percutaneous Pharmacomechanical Intervention For PE: An Overview  
*Nils Kucher, MD*
- 10:39 – 10:48 The EKOS Strategy  
*Tod C. Engelhardt, MD*
- 10:49 – 10:58 The VORTEX Strategy  
*Christopher J. Kwolek, MD*
- 10:59 – 11:08 Angiojet Device To Treat Massive And Submassive PEs  
*Jeffrey Y. Wang, MD*
- 11:09 – 11:18 ECMO As The Bridge To Definitive Therapy For PE: Hybrid Approaches  
*Kenneth Rosenfield, MD*
- 11:19 – 11:28 Less May Be More: The Use Of Catheter Directed Thrombolysis In Conjunction With IVC Filters For Massive And Submassive PE  
*Gary M. Ansel, MD*
- 11:29 – 11:38 Techniques, Tips And Tricks For Endovascular Management Of Pulmonary Embolism  
*Ali Amin, MD, RVT*
- 11:39 – 11:48 Interventional Management Of Occlusive Iliofemoral Deep Venous Thrombosis: Another Evolution To A Revolution?  
*Mark H. Meissner, MD*
- 11:49 – 12:00 Panel Discussion/Questions And Answers
- 12:00 Adjourn
- 12:00 – 1:00 Lunch Break – Americas Hall 1, 3rd Floor  
Visit Exhibits and Pavilions (2nd and 3rd Floors)

SESSION 4 (Grand Ballroom West, 3rd Floor)

## MANAGEMENT OF PROXIMAL VENOUS OBSTRUCTION

**Moderators:** *Kenneth Ouriel, MD, MBA*  
*Peter Gloviczki, MD*

- 1:00 – 1:05 Introduction To The Session  
*Kenneth Ouriel, MD, MBA*  
*Frank J. Veith, MD*

**DEBATE: Should Acute Isolated Femoropopliteal DVT Be Managed Aggressively**

- 1:06 – 1:13 Yes, Remove The Thrombus With Pharmacomechanical Means  
*Cynthia K. Shortell, MD*
- 1:14 – 1:21 No, Anticoagulation Alone Is Best  
*Thomas W. Wakefield, MD*
- 1:22 – 1:30 Discussion And Vote

**DEBATE: Venous Thoracic Outlet Syndrome: Intervention Or Observation?**

- 1:31 – 1:38 Axillo-Subclavian Vein Thrombosis Should Be Treated With Early Thrombolysis, First Rib Resection And Open Venous Reconstruction  
*Robert W. Thompson, MD*
- 1:39 – 1:46 There Is No Evidence That Intervention Is Better Than Anticoagulation For Acute Axillo-Subclavian Vein Thrombosis  
*Mark H. Meissner, MD*
- 1:47 – 1:55 Discussion And Vote

**DEBATE: How Should We Manage May-Thurner Syndrome?**

- 1:56 – 2:03 May-Thurner Syndrome Should Be Treated Aggressively With Venous Stenting In All Symptomatic Patients  
*Seshadri Raju, MD*
- 2:04 – 2:11 Compression Treatment Alone Is Best For May-Thurner Syndrome  
*Gregory L. Moneta, MD*
- 2:12 – 2:20 Discussion And Vote

**DEBATE: The Best First-Line Modality For Iliofemoral Venous Thrombus Is . . .**

- 2:21 – 2:28 Open Surgical Thrombectomy Is The Standard  
*Anthony J. Comerota, MD*
- 2:29 – 2:36 Thrombolysis With Ultrasound Is Best  
*Mark J. Garcia, MD*
- 2:37 – 2:45 Discussion And Vote

**DEBATE: The Nutcracker Syndrome: We Can Treat It But Should We?**

- 2:46 – 2:53 Nutcracker Syndrome Is Best Managed By Open Surgical Reconstruction  
*Peter Gloviczki, MD*
- 2:54 – 3:01 Non-Aggressive Management Of Renal And Pelvic Venous Congestion Is Best  
*Cees H.A. Wittens, MD, PhD*
- 3:02 – 3:10 Discussion And Vote
- 3:11 – 3:15 Summary And Conclusions  
*Peter Gloviczki, MD*  
*Kenneth Ouriel, MD, MBA*
- 3:15 Adjourn  
Visit Exhibits and Pavilions (2nd and 3rd Floors)

SESSION 5 (Grand Ballroom East, 3rd Floor)

## ENDOVENOUS MANAGEMENT OF VARICOSE VEINS – PART I

*Moderators: Jose I. Almeida, MD, RVT  
Lowell S. Kabnick, MD*

- 8:00 – 8:06** Welcome – Endovascular Venous Surgery At A Glance  
*Jose I. Almeida, MD, RVT*
- 8:07 – 8:12** Anatomy And Nomenclature Of The Venous System  
*Mark A. Adelman, MD*
- 8:13 – 8:18** Standards For Venous Mapping And Reflux Study  
*Nicos Labropoulos, BSc (Med), PhD, DIC, RVT*
- 8:19 – 8:24** Clinical Evaluation Of The Venous Patient  
*Mark H. Meissner, MD*
- 8:25 – 8:30** Why Treat Varicose Veins: Is There Evidence?  
*Apostolos K. Tassiopoulos, MD*
- 8:31 – 8:36** How To Use CEAP And VCSS In Clinical Practice?  
*Michael A. Vasquez, MD, RVT*
- 8:37 – 8:42** Step-By Step Endovenous Thermal Ablation Of The GSV  
*Edward G. Mackay, MD*
- 8:43 – 8:48** Step-By Step Endovenous Thermal Ablation Of The SSV  
*Caron B. Rockman, MD*
- 8:49 – 8:54** Step-By Step Endovenous Chemical Ablation Of The GSV  
*Ted King, MD*
- 8:55 – 9:00** It Does Not Matter Which Device For Truncal Vein Ablation, The Results Are The Same  
*Alun H. Davies, MA, DM*
- 9:01 – 9:06** Modern Day Stripping Is As Good As Endovenous Thermal Ablation  
*Cees H.A. Wittens, MD, PhD*
- 9:07 – 9:12** Review Of Randomized Controlled Trials Comparing Endovenous Thermal And Chemical Ablation  
*Bo G. Eklof, MD, PhD*
- 9:13 – 9:18** Step-By Step: Ambulatory Phlebectomy  
*Paul Pittaluga, MD*
- 9:19 – 9:24** “Powered” Phlebectomy: Are We There Yet For Significant Branch Varicosities?  
*Thomas W. Wakefield, MD*
- 9:25 – 9:30** Should Adjuvant Procedures Be Performed At The Same Time As Endovenous Thermal Ablation? Evidenced Based  
*Peter J. Pappas, MD*
- 9:31 – 9:36** Guidelines (USA vs UK) In The Management Of Superficial Venous Disease  
*Peter Gloviczki, MD*
- 9:37 – 9:42** Endovenous Thermal Ablation: Technical Pearls For Complex Anatomy  
*Jose I. Almeida, MD, RVT*
- 9:43 – 9:48** Update: Endovenous Laser Ablation  
*Lowell S. Kabnick, MD*
- 9:49 – 9:54** When Is Prophylaxis Needed During GSV/SSV Ablation?  
*Caron B. Rockman, MD*
- 9:55 – 10:00** **DEBATE:** C2 Venous Disease Is Progressive: Its Treatment Should Be A Covered Insurance Benefit  
*Alun H. Davies, MA, DM*

- 10:01 – 10:06** **DEBATE:** C2 Venous Disease Is Progressive: Its Treatment Should Not Be A Covered Insurance Benefit  
*Jose I. Almeida, MD, RVT*
- 10:07 – 10:12** Hurt Locker: Complications Of Endovenous Therapy  
*Renate R. van den Bos, MD, PhD*
- 10:13 – 10:18** Hurt Locker: Complications Of Foam And Liquid Sclerotherapy  
*Edward G. Mackay, MD*
- 10:19 – 10:24** Hurt Locker: Steps To Avoid Endothermal Heat Induced Thrombosis  
*Mikel Sadek, MD*
- 10:25 – 10:30** Hurt Locker: Steps To Avoid Saphenous And Sural Nerve Paresthesia  
*Jean Luc Gerard, MD*
- 10:31 – 10:36** Hurt Locker: Steps To Avoid Lymphatic Complications After Varicose Vein Surgery  
*Paul Pittaluga, MD*
- 10:37 – 10:42** Hurt Locker: Complications From The Treatment Of Klippel-Trenaunay Syndrome  
*Byung-Boong Lee, MD*
- 10:43 – 10:48** How To Differentiate Venous Ulcers From Others  
*Raghu Kolluri, MD*
- 10:49 – 10:54** Other Adjuncts To Heal Ulcers  
*William A. Marston, MD*
- 10:55 – 11:00** Reducing Venous Ulcers By 50% In 10 Years: The Next Steps  
*Peter Henke, MD*
- 11:01 – 11:06** Are We Really To Believe That Correction Of Saphenous Reflux Does Not Aid Ulcer Healing? Debunking The ESCHAR Trial  
*Thomas F. O'Donnell, Jr., MD*
- 11:07 – 11:12** **DEBATE:** Perforator Ablation Is Overused  
*Steve Elias, MD*
- 11:13 – 11:18** **DEBATE:** Perforator Ablation Is Not Overused  
*Mark S. Whiteley, MS*
- 11:19 – 11:24** Combined Treatment With Compression Therapy And Ablation Of Incompetent Superficial And Perforating Veins Reduces Ulcer Recurrence In Patients With CEAP 5 Venous Disease  
*Peter F. Lawrence, MD*
- 11:25 – 11:30** Update On Varicose Vein Recurrence: The REVATA Trial  
*Ronald G. Bush, MD*
- 11:31 – 11:36** Update On Commercially Available Foam Sclerotherapy: Results Of Phase 3 FDA Trial  
*Lowell S. Kabnick, MD*
- 11:37 – 12:00** Panel Discussion  
Panelists: *Jose I. Almeida, MD, RVT*  
*Lowell S. Kabnick, MD*  
*Mark A. Adelman, MD*  
*Michael C. Dalsing, MD*  
*Alun H. Davies, MA, DM*  
*Peter Gloviczki, MD*  
*William A. Marston, MD*  
*Thomas F. O'Donnell, Jr., MD*  
*Thomas W. Wakefield, MD*  
*Cees H.A. Wittens, MD, PhD*
- 12:00 – 1:00** Lunch Break – Americas Hall 1, 3rd Floor  
Visit Exhibits and Pavilions (2nd and 3rd Floors)

SESSION 6 (Grand Ballroom East, 3rd Floor)

## ENDOVENOUS MANAGEMENT OF VARICOSE VEINS – PART 2

**Moderators:** *Jose I. Almeida, MD, RVT*

*Lowell S. Kabnick, MD*

- 1:00 – 1:05** Compression Therapy For Lymphatic Disease Treatment: Is That All There Is?  
*Raghu Kolluri, MD*
- 1:06 – 1:11** Compression: Should We Use Post Saphenous Ablation? Evidence?  
*Todd Berland, MD*
- 1:12 – 1:17** Compression: Medical Necessity Requirement Prior To Treatment: Really? Evidence?  
*Glenn Jacobowitz, MD*
- 1:18 – 1:23** Compression: Should We Use During Sports: Evidence?  
*Steve Elias, MD*
- 1:24 – 1:29** Introduction Of IACVC: Accreditation Of Vein Centers  
*John Blebea, MD, MBA*
- 1:30 – 1:35** If I Were To Build & Credential The “Ideal Vein Doctor” I Would Add These Ingredients...  
*Michael C. Dalsing, MD*
- 1:36 – 1:41** Misperceptions Of The American Board of Phlebology  
*Anthony J. Comerota, MD*
- 1:42 – 1:47** Update: Cyanoacrylate For GSV Ablation  
*Jose I. Almeida, MD, RVT*
- 1:48 – 1:53** Update: Mechanochemical GSV Ablation  
*Steve Elias, MD*
- 1:54 – 1:59** Should Endovenous Ablation Of Small Diameter Great Saphenous Veins Be Performed On Patients With Symptomatic Varicose Veins?  
*Alan M. Dietzek, MD, RPVI*
- 2:00 – 2:05** Update: Steam Ablation For GSV Ablation  
*Renate R. van den Bos, MD, PhD*
- 2:06 – 2:11** Can Venous Ablation Be Performed In Patients With A History Of Ipsilateral DVT?  
*Lowell S. Kabnick, MD*
- 2:12 – 2:17** Where Will We Be In 2015?  
*Lowell S. Kabnick, MD*
- 2:18 – 2:23** Present And Future Of Chronic Cerebrospinal Venous Insufficiency (CCSVI): Is This A Real Syndrome?  
*Mark H. Meissner, MD*
- 2:24 – 2:29** CCSVI: Our Results And Should We Continue To Treat?  
*Marzia Lugli, MD*
- 2:30 – 2:35** The Next Breakthrough In Venous Research  
*Joseph D. Raffetto, MD*
- 2:36 – 2:41** Is Venous Disease Arterial?  
*Seshadri Raju, MD*
- 2:42 – 2:47** Implications Of Expanded Venous Reflux Study  
*Thomas W. Wakefield, MD*
- 2:48 – 2:53** Detecting Iliac, IVC, Ovarian Vessels By Duplex Ultrasound  
*Judy M. Holdstock, DMU, DCR*
- 2:54 – 2:59** Pelvic Reflux With Or Without Pelvic Symptoms (C2 Or Higher): Should We Treat And How?  
*Mark S. Whiteley, MS*
- 3:00 – 3:05** Best Imaging Techniques For Deep Venous Evaluation  
*Barry Stein, MD*
- 3:06 – 3:11** What Is The Skinny On Caval Interruption? Overuse?  
*Robert B. McLafferty, MD*



- 3:12 – 3:17 Proposed Classification System For Iliocaval Occlusion  
*William A. Marston, MD*
- 3:18 – 3:23 Iliac Vein Stenting For Advanced Chronic Venous Disease: When Will It Improve Symptoms And When Will It Not?  
*Enrico Ascher, MD*
- 3:24 – 3:29 My Approach To Iliac Vein Outflow Occlusive Disease  
*Jose I. Almeida, MD, RVT*
- 3:30 – 3:35 Endovascular Treatment Of Chronic Venous Obstruction: Tips And Tricks Including Complete Obstruction  
*Mark J. Garcia, MD*
- 3:36 – 3:41 **DEBATE:** We Should Treat Intramuscular Calf Vein DVT With Standard Anticoagulation  
*Joann Lohr, MD*
- 3:42 – 3:47 **DEBATE:** We Should Not Treat Intramuscular Calf Vein DVT With Standard Anticoagulation  
*Clifford M. Sales, MD, MBA*
- 3:48 – 3:53 Superficial Venous Thrombophlebitis: To Treat Or Not To Treat?  
*Joseph D. Raffetto, MD*
- 3:54 – 3:59 2012 Chest Guidelines - Important Changes  
*Anthony J. Comerota, MD*
- 4:00 – 4:05 Importance Of A Venous Registry And Opportunities In The Vascular Quality Initiative (SVS)  
*Jack L. Cronenwett, MD*
- 4:06 – 4:11 What Drugs Should We Be Using For DVT Treatment?  
*Russell H. Samson, MD, RVT*
- 4:12 – 4:17 Timing And Patient Selection For Thrombolysis  
*Antonios P. Gasparis, MD*
- 4:18 – 4:23 Should We Use The D-Dimer Test And/Or Residual Thrombus To Manage DVT?  
*Timothy K. Liem, MD*
- 4:24 – 4:29 Association Of Deep Vein Reflux And Obstruction In PTS: Which Is The Culprit?  
*Seshadri Raju, MD*
- 4:30 – 4:35 What Is A Saphenous Vein Aneurysm And How Should It Be Treated  
*Ronald G. Bush, MD*
- 4:36 – 4:41 Mechanism Of Venous Valve Closure And The Role Of The Valve In Circulation  
*Fedor Lurie, MD, PhD*
- 4:42 – 4:47 Deep Venous Valvular Reconstruction: Indications, How And Results  
*Marzia Lugli, MD*
- 4:48 – 4:53 Natural History Of Advanced CVI (CEAP 4-6) Following Endovenous Ablation  
*Jennifer A. Heller, MD*
- 4:54 – 5:15 Panel Discussion  
Panelists: *Jose I. Almeida, MD, RVT*  
*Enrico Ascher, MD*  
*Lowell S. Kabnick, MD*  
*Anthony J. Comerota, MD*  
*Jack L. Cronenwett, MD*  
*Alan M. Dietzek, MD, RPVI*  
*Antonios P. Gasparis, MD*  
*Marzia Lugli, MD*  
*William A. Marston, MD*  
*Mark H. Meissner, MD*  
*Mark S. Whiteley, MS*
- 5:15 Adjourn

SESSION 7 (Gramercy Suites A&B, 2nd Floor)

**WOUNDS – PART 1**

**9:00 – 9:10** Opening Remarks  
*Dieter O. Mayer, MD*

**PART 1A: NEW CONCEPTS IN WOUND CARE**  
**Moderator: Giacomo Clerici, MD**

**9:10 – 9:20** Utility Of V.A.C.® Therapy For Split-Thickness Skin Grafting  
*Bauer E. Sumpio, MD, PhD*

**9:20 – 9:30** Discussion

**9:30 – 9:40** Topical Oxygen; Breathing New Life Into Chronic Wounds  
*Giacomo Clerici, MD*

**9:40 – 9:50** Discussion

**9:50 – 10:00** Diagnosis And Management Of Atypical Wounds Of The Lower Leg: An Update  
*Marco Romanelli, MD, PhD*

**10:00 – 10:10** Discussion

**10:10 – 10:20** A Systematic Approach To Surgical Debridement  
*Dieter O. Mayer, MD*

**10:20 – 10:30** Discussion

**10:30 – 11:00** Break – Visit Exhibits and Pavilions (2nd and 3rd Floors)

**PART 1B: FREE PAPER SESSION**  
**Moderator: Dieter O. Mayer, MD**

**11:00 – 11:07** Critical Limb Ischemia: Endovascular Below-The-Knee Maximal Revascularization Increases Wound Healing  
*Nirvana Sadaghiyanloo, MD*

**11:07 – 11:12** Discussion

**11:12 – 11:19** Maggot Therapy For Chronic Ulcer: Systematic Review, Meta-analysis And Cost-Effective  
*Chumpon Wilasrusmee, MD, MSc*

**11:19 – 11:24** Discussion

**11:24 – 11:31** A Novel Robotic Monofilament Test For Diabetic Neuropathy  
*Chumpon Wilasrusmee, MD, MSc*

**11:31 – 11:36** Discussion

**11:36 – 11:43** Can Audible Doppler Signal Be Used As An Alternative To Ankle Brachial Pressure Index  
*Afsaneh Alavi, MD*

**11:43 – 11:48** Discussion

**11:48 – 11:55** How Frequently Does A Malignant Wound Present As Leg Ulcer?  
*Afsaneh Alavi, MD*

**11:55 – 12:00** Discussion

**12:00 – 12:30** Lunch Break – Americas Hall 1, 3rd Floor  
Visit Exhibits and Pavilions (2nd and 3rd Floors)

SESSION 8 (Gramercy Suites A&B, 2nd Floor)

**WOUNDS – PART 2**

**PART 2A: EVIDENCE BASED MEDICINE IN WOUND CARE**  
**Moderator: Bauer E. Sumpio, MD, PhD**

**12:30 – 12:40** How To Implement EBM In Our Wound Clinic Or Surgical Department  
*Hester Vermeulen, PhD*

- 12:40 – 12:50** Delphi Studies In Wound Care Research: A New Better Tool For EBM?  
*Anne M. Eskes, RN, MSc*
- 12:50 – 1:00** How To Treat Donor Site Wounds: An Evidence Based Approach  
*Fleur E. Brölmann, MD*
- 1:00 – 1:20** Panel Discussion
- 1:20 – 1:30** The Association Of Ulceration Of The Foot With Cardiovascular And All-Cause Mortality In Patients With Diabetes: A Meta-analysis  
*Robert J. Hinchliffe, MD*
- 1:30 – 1:40** Evidence Based Update: Diabetic Foot Ulcers And The Wound Bed Preparation Model  
*R. Gary Sibbald, MD*
- 1:40 – 1:50** Panel Discussion

**PART 2B: CONCEPTS FOR THE DIABETIC FOOT**

**Moderators:** *Giacomo Clerici, MD*  
*Marc A. Brenner, DPM*

- 1:50 – 2:10** Facts That Every Vascular Surgeon Needs To Know About The Diabetic Foot  
*Michael E. Edmonds, MD*
- 2:10 – 2:20** Discussion
- 2:20 – 2:40** Foot Deformities In The Diabetic - More Than Charcot Foot  
*Thomas Boeni, MD*
- 2:40 – 2:50** Discussion
- 2:50 – 3:00** A New Device For Topical Intermittent Rapid Oxygenation – Compression To Increase Hyperoxygenated Blood Flow To The Horrendous Septic Diabetic Foot  
*Magdiel Trinidad-Vasquez, MD*
- 3:00 – 3:10** Discussion
- 3:10 – 3:20** Achilles Tendon Complete Tenotomy: THE Solution For Treating Neuropathic Diabetes Mellitus Foot Ulcers?  
*Wayne Caputo, DPM*
- 3:20 – 3:30** Discussion
- 3:30 – 3:50** Break – Visit Exhibits and Pavilions (2nd and 3rd Floors)

**PART 2C: VASCULAR INTERVENTIONS IN WOUND CARE**

**Moderator:** *Joseph L. Mills, MD*

- 3:50 – 4:00** Peripheral VORTEC Procedures: Who Really Profits And Who Maybe Does Not?  
*Gabriel Szendro, MD*
- 4:00 – 4:10** Discussion
- 4:10 – 4:20** Provide Me An Inflow And I Will Heal Your Foot  
*Marc A. Brenner, DPM*
- 4:20 – 4:30** Discussion
- 4:30 – 4:40** Below-The-Knee Stent Or Balloon In Severe Critical Limb Ischemia With Extensive Wounds: Is It Worth The Effort?  
*Sebastian E. Debus, MD, PhD*
- 4:40 – 4:50** Discussion
- 4:50 – 5:00** Is Tibial Angioplasty Effective To Improve Wound Healing In Patients With End-Stage Renal Disease (ESRD)?  
*Werner Lang, MD*
- 5:00 – 5:10** Discussion

**5:10 – 5:20** Closing Remarks  
*Dieter O. Mayer, MD*

**5:20** Adjourn

SESSION 9 (Murray Hill Suites A&B, 2nd Floor)  
**MULTIDISCIPLINARY ACUTE STROKE  
MANAGEMENT – PART I**

**7:55 – 8:00** Welcome And Introduction  
*Allan L. Brook, MD*

**PART 1A: THE BASICS OF STROKE - INCLUDING THE  
EPIDEMIOLOGY AND NATURAL HISTORY**

**Moderators:** *Allan L. Brook, MD*  
*Joshua A. Hirsch, MD*

**8:00 – 8:07** Stroke: Where We Have Been And Now The 21st  
Century And Things To Look Forward To  
*Lou Caplan, MD*

**8:08 – 8:16** TIAs - What Is New: Diagnosis And When To Treat  
Aggressively  
*David S. Liebeskind, MD*

**8:17 – 8:25** Brain Blood Flow - Physiology And Understanding  
The Basics: CBF, CBV, MTT: What Is Being Measured  
And What Matters The Most  
*Colin P. Derdeyn, MD*

**8:26 – 8:34** Posterior Fossa: Why Do We Have A Longer Window?  
Or Do We Just Not Understand The Physiology?  
*Lou Caplan, MD*

**8:35 – 8:47** The Clinical Exam: Quick Pearls That Tell You: Large  
Or Small Vessel Occlusion  
*Daniel L. Labovitz, MD*

**8:48 – 8:56** Door To Revascularization Time: Optimization And  
Where Should We Be In 5 Years And Why  
*Edward C. Jauch, MD, MS*

**8:57 – 9:16** Panel Discussion

**PART 1B: STATE-OF-THE-ART IMAGING**

**Moderators:** *Lawrence Wechsler, MD*  
*David S. Liebeskind, MD*

**9:17 – 9:25** Why Does Clot Location, Composition And Size  
Really Matter?  
*Albert J. Yoo, MD*

**9:26 – 9:34** The Neuroimaging Protocol Made Easy: Quick,  
Accurate And Reliable Anatomic And Physiologic  
Imaging  
*Howard A. Rowley, MD*

**9:35 – 9:47** Summarization Of The Latest Trials And Learning  
Points  
*Lawrence Wechsler, MD*

**9:48 – 9:56** Collaterals And Definitive Reperfusion  
*David S. Liebeskind, MD*

**9:57 – 10:15** Panel Discussion

**10:15 – 10:30** Break – Visit Exhibits and Pavilions  
(2nd and 3rd Floors)

**PART 1C: TRIAGE ISSUES AND DEBATES**

**Moderators:** *Edward C. Jauch, MD, MS*  
*Lawrence Wechsler, MD*

**10:31 – 10:38** Triage At Its Best: My Brooklyn Pearls  
*Steven H. Rudolph, MD*

- 10:39 – 10:46** "Telestroke" 2012: From Far And Away The Specialist Can Make The Difference  
*Leonard Dimitri DaSilva, MD*
- 10:47 – 10:53** Why Has Imaging Failed To Find The Optimum Patients For Revascularization?  
*Lawrence Wechsler, MD*
- 10:54 – 11:00** Best Stroke Imaging Of The Future And Why  
*Pamela W. Schaefer, MD*

**PART 1D: ACUTE STROKE TREATMENT**

**Moderators:** *Peter A. Rasmussen, MD*  
*Joshua A. Hirsch, MD*

- 11:01 – 11:08** IV TPA Recent Updated Guidelines: Does 3, 4, Or 6 Hours Really Have A Basis In The Literature Or In Pathophysiology?  
*Osama O. Zaidat, MD*
- 11:08 – 11:16** IA Medical Nuances - When And How Much: Does Temporary Stenting Revisit The Need For Thrombolytics  
*Don Frei, MD*
- 11:17 – 11:23** Thrombectomy: Summary Of The Clotted Data And Outcomes  
*Aquilla S. Turk, DO*
- 11:24 – 11:31** Antiplatelet Therapy And Beyond: How It Relates To Intracranial Stenting And More  
*Lucie G. Thibault, Pharm.D*
- 11:32 – 11:39** Angioplasty, Stenting And Temporary Stenting (A True Bridging Protocol): Facts And Fictions: My Opinion!  
*David Fiorella, MD*
- 11:40 – 11:47** Is It Device Or Patient Criteria That Are Most Important To Make An Impact In Early Revascularization With Efficacy?  
*Peter A. Rasmussen, MD*
- 11:48 – 12:00** Panel Discussion

SESSION 10 (Murray Hill Suites A&B, 2nd Floor)  
**MULTIDISCIPLINARY ACUTE STROKE MANAGEMENT – PART 2**

**PART 2A: POWER LUNCHEON SYMPOSIUM: CAROTID AND INTRACRANIAL STENTING: WHAT WENT WRONG WITH THE TRIALS?**

**Moderators:** *Thomas G. Brott, MD*  
*Joshua A. Hirsch, MD*  
*Peter K. Nelson, MD*  
*Philip M. Meyers, MD*

- 12:15 – 12:25** CREST: Salient Points And Implications For The Future  
*Thomas G. Brott, MD*
- 12:26 – 12:36** Facts, Unknowns And Reasons For The Ongoing Controversy About The Best Treatment For Asymptomatic Carotid Stenosis  
*Frank J. Veith, MD*
- 12:37 – 12:47** Doppler Is Not Enough To Send My Patient For Revascularization And Why: The Neurological Perspective  
*Don Heck, MD*
- 12:48 – 12:59** Discussion



- 1:00 – 1:10** SAMMPRIS: Summary From The PI And Future Implications  
*Colin P. Derdeyn, MD*
- 1:11 – 1:21** SAMMPRIS Results: Why I Advocate A New Trial And Why Patients Need Technology  
*David Fiorella, MD*
- 1:22 – 1:32** IMS III – Latest Trial Results And Reason To Pause, Or Proceed With New Interest And Ideas: Unofficial Comments  
*Edward C. Jauch, MD, MS*
- 1:33 – 1:43** Stroke Trials: Lessons Learned: The Next Horizon To Make An Impact On Stroke Reversal Or Prevention  
*J. Mocco, MD, MS*
- 1:44 – 1:59** Discussion

**PART 2B: THE OTHER SIDE OF STROKE: SUBARACHNOID HEMORRHAGE MANAGEMENT**

**Moderators:** *David Gordon, MD*  
*Aquilla S. Turk, DO*

- 2:00 – 2:10** Subarachnoid Hemorrhage: Vasospasm Latest Developments  
*Aman B. Patel, MD*
- 2:11 – 2:21** Neuroanesthesia: Elements For Success  
*Apalonia E. Abramowicz, MD*
- 2:22 – 2:32** Latest Devices For Aneurysm Therapy: Are Coils Becoming The Second Option?  
*Peter K. Nelson, MD*
- 2:33 – 2:43** Surgical Clipping Of Aneurysms Is Still A Necessary Evil: Case Selection From An Experienced Cerebrovascular Neurosurgeon  
*Eugene S. Flamm, MD*
- 2:44 – 2:54** Endovascular Cases That Make Me Nervous: Location, Geometry, And Beyond  
*Aaron S. Dumont, MD*
- 2:55 – 3:05** Unruptured Aneurysms: Why Do We Treat Them? The US Experience vs. The Rest Of The World Opinion  
*TBD*
- 3:06 – 3:16** Intracranial Bypass: Has A Dinosaur Come Back From Extinction? Best Indications And State-Of-The Art Techniques/NOVA  
*David J. Langer, MD*
- 3:17 – 3:22** Most Common Medical Legal Issues  
*Gregg H. Zoarski, MD*
- 3:23 – 3:28** Ways To Avoid Facing The Wrong Side Of The Jury  
*Michael I. Weintraub, MD*
- 3:29 – 4:00** Discussion
- 4:00** Adjourn
- Visit Exhibits and Pavilions (2nd and 3rd Floors)

## THURSDAY, NOVEMBER 15, 2012

6:00 A.M. General Registration – 2nd Floor Promenade  
Faculty Registration – Morgan Suite – 2nd Floor  
Continental Breakfast – Sutton Complex, 2nd Floor

### CONCURRENT THURSDAY MORNING PROGRAMS

#### PROGRAM A

(SESSIONS 11 – 13)

#### Cardiac And Thoracic Aortic Diseases And Their Treatment

6:30 A.M. – 9:54 A.M.

Grand Ballroom East and West, 3rd Floor

#### PROGRAM B

(SESSIONS 14 – 16)

#### New Endovascular Approaches To Lower Extremity And Below-Knee Arterial Disease And Its Treatment

6:35 A.M. – 9:54 A.M.

Trianon Ballroom, 3rd Floor

#### PROGRAM A (SESSIONS 11 – 13)

TOPICS DEALING WITH CARDIAC AND THORACIC AORTIC DISEASES AND THEIR TREATMENT

(GRAND BALLROOM EAST AND WEST, 3RD FLOOR)

**6:30 – 6:35** Opening Remarks  
*Frank J. Veith, MD*

SESSION 11 (Grand Ballroom East and West, 3rd Floor)  
PROGRESS IN TRANSCATHETER HEART VALVES,  
NEW APPROACHES TO THE ASCENDING AORTA  
AND THORACIC AORTIC DISEASE  
(5-MINUTE TALKS)

*Moderators: Roy K. Greenberg, MD  
Peter R. Taylor, MA, MChir*

**6:35 – 6:40** Transcatheter Aortic Valve Implantation (TAVI)  
For Unsatisfactory Surgical Valve Implantations: Will  
It Be An Exception Or The Routine In The Future  
*Dietmar H. Koschyk, MD*

**6:41 – 6:46** Why Vascular Surgeons Must Play A Role In TAVI  
Procedures: Why Is Their Expertise Important  
*Marc R.H.M. van Sambeek, MD, PhD*

**6:47 – 6:52** New Developments In Transcatheter Mitral Valve  
Repair  
*Ted Feldman, MD*

**6:53 – 6:58** Present Status And Future Potential Of TAVI  
*Martin B. Leon, MD*

**6:59 – 7:04** Wrapping Procedure For Dilated Ascending Aorta:  
When And How To Do It  
*Mario Lachat, MD*

**7:05 – 7:10** Status Of Endovascular Graft Repair For Aortic Arch  
Lesions: What Endovascular Solutions Are Working  
And What Are Not Working  
*Timothy A.M. Chuter, DM*

**7:11 – 7:16** Quantifying Ascending Aorta And Arch Deformation  
From Respiratory And Cardiac Motion: Implications  
For Branched Devices  
*Ronald L. Dalman, MD*

- 7:17 – 7:22** Retrograde Dissection During Endovascular Treatment Of Aortic Arch Pathology: How Can It Be Prevented And Treated  
*Germano Melissano, MD*  
*Roberto Chiesa, MD*
- 7:23 – 7:28** Risk Factors Of Stroke In Thoracic Endovascular Aortic Repair (TEVAR) And How To Offset Them  
*Wei Guo Fu, MD*
- 7:29 – 7:34** Hybrid Rescue Techniques For Failed TEVAR Procedures  
*Eric E. Roselli, MD*
- 7:35 – 7:41** Panel Discussion

SESSION 12 (Grand Ballroom East and West, 3rd Floor)  
**NEW DEVELOPMENTS IN TREATMENT OF THE ASCENDING AORTA, ARCH LESIONS AND AORTIC DISSECTIONS (5-MINUTE TALKS)**

**Moderators:** *Larry H. Hollier, MD*  
*Richard P. Cambria, MD*

- 7:41 – 7:46** Future Of Endovascular Treatment Of Ascending Aortic Lesions  
*Christoph A. Nienaber, MD, PhD*
- 7:47 – 7:52** Unusual Access Routes To The Ascending Aorta And Arch For Endograft Placement: Advantages, Limitations And Precautions  
*Tilo Koelbel, MD, PhD*
- 7:53 – 7:58** Experience With Endograft Treatment Of Ascending Aortic Lesions And Type A Dissections  
*Robert J. Hinchliffe, MD*  
*Matt M. Thompson, MD*
- 7:59 – 8:04** Endovascular Graft Treatment Of Type A Dissections: Technique And In What Proportion Of Patients Will It Be Possible  
*Zaiping Jing, MD*
- 8:05 – 8:10** Complete Endovascular Graft Exclusion Of Arch Aneurysms Using A Non-Custom-Made Branched Arch Device (Cook)  
*Krassi Ivancev, MD, PhD*
- 8:11 – 8:16** New Developments In Endovascular Repair Of Zone 0 Aortic Arch Pathologies  
*Toru Kuratani, MD, PhD*
- 8:17 – 8:22** Experience With The Bolton Arch Branch Endograft  
*W. Anthony Lee, MD*
- 8:23 – 8:28** Advantages Of A Precurved Fenestrated Endograft For Treating Arch Aneurysms And Dissections  
*Yoshihiko Yokoi, MD*
- 8:29 – 8:34** Hybrid (Open And Endo) Treatment Of Aortic Arch Aneurysms And Dissections: How Laparoscopy Can Help In Evaluating Patients With Malperfusion  
*Roberto Chiesa, MD*
- 8:35 – 8:40** Update On In Situ Fenestration For Arch Repair: Will Endovascular Total Arch Repair Replace Open Techniques  
*Björn Sonesson, MD, PhD*
- 8:41 – 8:47** Panel Discussion

SESSION 13 (Grand Ballroom East and West, 3rd Floor)  
PROGRESS IN TREATING DISEASES OF THE  
THORACIC AORTA, INCLUDING DISSECTIONS  
AND MANAGING COMPLICATIONS  
(5-MINUTE TALKS)

Moderators: *Ronald M. Fairman, MD*  
*Christoph A. Nienaber, MD, PhD*

- 8:47 – 8:52** Open Surgical vs. Endovascular Treatment Of Thoracic Aortic Pathology In Marfan's Syndrome: Is Endo Safe And When  
*Roberto Chiesa, MD*
- 8:53 – 8:58** TEVAR For Type B Aortic Dissections In Marfan's Syndrome Can Work  
*Chang Shu, MD*
- 8:59 – 9:04** When Is TEVAR Contraindicated And Open Repair Needed With Thoracic Aortic Lesions  
*Michael J. Jacobs, MD*
- 9:05 – 9:10** What Is In And What Is Out With Type B Aortic Dissections And Their Endovascular Treatment  
*Zhong Gao Wang, MD*
- 9:11 – 9:16** Long-Term (5-Year) Data On Aortic Remodeling After TEVAR Treatment Of Type B Aortic Dissection Supports Early Intervention  
*Mark Conrad, MD*  
*Richard P. Cambria, MD*
- 9:17 – 9:22** When Is TEVAR Inadequate Treatment For Type B Aortic Dissections  
*Götz M. Richter, MD, PhD*
- 9:23 – 9:28** **DEBATE:** Revascularization Of The Left Subclavian: When It Is Covered During TEVAR Matters: But Only With Aneurysms Not With Dissections  
*Robert J. Hinchliffe, MD*  
*Matt M. Thompson, MD*
- 9:29 – 9:34** **DEBATE:** Revascularization Of The Left Subclavian: When It Is Covered During TEVAR Only Matters In Exceptional Circumstances  
*Thomas S. Maldonado, MD*
- 9:35 – 9:40** **DEBATE:** Routine Revascularization Of The Left Subclavian For All Zone 2 TEVARs Is Unnecessary And Probably Harmful  
*Frank J. Criado, MD*
- 9:41 – 9:46** Managing Progression Of Aortic Disease After TEVAR: Open Surgery Will Always Be Needed For Some Thoracic And Thoracoabdominal Aneurysms  
*Hazim J. Safi, MD*
- 9:47 – 9:54** Panel Discussion  
Conclusion Of Program A.
- 9:54 – 10:10** Break - Visit Exhibits and Pavilions  
(2nd and 3rd Floors)

PROGRAM B (SESSIONS 14 – 16)  
NEW ENDOVASCULAR APPROACHES TO LOWER EXTREMITY  
AND BELOW-KNEE ARTERIAL DISEASE AND ITS TREATMENT  
(TRIANON BALLROOM, 3RD FLOOR)

- 6:35 – 6:40** Opening Remarks  
*Frank J. Veith, MD*

SESSION 14 (Trianon Ballroom, 3rd Floor)  
**LOWER EXTREMITY HOT TOPICS I**  
(5-MINUTE TALKS)

*Moderators: Enrico Ascher, MD*  
*Bruce J. Brener, MD*

- 6:40 – 6:45** **DEBATE:** 2-3 Year Comparison Of Sirolimus Eluting Stents (SESts) vs. Bare Metal Stents (BMSs) For Below-Knee And Tibial Occlusive Disease (YUKON Trial)  
*Gunnar Tepe, MD*
- 6:46 – 6:51** **DEBATE:** Drug Eluting Balloons (DEBs) Are Better For Below-Knee Lesions Than SESts: 1-Year Results  
*Francesco Liistro, MD*
- 6:52 – 6:57** Use Of 4 French Systems For Treating Fem-Pop Lesions: Advantages And Disadvantages: Lessons From The 4EVER Trial Using Astron Pulsar Stents And No Closure Devices  
*Koen Deloose, MD*  
*Marc Bosiers, MD*
- 6:58 – 7:03** New Developments In Distal Puncture Techniques For Treating CTOs Of Lower Extremity Arteries: The Funnel Balloon Catheter; 3 Fr Sheath; Needle Extensions And COR Balloons  
*Andrej Schmidt, MD*
- 7:04 – 7:09** Best Treatment Of Popliteal Lesions: Stent vs. PTA: The ETAP Trial  
*Thomas Zeller, MD*
- 7:10 – 7:15** Value Of The Biodegradable Balloon Expandable Remedy Stent For Lower Extremity Lesions: The GAIA Trial Results  
*Dierk Scheinert, MD*
- 7:16 – 7:21** Does Atherectomy Help To Treat Resistant Calcified SFA Lesions: Does It Require A Distal Filter For Safety  
*Daniel G. Clair, MD*
- 7:22 – 7:27** **DEBATE:** Current Role Of New Atherectomy Devices: They Work And Justify The Costs  
*James F. McKinsey, MD*
- 7:28 – 7:33** **DEBATE:** Debulking With Atherectomy And Laser Is A Good Idea Whose Time Has Passed  
*Frank J. Criado, MD*
- 7:34 – 7:40** Panel Discussion

SESSION 15 (Trianon Ballroom, 3rd Floor)  
**LOWER EXTREMITY HOT TOPICS II**  
(5-MINUTE TALKS)

*Moderators: Kenneth Ouriel, MD, MBA*  
*Evan C. Lipsitz, MD*

- 7:40 – 7:45** Long-Term Evaluation (To 5 Years) Of SFA Stents In 1000 Patients: Importance Of TASC Classification, Stent Type And Lesion Length (Belgian/German Study)  
*Marc Bosiers, MD*  
*Giovanni Torsello, MD*  
*Patrick Peeters, MD*
- 7:46 – 7:51** The Many Uses And Advantages Of The Supera Veritas Stent (IDEV) To Treat Femoropopliteal Lesions  
*Peter C.J. Goverde, MD*  
*Dierk Scheinert, MD*

- 7:52 – 7:57** 1-Year Results Of The Protege Everflex Stent (ev3) To Treat Popliteal Lesions: DURABILITY-POP Study  
*Patrick Peeters, MD*
- 7:58 – 8:03** **DEBATE:** CFA And DFA Occlusive Lesions Are Best Treated By Endovascular Techniques  
*Thomas Zeller, MD*
- 8:04 – 8:09** **DEBATE:** How Should CFA And DFA Occlusive Lesions Best Be Treated  
*Gustavo S. Oderich, MD*
- 8:10 – 8:15** Extreme Approaches To CTOs via Retrograde Puncture Of Pedal Loop And Digital Arteries: How To Do It  
*Marco G. Manzi, MD*
- 8:16 – 8:21** **DEBATE:** Stenting Is Still First Line Treatment For SFA Occlusive Disease  
*Erich Minar, MD*
- 8:22 – 8:27** **DEBATE:** Why Should Metal Be Avoided In The SFA And How To Do It  
*Giancarlo Biamino, MD, PhD*
- 8:28 – 8:33** How To Remove Small Procedural Emboli From Tibial Arteries  
*Andrej Schmidt, MD*
- 8:34 – 8:39** What To Do For CLI Patients When There Are No Patent Outflow Arteries: Can DEBs Help  
*Roberto Ferraresi, MD*
- 8:40 – 8:46** Panel Discussion

SESSION 16 (Trianon Ballroom, 3rd Floor)  
**LOWER EXTREMITY HOT TOPICS III**  
**(5-MINUTE TALKS)**

**Moderators:** *Jacques Busquet, MD*  
*Luis A. Sanchez, MD*

- 8:46 – 8:51** **DEBATE:** Atherectomy And DEBs For Native Disease And In Stent Restenosis In The SFA And Popliteal: Stents Can Be Avoided Completely  
*Thomas Zeller, MD*
- 8:52 – 8:57** **DEBATE:** DEBs Won't Do The Job Alone: Stents Will Be Needed Sometimes For Recoil Or Dissection  
*Dierk Scheinert, MD*
- 8:58 – 9:03** The Tack-It Device: An Endovascular Stapler For Imperfect PTAs To Avoid Stenting  
*Peter A. Schneider, MD*
- 9:04 – 9:09** 3-Year Results Of The RESILIENT Trial With The Lifestent: Are The Results Of SFA Stents Durable  
*John R. Laird, MD*
- 9:10 – 9:15** 3-Year Results From The ZILVER PTX Drug Eluting Stent (DES) Trial: Are The Results Durable And How Do Patterns Of Restenosis Differ  
*Michael D. Dake, MD*  
*Gary M. Ansel, MD*
- 9:16 – 9:21** 2-Year Outcomes Of Stent Supported PTA For Iliac Lesions: Balloon vs. Self-Expanding Stents: Influence Of TASC Classification: The BRAVISSIMO Trial  
*Patrick Peeters, MD*
- 9:22 – 9:27** **DEBATE:** To Treat Lower Extremity Chronic Total Occlusions (CTOs) One Only Needs A Wire And A Catheter And Not All This Expensive Nonsense  
*Amman Bolia, MD*

- 9:28 – 9:33** **DEBATE:** We Need All This Stuff And More To Meet Unmet Needs With Lower Extremity Occlusive Disease  
*Gary M. Ansel, MD*
- 9:34 – 9:39** How To Use A Radiofrequency Wire To Cross Difficult CTOs: Advantages, Precautions, Limitations  
*Marcelo S. Guimaraes, MD*
- 9:40 – 9:45** ALL CLI Is Not The Same: This And Diabetic Status Render Limb Salvage Rates A Poor Index Of Success With Revascularization Procedures: Some Limbs With CLI Survive With Conservative Treatment And Prayer  
*Francesco Serino, MD*
- 9:46 – 9:54** Panel Discussion
- 9:54 – 10:10** Break - Visit Exhibits and Pavilions (2nd and 3rd Floors)  
**Conclusion of Program B. VEITH Symposium continues in the Grand Ballroom, 3rd Floor.**

SESSION 17 (Grand Ballroom East and West, 3rd Floor)  
**NEW DEVELOPMENTS IN SFA AND CRURAL ARTERY TREATMENT OF CRITICAL LIMB ISCHEMIA (CLI) (5-MINUTE TALKS)**

**Moderators:** *Frank J. Veith, MD*  
*Barry T. Katzen, MD*

- 10:10 – 10:15** Why Is Duplex For Guidance For Lower Extremity Endovascular Procedures Not Replacing Fluoroscopy: Duplex Is So Much Better  
*Enrico Ascher, MD*
- 10:16 – 10:21** 13 Steps To Successful Pedal Access  
*Craig M. Walker, MD*
- 10:22 – 10:27** Drug Eluting Balloons (DEBs) Really Work: Comparative Results Prove It: When And Where Are DEBs Indicated  
*Gunnar Tepe, MD*
- 10:28 – 10:33** How Have DEBs Changed Lower Extremity Interventional Practice In Germany: Above And Below The Knee  
*Andrej Schmidt, MD*
- 10:34 – 10:39** How DEBs Have Changed Lower Extremity Interventional Practice In Italy: Are They Worth The Increased Cost  
*Giancarlo Biamino, MD, PhD*
- 10:40 – 10:45** Drug-Eluting Stents For Focal Infrapopliteal Lesions: Meta-Analysis Of The ACHILLES, DESTINY And YUKON-BTX Trials  
*Konstantinos Katsanos, MSc, MD, PhD*
- 10:46 – 10:51** Differences In Amputation Rates Following Treatment For Tissue Loss (Gangrene) And Rest Pain: Their Importance In Trials Evaluating Stem Cell And Other New Treatments  
*Thomas F. O'Donnell, Jr., MD*
- 10:52 – 10:57** Why Are DESs Not Going To Work In CLI Patients Based On The Anatomy Of Their Lesions  
*Nicholas A. Diehm, MD*
- 10:58 – 11:03** The Case For Subintimal PTA Above And Below The Inguinal Ligament  
*George H. Meier III, MD*



- 11:04 – 11:09** Open Bypass Procedures Have Value And Can Work When Endovascular Interventions Have Failed: What Percentage Of CLI Patients Will Need A Bypass: Endo First Is Not The Way To Go In Some Patients Since Bridges Are Burned  
*Francesco Spinelli, MD*
- 11:10 – 11:15** Pedal Bypasses Are Definitely Superior To PTA For Long Tibial Lesions  
*Werner Lang, MD*
- 11:16 – 11:21** Wound Related And Flow Guided Treatment For CLI With Necrotic Foot Lesions  
*Roberto Ferraresi, MD*
- 11:22 – 11:27** **DEBATE:** The Case For The Angiosome Concept  
*Richard F. Neville, MD*
- 11:28 – 11:33** **DEBATE:** The Angiosome Concept Is Not Important Except Possibly In Dialysis Patients  
*Nobuyoshi Azuma, MD*
- 11:34 – 11:39** **DEBATE:** A Patent Pedal Arch Is More Important Than The Angiosome Concept: But Foot Healing Can Occur Without An Intact Pedal Arch  
*Hisham Rashid, MSc*
- 11:40 – 11:45** Indocyanine Green Angiography: A Method To Study The Angiosome Concept  
*Joseph L. Mills, MD*
- 11:46 – 11:51** Stem Cell Therapy Will Have An Increasing Role In The Treatment Of CLI: It Really Works And A Glimpse Into The Future: Based On The RESTORE CLI Phase 2b Trial  
*Richard J. Powell, MD*
- 11:52 – 12:00** Panel Discussion
- 12:00 – 1:00** Lunch Break - Americas Hall I, 3rd Floor  
Visit Exhibits and Pavilions (2nd and 3rd Floors)

**CONCURRENT THURSDAY AFTERNOON PROGRAMS  
(1:00 P.M. – 6:55 P.M.)**

PROGRAM C

(SESSIONS 18 – 22)

**TEVAR, EVAR (18); Carotid Stenting (19); (20) Lower Extremity Stent-Graft; Vascular Disease And CCSVI For MS (21); Endoleaks (22)**

1:00 P.M. – 6:55 P.M.

Grand Ballroom East, 3rd Floor

PROGRAM D

(SESSIONS 23 – 25)

**Short Topics Relevant To Other Parts Of Program C On Lower Extremity (23); Thoracic And Abdominal Aorta (24); Miscellaneous And CCSVI (25)**

1:00 P.M. – 5:45 P.M.

Grand Ballroom West, 3rd Floor

PROGRAM C (SESSIONS 18 – 22)

SESSION 18 (GRAND BALLROOM EAST, 3RD FLOOR)

## NEW DEVELOPMENTS IN TEVAR AND EVAR (5-MINUTE TALKS)

*Moderators: Juan C. Parodi, MD  
Hazim J. Safi, MD*

- 1:00 – 1:05** Axillofemoral Bypass To Prevent Limb Ischemia During Prolonged Iliac Sheath Occlusion For Complex EVARs  
*Krassi Ivancev, MD, PhD*
- 1:06 – 1:11** Lessons Learned And Precautions Needed With Fenestrated And Branched Grafts For Complex Aneurysm Repairs  
*Piotr M. Kasprzak, MD*
- 1:12 – 1:17** Pathogenesis Of Spinal Cord Ischemia (SCI) During TEVAR And Open Repair: Is It The Same Or Different: Implications For Prevention And Treatment  
*Charles W. Acher, MD*
- 1:18 – 1:23** How To Prevent SCI After TEVAR  
*Michael J. Jacobs, MD*
- 1:24 – 1:29** Tips And Tricks For Performing CSF Drainage Optimally With TEVAR Or Open Repair  
*Vicente Rimbau, MD, PhD*
- 1:30 – 1:35** **DEBATE:** Endovascular Graft Treatment Of Acute Uncomplicated Type B Aortic Dissection May Not Be A Good Idea: Medical Treatment May Be As Good (Video)  
*Sebastian E. Debus, MD, PhD*
- 1:36 – 1:41** **DEBATE:** Experience With Early TEVAR Treatment Of Uncomplicated Type B Aortic Dissection: It Really Is The Right Thing To Do Based On False Lumen/True Lumen Measurements  
*Rodney A. White, MD*
- 1:42 – 1:47** Long-Term (3-5 Year) Results Of The INSTEAD Trial Shows The Benefit Of Early TEVAR Treatment Of Uncomplicated Type B Aortic Dissections: Game Changing Results  
*Christoph A. Nienaber, MD, PhD*
- 1:48 – 1:53** Results Of TEVAR In Acute Type B Aortic Dissection vs. Best Medical Treatment: First Results Of The ADSORB Trial: A Randomized Controlled Trial  
*Jan S. Brunkwall, MD, PhD*
- 1:54 – 1:59** Some Concerns After Aortic Endografting For Type B Aortic Dissections  
*Stephen W.K. Cheng, MBBS*
- 2:00 – 2:05** How Valuable Are The Aptus HeliFX Staples (EndoAnchors): Results From The ANCHOR Registry  
*William D. Jordan, Jr., MD*
- 2:06 – 2:12** Panel Discussion

SESSION 19 (Grand Ballroom East, 3rd Floor)

## CRITICAL EVALUATION OF CAROTID ARTERY STENTING (CAS) IN NOVEMBER 2012: WHERE IS IT AND WHERE IS IT GOING (5-MINUTE TALKS)

*Moderators: Giorgio M. Biasi, MD  
Frank J. Veith, MD*

- 2:12 – 2:17** Why MRI Should Be Done Before All Revascularization Procedures (CAS And CEA): Duplex Is Not Enough  
*Emmanuel M. Houdart, MD*

- 2:18 – 2:23** Closed vs. Open Cell Stents For CAS: The Number Of Embolic Particles Are No Greater Nor Are Outcomes Worse With Open Cell Stents  
*Peter L. Faries, MD*
- 2:24 – 2:29** CAS For Total Carotid Occlusion: It Can Work And Be Beneficial: Under What Circumstances  
*Paul H.L. Kao, MD*
- 2:30 – 2:35** **DEBATE:** CAS Is Good Treatment For Most Patients With Symptomatic And Asymptomatic Carotid Stenosis  
*Klaus D. Mathias, MD*
- 2:36 – 2:41** **DEBATE:** CAS Is Not Good Treatment For Most Patients With Symptomatic And Asymptomatic Carotid Stenosis  
*Bruce A. Perler, MD, MBA*
- 2:42 – 2:47** Is Current Best Medical Treatment (BMT) Feasible And Does It Work To Decrease Strokes From Intracranial Disease In A High Risk Population: Results From The SAMMPRIS Trial Suggest BMT Can Decrease Strokes Markedly  
*Marc Chimowitz, MD*
- 2:48 – 2:53** Analysis Of CREST By A Neuroradiologist: What Is The Significance Of A Minor Stroke  
*Emmanuel M. Houdart, MD*
- 2:54 – 2:59** **DEBATE:** Cardiac Events Are An Appropriate End-Point For Evaluating CAS vs. CEA Outcomes; And In CREST, CAS Results Improved With Time  
*William A. Gray, MD*
- 3:00 – 3:05** **DEBATE:** Cardiac Events Are Not An Appropriate End-Point For Evaluating CAS vs. CEA Outcomes; And In CREST, CAS Results Did Not Improve With Time  
*Wesley S. Moore, MD*
- 3:06 – 3:11** Interventions Performed Within 1 Week Of A Neurological Event: Outcomes Of CEA Are Better Than CAS  
*Hans-Henning Eckstein, MD, PhD*
- 3:12 – 3:17** The Case Against Embolic Protection Devices In CAS: Why Therefore Are They So Widely Used  
*Michel S. Makaroun, MD*
- 3:18 – 3:23** Meta-analysis Of CAS By Cervical Access Shows Dramatic Reduction In Neurological Events  
*Patrice F. Bergeron, MD*  
*Petrosian Andranik, MD*
- 3:24 – 3:29** A Specialized Device For Performing CAS Via A Cervical Approach With Flow Reversal (FAST-CAS System): Early Results From The PROOF Trial  
*Ralf R. Kolvenbach, MD*
- 3:30 – 3:35** **DEBATE:** Why Is It Difficult To Randomize Asymptomatic Carotid Stenosis Patients To A 3-Armed Trial: CEA vs. CAS vs. BMT  
*Hans-Henning Eckstein, MD, PhD*
- 3:36 – 3:41** **DEBATE:** Why We Must Have A Trial Comparing BMT To CAS And CEA In Asymptomatic Patients With Carotid Stenosis  
*Anne L. Abbott, MD, PhD*
- 3:42 – 3:47** TCD Embolic Signals, Silent Infarcts On CT-Brain Scans, Or The Size Of Juxtaluminal Black Area In Evaluating Stroke Potential Of Asymptomatic Carotid Lesions  
*Andrew N. Nicolaidis, MS*

**3:48 – 4:00** Panel Discussion And Break  
Visit Exhibits and Pavilions (2nd and 3rd Floors)

SESSION 20 (Grand Ballroom East, 3rd Floor)

## NEW DEVELOPMENTS IN LOWER EXTREMITY STENT-GRAFTS (5-MINUTE TALKS)

*Moderators: Mark A. Adelman, MD*

*Darren B. Schneider, MD*

**4:00 – 4:05** Patency Of Viabahn Stent Grafts Is Better Than Bare Metal Stents For SFA Occlusive Disease: Final Results Of The VIASTAR Trial  
*Johannes Lammer, MD*

**4:06 – 4:11** Are Stent Grafts The Solution For In-Stent Restenosis After SFA Stenting  
*Marc Bosiers, MD*  
*Koen Deloose, MD*

**4:12 – 4:17** Technical Considerations To Improve Results With SFA Stent-Grafting For Occlusive Disease: Lessons Learned From The VIPER Trial With Heparin-Bonded Viabahn Stent-Grafts  
*Richard R. Saxon, MD*

**4:18 – 4:23** Why Do Viabahn Stent-Grafts Fail In The First Year: Does Collateral Coverage And Antiplatelet Treatment Matter  
*Michael S. Conte, MD*

**4:24 – 4:29** Standard Fempop Bypasses Are Better Than Endoluminal Stent-Graft “Bypasses” For 5-25 cm SFA Occlusions: An Older RCT: Is It Still Relevant  
*Mauri J.A. Lepantalo, MD*

**4:30 – 4:35** Current Status Of Heparin Bonded Viabahn Stent-Grafts Based On European Studies  
*Thomas Zeller, MD*

**4:36 – 4:41** Current Status Of Viabahn Endografts For Treatment Of Popliteal Aneurysms: Which Patients Should Not Be Treated Endovascularly  
*Eric L.G. Verhoeven, MD, PhD*

**4:42 – 4:47** Can Covered Stents Safely Be Placed Across The Inguinal Ligament And In The CFA  
*Keith D. Calligaro, MD*

**4:48 – 4:55** Panel Discussion

SESSION 21 (Grand Ballroom East, 3rd Floor)

## NEW OR IMPROVED CONCEPTS IN VASCULAR DISEASE TREATMENT AND THE CONTROVERSY OVER THE INTERVENTIONAL TREATMENT OF CCSVI FOR MULTIPLE SCLEROSIS (5-MINUTE TALKS)

*Moderators: Bruce A. Perler, MD, MBA*

*Jean-Baptiste Ricco, MD, PhD*

**4:55 – 5:00** Tips And Tricks For Vascular Disease Intervention In Pediatric Patients  
*Furuzan Numan, MD*

**5:01 – 5:06** **DEBATE:** Update On The Treatment Of Vasculogenic Impotence: Viagra, Cialis And Levitra Are Most Often Enough  
*Ralph G. DePalma, MD*

**5:07 – 5:12** **DEBATE:** Not True, Some Patients Need Internal Pudendal Stenting: Current Status Of The Endovascular Treatment Of Erectile Dysfunction  
*Krishna J. Rocha-Singh, MD*

**The CCSVI Controversy In Multiple Sclerosis**

- 5:13 – 5:18 What's New In The Diagnosis And Endovascular Treatment Of CCSVI In MS Patients  
*Paolo Zamboni, MD*
- 5:19 – 5:24 Endovascular Treatment Of CCSVI In MS Patients Really Works: The Benefits Of Treating Venous Brain Congestion Can Be Documented  
*Ivo Petrov, MD, PhD*
- 5:25 – 5:30 Does Interventional Treatment Help MS Patients: A Skeptical Vascular Surgeon Remains Skeptical  
*Jean-Baptiste Ricco, MD, PhD*
- 5:31 – 5:36 Intrinsic And Extrinsic Cerebrospinal Venous Abnormalities In Neurological Diseases: Anatomic And Physiological Evidence  
*Michael D. Dake, MD*
- 5:37 – 5:42 Interventional Treatment Of CCSVI Can Improve MS: A Vascular Surgeon Who Is Convinced  
*Manish Mehta, MD, MPH*
- 5:43 – 5:48 **DEBATE:** The Case Against Treating CCSVI In MS Patients  
*Emmanuel M. Houdart, MD*
- 5:49 – 5:54 **DEBATE:** The Case For Treating CCSVI In MS Patients  
*Donald B. Reid, MD*
- 5:55 – 6:00 **DEBATE:** Venous Angioplasty For MS Is Voodoo Medicine  
*Mark H. Wholey, MD*
- 6:01 – 6:06 Panel Discussion

SESSION 22 (Grand Ballroom East, 3rd Floor)

**NEW OR BETTER TECHNIQUES FOR TREATING ENDOLEAKS AND OTHER EVAR AND TEVAR TOPICS (5-MINUTE TALKS)**

**Moderators:** *Timur P. Sarac, MD*  
*Luis A. Sanchez, MD*

- 6:06 – 6:11 How And When Is It Safe To Treat Type I Endoleaks After EVAR Non-Interventionally: A 13-Year Experience  
*James May, MD, MS*
- 6:12 – 6:17 How Embolization With Onyx Can Be An Effective Solution For Type I Endoleaks And Other Novel Solutions For Endoleaks After EVAR And TEVAR  
*Robert A. Morgan, MD*
- 6:18 – 6:23 Long-Term Follow-up Of Treated Type II Endoleaks Shows The Need For Close Surveillance And Frequent Re-Treatment  
*Timur P. Sarac, MD*
- 6:24 – 6:29 When Does Translumbar Glue Embolization Of Type II Endoleaks Work And When Does It Not: Tips And Tricks To Make It Effective  
*Neal S. Cayne, MD*
- 6:30 – 6:35 Tips And Tricks On How To Use Onyx In The Treatment Of Type I And Other Major Endoleaks  
*Thomas Larzon, MD*
- 6:36 – 6:41 The Anaconda Fenestrated Graft For Juxtarenal AAAs: Advantages, Limitations And 1-Year Registry Results  
*Nick J. Burfitt, BSc, MB, BChir, MRCS*

- 6:42 – 6:47** Interplay Between Anatomy And Indications (Pathology) In TEVAR Outcomes: Anatomic Complexity Drives Outcomes More Than Indications (Pathology)  
*Michael C. Stoner, MD*
- 6:48 – 6:55** Panel Discussion  
Conclusion of Program C.

PROGRAM D (SESSIONS 23 – 25)  
SHORT TOPICS RELEVANT TO OTHER PARTS OF THE PROGRAM ON LOWER EXTREMITY, THORACIC AND ABDOMINAL AORTA; MISCELLANEOUS AND CCSVI (GRAND BALLROOM WEST, 3RD FLOOR)

SESSION 23 (Grand Ballroom West, 3rd Floor)

**LOWER EXTREMITY ADDITIONAL TOPICS  
(4-MINUTE TALKS)**

**Moderators:** *Peter L. Faries, MD*  
*Ross Milner, MD*

- 1:00 – 1:04** Bringing Atherectomy To The Next Level: What Is Its Future  
*Jos C. van den Berg, MD, PhD*
- 1:05 – 1:09** Optical Coherence Tomography Of The Femoral Arteries: How Is It Done And What Is Its Value  
*Konstantinos Katsanos, MSc, MD, PhD*
- 1:10 – 1:14** Will Plaque Excision By Atherectomy Become The Treatment Of Choice For Popliteal Occlusive Disease: 1-Year Results From The DEFINITIVE LE Trial In 800 Patients  
*James F. McKinsey, MD*
- 1:15 – 1:19** The True Path Rotating Tip Device For Crossing Chronic Total Occlusion (CTO): How Does It Work And How Well Does It Work  
*John R. Laird, MD*
- 1:20 – 1:24** Relevance Of In-Stent Restenosis In Various Territories And Best Strategies For Treatment  
*John R. Laird, MD*
- 1:25 – 1:29** Laser Debulking And DEB For In-Stent Restenosis  
*Jos C. van den Berg, MD, PhD*
- 1:30 – 1:34** The Wildcat Catheter From Avinger In Crossing Difficult Aortoiliac Occlusions  
*Patrick E. Muck, MD*
- 1:35 – 1:39** Status Of Biodegradable Stents And Will They Work In The Periphery  
*Ron Waksman, MD*
- 1:40 – 1:44** Long-Term Results Of The ABSORB Trial Showing Benefits Of Biodegradable Coronary Stents: When Will We Know If They Will Work Elsewhere  
*Lewis B. Schwartz, MD*
- 1:45 – 1:49** Heparin Bonded Bypass Grafts, Stent-Grafts And Hybrid Grafts: Will They Make A Difference  
*Edward Y. Woo, MD*
- 1:50 – 1:54** Improved 3-Year Patency Of Heparin Bonded PTFE Grafts vs. PTFE Grafts Without Heparin  
*Russell H. Samson, MD, RVT*
- 1:55 – 1:59** Best Treatment For In-Stent Restenosis After Renal Artery Stenting  
*Robert A. Lookstein, MD*
- 2:00 – 2:04** Current Optimal Treatment For Long SFA Occlusions  
*Gary M. Ansel, MD*

- 2:05 – 2:09** Tips And Tricks For Successful Stent-Graft Treatment Of Popliteal Aneurysms  
*Irwin V. Mohan, MD*
- 2:10 – 2:14** Is Functional Popliteal Entrapment A Myth Or Reality  
*Cynthia K. Shortell, MD*
- 2:15 – 2:19** Prior Contralateral Major Amputation Predicts Worse Outcomes For Lower Extremity Revascularization In The Intact Limb  
*Andres Schanzer, MD*
- 2:20 – 2:24** Outcomes Of Single Segment Greater Saphenous Vein Graft Bypasses Are Better Than Those Of Alternative Autologous Vein Bypasses  
*Mauri J.A. Lepantalo, MD*
- 2:25 – 2:30** Panel Discussion

SESSION 24 (Grand Ballroom West, 3rd Floor)

## ADDITIONAL THORACIC AND ABDOMINAL AORTA TOPICS (4-MINUTE TALKS)

**Moderators:** *Jerry Goldstone, MD*  
*Gary Giangola, MD*

- 2:30 – 2:34** How Much Does Stent Design Matter For The Various Thoracic Aortic Pathologies: What Are The Unmet Needs  
*Michael D. Dake, MD*
- 2:35 – 2:39** Initial Experience With Ascending Aortic Endografting Using The Cook Endograft For Type A Dissection  
*Ralf R. Kolvenbach, MD*
- 2:40 – 2:44** Do Distal Bare Stents Have Value In The Treatment Of Type B Aortic Dissections  
*Burkhardt Zipfel, MD*
- 2:45 – 2:49** The Umbrella Aortic Arch Embolic Deflector: Does It Work: What Precautions Must Be Used And What Are Its Complications  
*Jeffrey P. Carpenter, MD*
- 2:50 – 2:54** New Classification System For Blunt Traumatic Aortic Injury To Guide In Conservative Or Endograft Treatment  
*Benjamin W. Starnes, MD*
- 2:55 – 2:59** Pros And Cons Of Early TEVAR With Extensive Coverage Of The Thoracic Aorta In Type B Aortic Dissections  
*Frank J. Criado, MD*
- 3:00 – 3:04** Diagrams Showing How To Make Sandwich Grafting Technique Work For Endovascular Treatment Of Thoracoabdominal Aneurysms  
*Armando C. Lobato, MD, PhD*
- 3:05 – 3:09** How Do Pressure Changes In The Excluded Aneurysm Sac Impact On Spinal Cord Ischemia After TEVAR  
*Björn Sonesson, MD, PhD*
- 3:10 – 3:14** How Do Outcomes From A Contemporary EVAR Registry (ENGAGE Registry) Differ From Those From Older Registries Like EUROSTAR: EVAR Is Getting Better  
*Marc R.H. van Sambeek, MD, PhD*
- 3:15 – 3:19** Decreasing Prevalence Of AAAs And Improving Short-Term And Long-Term Outcomes After EVAR In Sweden: What Are The Reasons For Them  
*Anders Wanhainen, MD, PhD*  
*Martin Björck, MD, PhD*



- 3:20 – 3:24** What Is The Annual Rupture Risk Of AAAs That Have Increasing Sac Size After EVAR But No Detectable Endoleak  
*Frans L. Moll, MD, PhD*
- 3:25 – 3:29** How Well Are The Complex (Fenestrated) Stent-Grafts Doing: UK Multicenter Study  
*S. Rao Vallabhaneni, MD*  
*Richard G. McWilliams, MD*
- 3:30 – 3:34** Optimal Current Treatment Of Infected AAAs: The Role Of Endografts  
*Kamphol Laohapensang, MD*
- 3:35 – 3:39** 1-Day Surgery For EVAR: Experience In >60 Patients  
*Zoran Rancic, MD, PhD*
- 3:40 – 3:44** How Well Do Endografts Do In The Treatment Of Aortoduodenal And Aortoesophageal Fistulas: How Can Survival Be Achieved  
*Bart E. Muhs, MD, PhD*
- 3:45 – 3:49** Tips And Tricks For Managing Difficult Iliac Arteries: Tug-Wire Technique To Overcome Tortuous Arteries And Balloon Slide Technique To Overcome Tiny Arteries  
*Thomas Larzon, MD*
- 3:50 – 3:59** Panel Discussion

SESSION 25 (Grand Ballroom West, 3rd Floor)

## MISCELLANEOUS IMPORTANT TOPICS (4-MINUTE TALKS)

*Moderators: Michael D. Dake, MD*

*Krassi Ivancev, MD, PhD*

### **The CCSVI Controversy In Multiple Sclerosis**

- 4:00 – 4:04** Creation Of A New IVC In A Patient Whose IVC Was Obliterated By Trauma: An Interventional Approach  
*Thomas A. Sos, MD*  
*Akhilesh Sista, MD*
- 4:05 – 4:09** What's Happening To The Randomized Trials Comparing Interventional Treatment To Placebo Treatment Of CCSVI In MS Patients  
*L. Nelson Hopkins, MD*
- 4:10 – 4:14** Incidence Of Internal Jugular Vein Stenosis In Thoracic Outlet Syndrome Patients: How Does This Relate To MS And CCSVI  
*Sam S. Ahn, MD, MBA*
- 4:15 – 4:19** Are Venous Anomalies In MS Patients Relevant Or Not  
*Alun H. Davies, MA, DM*
- 4:20 – 4:24** MS And CCSVI: Is The Relationship Real And Causally Important  
*Andrew N. Nicolaidis, MS*
- 4:25 – 4:29** Improving Contemporary Usage And Techniques Result In Better Patency With Nitinol SFA Stents (Smart Stents): Based On The STROLL Trial  
*Marc H. Glickman, MD*
- More About Abdominal And Thoracoabdominal Aneurysms**
- 4:30 – 4:34** New Classification Of Suprarenal Aneurysms Based On Location Of The Proximal Seal Zone: Correlates With Mortality And Morbidity Of Fenestrated And Branched Endografts  
*Krassi Ivancev, MD, PhD*

- 4:35 – 4:39** Is Medical Treatment To Slow Growth Of AAAs Effective: The STOPS Trial  
*Ronald L. Dalman, MD*
- 4:40 – 4:44** An Improved Method For Measuring AAA Size With EKG Gated 3D Ultrasound  
*Henrik Sillesen, MD, DMSc*
- 4:45 – 4:49** What Is The “Best” Treatment For Perigraft Hygroma With AAA Sac Enlargement After EVAR  
*John Blebea, MD, MBA*
- 4:50 – 4:54** Novel Method For Making Cannulation Of The Contralateral Limb Quick (<10 Seconds) And Easy During EVAR  
*Willem Wisselink, MD*
- 4:55 – 5:00** Panel Discussion

**Miscellaneous Topics**

*Moderators: John B. Chang, MD  
Elliot L. Chaikof, MD, PhD*

- 5:01 – 5:05** What Will Happen In The Effort To Separate Doctors From Industry: Predictions For The Future And What Is Happening In Massachusetts  
*Richard A. Baum, MD, MPA, MBA*
- 5:06 – 5:10** Principles Of “Best” Medical Treatment To Prevent Stroke  
*Anne L. Abbott, MD, PhD*
- 5:11 – 5:15** Managing Complications Of CAS  
*Klaus D. Mathias, MD*
- 5:16 – 5:20** Stroke Prevention And PFO Closure: Dead Or Alive  
*William A. Gray, MD*
- 5:21 – 5:25** Catheter Directed Thrombolysis As Treatment For Acute SMA Occlusion  
*Björn Sonesson, MD, PhD  
Martin Björck, MD, PhD  
Timothy A. Resch, MD, PhD*
- 5:26 – 5:30** Novel Endovascular Techniques For Treating Complex Iliac Aneurysmal Disease  
*Joseph L. Mills, MD  
Luis R. Leon, MD, RVT*
- 5:31 – 5:35** Laparoscopic Sutureless Aortobifemoral Bypass Using The Lachat Viabahn (VORTEC) Technique  
*Ralf R. Kolvenbach, MD*
- 5:36 – 5:40** How Do Long Bare Metal SFA Stents Perform: The DURABILITY Trial Clinical Outcomes, Treadmill Data, Objective Patency, And Routine Stent Fracture Assessment  
*Jon S. Matsumura, MD*
- 5:41 – 5:45** Homocysteine Is A Predictor Of Vascular Mortality: A Useful Marker Misunderstood  
*Afshin Assadian, MD*
- 5:46 – 5:51** Use Of Duplex Ultrasound To Facilitate Distal Tibial And Pedal Access To Treat Lower Extremity Occlusive Disease  
*Jihad A. Mustapha, MD*
- 5:51 – 6:00** Panel Discussion  
Conclusion of Program D.

## FRIDAY, NOVEMBER 16, 2012

6:00 A.M. General Registration – 2nd Floor Promenade  
Faculty Registration – Morgan Suite – 2nd Floor  
Continental Breakfast – Sutton Complex, 2nd Floor

### CONCURRENT FRIDAY MORNING PROGRAMS

#### PROGRAM E

(SESSIONS 26 – 29)

**New Techniques And Technologies (26); TAAAs And CHIMPS (27); Lower Extremity Ischemia – CLI (28); Medical Therapy And Medical Problems (29)**

6:40 A.M. – 12:00 P.M.

Grand Ballroom East, 3rd Floor

#### PROGRAM F

(SESSIONS 30 – 32)

**Miscellaneous Hot Topics Related To Lower Extremity And Aortic Disease (30); Venous Topics (31-32)**

6:45 A.M. – 12:00 P.M.

Grand Ballroom West, 3rd Floor

#### PROGRAM E (SESSIONS 26 – 29)

(GRAND BALLROOM EAST, 3RD FLOOR)

SESSION 26 (Grand Ballroom East, 3rd Floor)

### NEW TECHNIQUES AND NEW ENDOVASCULAR TECHNOLOGY (5-MINUTE TALKS)

*Moderators: Nicholas J. Morrissey, MD*

*Michael L. Marin, MD*

- |                    |  |
|--------------------|--|
| <b>6:40 – 6:45</b> | Use Of Microbubbles In The Treatment Of Acute Arterial Occlusions: How Do They Work And Do They Have Clinical Value<br><i>Willem Wisselink, MD</i>   |
| <b>6:46 – 6:51</b> | How The Art-Assist Pneumatic Compression Device Can Heal Ulcers From CLI And Relieve Rest Pain Noninvasively<br><i>Andrew N. Nicolaides, MS</i>  |
| <b>6:52 – 6:57</b> | A New Device For Topical Intermittent Compression And Hyper-Oxygenation To Improve Healing Of Infected Ischemic Foot Wounds<br><i>Magdiel Trinidad-Vasquez, MD</i>   |
| <b>6:58 – 7:03</b> | US Experience With The Flow Altered Short Transcervical CAS (FAST-CAS) With Flow Reversal: The Pivotal US Trial<br><i>Christopher J. Kwolek, MD</i><br><i>Richard P. Cambria, MD</i>   |
| <b>7:04 – 7:09</b> | Use Of Pressure Wire And CO <sub>2</sub> Angiography To Make Renal Artery Stenting Safer And Better<br><i>Kim J. Hodgson, MD</i>   |
| <b>7:10 – 7:15</b> | Predicting The Results Of Interventional Treatment Using Computational Analysis Of Blood Flow And Lesion Resistance From CT Data: Is FFR (Fractional Flow Reserve) Applicable To Peripheral Arteries As Well As Coronaries<br><i>Christopher K. Zarins, MD</i> |
| <b>7:16 – 7:21</b> | Progress In Techniques For Treating Below-Elbow Occlusions For Critical Hand Ischemia<br><i>Roberto Ferraresi, MD</i>  |

**7:22 – 7:27** Management Of Median Arcuate Ligament: A New Treatment Paradigm Including Laparoscopic Ligament Division  
*Bauer E. Sumpio, MD, PhD*

**7:28 – 7:33** Panel Discussion

SESSION 27 (Grand Ballroom East, 3rd Floor)

THORACOABDOMINAL AORTIC ANEURYSMS (TAAAs) AND TECHNIQUES TO REVASCULARIZE RENAL AND VISCERAL ARTERIES: CHIMNEYS, PERISCOPES AND SANDWICH GRAFTS (CHIMPS) (5-MINUTE TALKS)

**Moderators:** *Mark A. Adelman, MD*

*Frank J. Veith, MD*

**7:33 – 7:38** Why Parallel Grafts (CHIMPS) Work And Why A Double D Configuration Can Be Achieved With Elimination Of Gutter Endoleaks: Theoretical Considerations And How To Calculate The Right Sizes Of The Parallel Grafts  
*Jerry Matteo, MD*

**7:39 – 7:44** Long-Term Results After Chimney And Periscope Grafts Up To 7 Years: Are They Durable And How To Make Them Work Well For Pararenal And TAAAs  
*Mario Lachat, MD*  
*Dieter O. Mayer, MD*  
*Zoran Rancic, MD, PhD*

**7:45 – 7:50** Tips And Tricks For Getting Good Results With CHIMPS: When Fenestrated vs. When CHIMPS  
*Giovanni Torsello, MD*  
*Konstantinos Donas, MD*

**7:51 – 7:56** Long-Term Results After Sandwich Grafts For TAAAs: Where And When Do They Work And What Precautions Must Be Taken  
*Armando C. Lobato, MD, PhD*

**7:57 – 8:02** When Do Chimneys Work And When Don't They: Experience In >140 Patients  
*Thomas Larzon, MD*

**8:03 – 8:08** How To Repair Juxtarenal AAAs Safely And Effectively With Double Chimney Grafts: Technique And Results  
*Jason T. Lee, MD*  
*Ronald L. Dalman, MD*

**8:09 – 8:14** Branched And Fenestrated Grafts Are Best: But What TAAAs Can't Be Treated With Them And Can Sandwich Grafts Solve The Problem  
*Martin Malina, MD, PhD*

**8:15 – 8:20** **DEBATE:** CHIMPS Are Better And Cheaper Than Branched And Fenestrated Grafts For Treating Complex Aneurysms: CHIMPS Will Always Have A Major Role  
*Ralf R. Kolvenbach, MD*

**8:21 – 8:26** **DEBATE:** CHIMPS Are Inferior To Branched And Fenestrated Grafts For Complex Aneurysms: Long-Term Results Will Prove It: CHIMPS Will Have Only A Minor Role  
*Stephan Haulon, MD*

**8:27 – 8:32** Fenestrated And Branched Grafts For EVAR - How Well Have They Performed In France When Used Widely: Based On A National Audit: How These Results Compare With Those Of The Cardiatis Multilayer Stent For Similar Lesions  
*Jean-Pierre Becquemin, MD*

- 8:33 – 8:38** Role Of Endo, Open And Hybrid For TAAAs: When Is Open Repair Still Best  
*Michael J. Jacobs, MD*
- 8:39 – 8:44** Advanced Techniques For Performing EVAR With Difficult Anatomy: How To Avoid Brachial Access When Placing Chimney Or Periscope Grafts  
*David J. Minion, MD*
- 8:45 – 8:50** Off-The-Shelf Bifurcated EVAR Grafts For TAAAs: Does It Hold Up And How To Get A Double D Configuration With Seal Of Parallel Grafts  
*Karthikeshwar Kasirajan, MD*
- 8:51 – 8:56** Late Results With Physician Modified Stent Grafts For Pararenal And TAAAs: They Are As Good As Manufactured Grafts If . . .  
*Gustavo S. Oderich, MD*
- 8:57 – 9:02** A New Simpler Device For Juxtarenal AAAs  
*Marcelo Ferreira, MD*
- 9:03 – 9:20** Panel Discussion And Break  
Visit Exhibits and Pavilions (2nd and 3rd Floors)

SESSION 28 (Grand Ballroom East, 3rd Floor)

NEW DEVELOPMENTS IN THE TREATMENT  
OF LOWER EXTREMITY ISCHEMIA AND CLI  
(5-MINUTE TALKS)

Moderators: *Peter F. Lawrence, MD*

*Gregg S. Landis, MD*

- 9:20 – 9:25** Long-Term Results With Drug Eluting Balloons (DEBs): Summary Of The Available Trials With Up To 5-Year Results Of THUNDER, DEBATE And PACIFIER Trials With Paclitaxil Coatings  
*Gunnar Tepe, MD*
- 9:26 – 9:31** Long-Term (2-5 Years) Results Of SFA Stent Performance In 1000 Patients (A Belgium/Germany Registry Report)  
*Giovanni Torsello, MD*  
*Marc Bosiers, MD*
- 9:32 – 9:37** Promising 1-Year Patency Results For A New Prosthetic Graft (The Fusion Graft) For Above Knee Femoropopliteal Bypass: The PERFECTION Trial  
*Hans-Henning Eckstein, MD, PhD*  
*Afshin Assadian, MD*
- 9:38 – 9:43** Extremity Arterial Reconstruction In Children: Tips And Precautions  
*James C. Stanley, MD*  
*Jonathan Eliason, MD*
- 9:44 – 9:49** **DEBATE:** All CLI Patients Should Be Treated First By Endovascular Techniques  
*Gary M. Ansel, MD*
- 9:50 – 9:55** **DEBATE:** Some CLI Patients Should Be Treated By A Bypass First: Which Ones And Has Anything Changed In The Past Year  
*Michael S. Conte, MD*
- 9:56 – 10:01** Pros And Cons Of Bypass And PTA For Treatment Of Intermittent Claudication From SFA Occlusive Disease: Does Bypass Still Have A Role  
*Marc L. Schermerhorn, MD*
- 10:02 – 10:07** Endovascular Treatment Of Infrainguinal Bypass Failure And Impending Failure  
*Nicholas A. Diehm, MD*

- 10:08 – 10:13** 3-Year Findings Of A RCT Comparing Heparin Bonded And Standard PTFE Grafts In Infrainguinal Bypasses: Is The Benefit Of Heparin Bonding Durable  
*Jes S. Lindholt, MD*
- 10:14 – 10:19** Pedal Bypass To Deep Vein For CLI Can Be Effective Treatment For Extensive Ischemic Ulcer With No Suitable Outflow Artery: Tips And Tricks To Make It Work  
*Pramook Mutirangura, MD*
- 10:20 – 10:25** Nordic Pole Walking Can Improve Intermittent Claudication And Cardiac Fitness: What Is It And How Does It Work  
*Jonathan D. Beard, MD*
- 10:26 – 10:31** Will Stem Cell Treatment Work For CLI: The HARVEST Bone Marrow And Astrom IX MYELO CELL Trials  
*Richard J. Powell, MD*  
*William A. Marston, MD*
- 10:32 – 10:37** For Claudication From Aortoiliac Occlusive Disease, Supervised Exercise Produces More Relief Than Best Medical Therapy Or Stenting: Results Of The CLEVER Trial  
*Anthony J. Comerota, MD*
- 10:38 – 10:45** Panel Discussion

SESSION 29 (Grand Ballroom East, 3rd Floor)

ADVANCES IN MEDICAL THERAPY OR TREATMENT OF MEDICAL PROBLEMS OR COMPLICATIONS (5-MINUTE TALKS)

*Moderators: Anton N. Sidawy, MD, MPH*  
*Plinio Rossi, MD*

- 10:45 – 10:50** Platelet Activity And Optimizing Antiplatelet Treatment: The Next Frontier In Vascular Disease Management  
*Jeffrey S. Berger, MD, MS*
- 10:51 – 10:56** What's New With Endovascular Ablation Procedures For Atrial And Ventricular Arrhythmias  
*Larry Chinitz, MD*
- 10:57 – 11:02** Why Do Statins Decrease Preoperative And Periprocedural Risks: What Is Optimal Drug Dose And Timing  
*Christos D. Liapis, MD*
- 11:03 – 11:08** What's All This Hoopla About Statins And Mental Fogginess, Increased Blood Sugar And Diabetes: Should It Make A Difference In Statin Usage Or Is It A Witch Hunt  
*Don Poldermans, MD*
- 11:09 – 11:14** New Concepts Regarding The Importance Of Plaque Instability And Stability In Coronary And Vascular Disease: How Instability Should Be Determined And Treated  
*Gregg W. Stone, MD*
- 11:15 – 11:20** High Incidence Of Asymptomatic Elevated Troponin Levels (Troponin-Only MIs) After Open Vascular Surgery: What Does It Mean And What Can Be Done To Decrease It  
*Caron B. Rockman, MD*
- 11:21 – 11:26** **DEBATE:** Why We Should Not Stop Screening For Asymptomatic Carotid Stenosis  
*Glenn Jacobowitz, MD*

- 11:27 – 11:32** **DEBATE:** We Should Stop Screening For Asymptomatic Carotid Stenosis Even Though There Is A Substantial Incidence Of Silent Cerebral Events In These Patients: What Should We Do About It  
*Alun H. Davies, MA, DM*
- 11:33 – 11:38** What's New About The Role Of Cilostazol In Patients With Vascular Disease: What Are Some Of Its Newly Found Benefits  
*Anthony J. Comerota, MD*
- 11:39 – 11:44** **DEBATE:** Should Vascular Patients Be Taking A Polypill (Or Multiple Pills) For Secondary Prophylaxis: Yes, It Decreases Risk And Is Cost Effective  
*Don Poldermans, MD*
- 11:45 – 11:50** **DEBATE:** Should Vascular Patients Be Taking A Polypill (Or Multiple Pills) For Secondary Prophylaxis: No, It Is Too Dangerous; Better To Wait For Symptoms  
*Erich Minar, MD*
- 11:51 – 12:00** Panel Discussion
- 12:00 – 1:00** Lunch Break – Americas Hall 1, 3rd Floor  
Visit Exhibits and Pavilions (2nd and 3rd Floors)

PROGRAM F (SESSIONS 30 – 32)  
(GRAND BALLROOM WEST, 3RD FLOOR)

SESSION 30 (Grand Ballroom West, 3rd Floor)

NEW LATE BREAKING CONCEPTS, UPDATES  
AND MISCELLANEOUS HOT TOPICS RELATED  
TO LOWER EXTREMITY AND AORTIC DISEASE  
(5-MINUTE TALKS)

*Moderators: Patrick J. Lamparello, MD*  
*Richard M. Green, MD*

- 6:45 – 6:50** When Are Prosthetic Grafts As Good As Vein Grafts For Leg Bypasses: An Analysis From The VSGNE  
*Jack L. Cronenwett, MD*
- 6:51 – 6:56** Are There Patients With CLI That We Cannot Treat Endovascularly And Tips For Treating Flush Occlusions Endovascularly  
*George H. Meier III, MD*
- 6:57 – 7:02** What Is The Current Role For Atherectomy: Do These Newer Devices Work Better Than Older Models: Which Device Is Best  
*Lawrence A. Garcia, MD*
- 7:03 – 7:08** Advantages Of Bioabsorbable Drug Eluting Stent In Iliac And Femoral Lesions: The ESPRIT Trial  
*Johannes Lammer, MD*
- 7:09 – 7:14** A New Composite (Goretex/Metal) Self Expanding SFA Stent: Potential Advantages And Early Results  
*John R. Laird, MD*
- 7:15 – 7:20** Propaten PTFE Graft: Is It As Good As Autologous Vein  
*Richard F. Neville, MD*
- 7:21 – 7:26** Use Of The Lachat VORTEC Sutureless Clamless Anastomotic Technique With An Endograft Connector To Simplify Femoropopliteal Bypasses  
*Gabriel Szendro, MD*
- 7:27 – 7:32** Creation Of A Sutureless Anastomosis With An Over-The-Wire Implantation Of A Gore Hybrid Vascular Graft For Various Bypasses And A-V Access: An Extension Of The Lachat VORTEC Technique  
*Edward Y. Woo, MD*



7:33 – 7:38 What Percent Of Diabetics With CLI Can Undergo Revascularization: With PTA: With Bypass  
*Giacomo Clerici, MD*

7:39 – 7:44 Use Of OCT (Optical Coherent Tomography) For Crossing Chronic Total Occlusions  
*Tony S. Das, MD*

7:45 – 7:53 Panel Discussion

**Moderators:** *Roger M. Greenhalgh, MD*  
*Ali F. AbuRahma, MD*

### Aortic Topics

7:53 – 7:58 A New One-Shot Aortic Occlusion Balloon  
*Benjamin W. Starnes, MD*

7:59 – 8:04 3D Imaging And Robotic Catheter Navigation: How Can They Work Together To Facilitate Complex Aortic Procedures  
*Alan B. Lumsden, MD*

8:05 – 8:10 **DEBATE:** The Long-Term Results Of Open Repair Are Better Than Those Of EVAR In Most Patients  
*Wilhelm Sandmann, MD*

8:11 – 8:16 **DEBATE:** The Long-Term Results Of EVAR Are Better Than Those Of Open Repair: The EVAR I Late Results Have Been Misinterpreted In The NEJM Article  
*Juan C. Parodi, MD*

8:17 – 8:22 EVAR I Results Are Not In Accord With Contemporary Practice Results: EVAR Is Better Than Open Repair With Superior Outcomes  
*Ian Loftus, MD*  
*Matt M. Thompson, MD*

8:23 – 8:28 **DEBATE:** IFUs For EVAR Should Not Be Stretched: The Results Don't Justify It  
*Andres Schanzer, MD*

8:29 – 8:34 **DEBATE:** A Propensity Matched Comparison Of EVAR And Open Repair Shows That EVAR Is Superior Even When IFUs Are Stretched Because Of Imperfect Anatomy  
*William D. Jordan, Jr., MD*

8:35 – 8:40 **DEBATE:** Bare Stents Are The Best Treatment For Most Adult Aortic Coarctations: Why Is This So  
*Christoph A. Nienaber, MD, PhD*

8:41 – 8:46 **DEBATE:** Covered Stents Are The Best Treatment For Most Adult Aortic Coarctations  
*Dietmar H. Koschyk, MD*

8:47 – 8:52 Update On Use Of Atrium Advanta V12 Balloon Expandable Stent-Grafts For Treatment Of Aortic Coarctation: Advantages, Limitations And Precautions: From The OUS Trial  
*Elchanan Bruckheimer, MBBS*

8:53 – 8:58 Are Fenestrated And Branched Endografts A Better Option For Treating Chronic Type B Aortic Dissections And Associated Aneurysms  
*Stephan Haulon, MD*

8:59 – 9:08 Panel Discussion

9:09 – 9:25 Break – Visit Exhibits And Pavilions (2nd and 3rd Floors)

SESSION 31 (Grand Ballroom West, 3rd Floor)

**PROGRESS IN THE TREATMENT OF VENOUS DISEASE – PART 1A (5-MINUTE TALKS)**

*Moderators: Mark H. Meissner, MD*

*Lowell S. Kabnick, MD*

- 9:25 – 9:30** Current Treatment For Giant A-V Fistulas Of Renal And Visceral Vessels: Is Endovascular Treatment Feasible And How  
*Peter Gloviczki, MD*
- 9:31 – 9:36** Current Optimal Surgical Treatment Of Phlegmasia Cerulea Dolens  
*Kamphol Laohapensang, MD*
- 9:37 – 9:42** Incidence Of Upper Extremity DVT After Central Venous Catheter Placement: Implications And What To Do About It  
*Gregory L. Moneta, MD*
- 9:43 – 9:48** Superior Vena Cava Aneurysm: Natural History And Indications For Treatment  
*J. Leonel Villavicencio, MD*
- 9:49 – 9:54** Venous Aneurysms: What Are They And Are They Dangerous: Rupture Risk Has Been Exaggerated And Not All Need To Be Repaired  
*Jerry Goldstone, MD*
- 9:55 – 10:00** Tips And Tricks For Iliac Vein And IVC Stenting: Access, Crossing Lesions, Stent Choice And Size  
*Ramesh K. Tripathi, MD*
- 10:01 – 10:06** Current Status Of Stenting For Iliac Vein And Caval Disease: Indications, Which Stent Is Best, Precautions  
*Seshadri Raju, MD*  
*Peter Neglen, MD, PhD*
- 10:07 – 10:12** Iliac Vein Stenting For Advanced Chronic Venous Disease: When Will It Improve Symptoms And When Will It Not: Is IVUS Essential  
*Anil P. Hingorani, MD*  
*Enrico Ascher, MD*
- 10:13 – 10:18** Connecticut Experience With Wall Stenting For Iliac Vein Disease Under IVUS Control: Raju And Neglen Are Right  
*Paul J. Gagne, MD*
- 10:19 – 10:24** Is There Any Treatment Available For Patients Who Already Have Postthrombotic Syndrome?  
*Jose I. Almeida, MD, RVT*
- 10:25 – 10:35** Panel Discussion

SESSION 32 (Grand Ballroom West, 3rd Floor)

**PROGRESS IN THE TREATMENT OF VENOUS DISEASE – PART 1B (5-MINUTE TALKS)**

*Moderators: Bo G. Eklof, MD, PhD*

*Jose I. Almeida, MD, RVT*

- 10:35 – 10:40** Current Optimal Management Of Paget-Schroetter's Syndrome  
*George H. Meier III, MD*
- 10:41 – 10:46** Upper Extremity DVT: Early Lysis And Rib Resection Improves Outcomes  
*Ian Loftus, MD*
- 10:47 – 10:52** 1-Stage Aggressive Treatment Of Paget-Schroetter Syndrome: What Does It Involve And Why Is It Best  
*Karl A. Illig, MD*

10:53 – 10:58	Robotic First Rib Resection For Paget-Schroetter Syndrome: Why Is It Better <i>Richard F. Neville, MD</i>
10:59 – 11:04	Current Results Of Thrombolysis Followed By Immediate Thoracic Outlet Decompression For Paget-Schroetter Syndrome <i>Enrique Criado, MD</i>
11:05 – 11:10	How To Treat Central Vein Stenoses: A Lesion Specific Approach <i>Ziv J. Haskal, MD</i>
11:11 – 11:16	<b>DEBATE:</b> The Postthrombotic Syndrome Is Underestimated In Iliofemoral DVT: It Is Decreased By Endovascular Treatment And Benefit Correlates With Elimination Of Clot <i>Anthony J. Comerota, MD</i>
11:17 – 11:22	<b>DEBATE:</b> The Postthrombotic Syndrome Is Not So Bad: Endovascular Treatment Is Rarely Indicated <i>Gregory L. Moneta, MD</i>
11:23 – 11:28	Current Status Of The Optimal Treatment For Managing Calf Vein DVT Based On The Latest Meta-analysis And Systematic Review <i>Elna M. Masuda, MD</i>
11:29 – 11:34	Long-Term Results After Lysis For DVT <i>Rabih A. Chaer, MD</i> <i>Michel S. Makaroun, MD</i>
11:35 – 11:40	The New Antithrombotic Drugs: When Should They Be Used And When Shouldn't They <i>Russell H. Samson, MD, RVT</i>
11:41 – 11:46	Treatment Of Central Venous Lesions With Covered Stents: Indications, Techniques And Results <i>Jean Bismuth, MD</i>
11:47 – 12:00	Panel Discussion
12:00 – 1:00	Lunch Break – Americas Hall 1, 3rd Floor Visit Exhibits and Pavilions (2nd and 3rd Floors)

## CONCURRENT FRIDAY AFTERNOON SESSIONS

### PROGRAM G

(SESSIONS 33 – 34)

**TAAAs And Multilayered Stents (33); Progress In Vascular Imaging (34)**

1:00 P.M. – 3:30 P.M.

Grand Ballroom East, 3rd Floor

### PROGRAM H

(SESSIONS 35 – 36)

**Abdominal And Thoracic Aneurysms (35); AAAs/TAAAs, CHIMPS (36)**

1:00 P.M. – 3:30 P.M.

Grand Ballroom West, 3rd Floor

### PROGRAM I

(SESSIONS 37 – 38: ARTERIAL)

**Ruptured AAAs (37); Aortic Transection And Dissections (38)**

3:30 P.M. – 6:00 P.M.

Grand Ballroom East, 3rd Floor

### PROGRAM J

(SESSIONS 39 – 40: VENOUS)

**Venous Hot Topics (39); Endotreatment Of Pulmonary Emboli (40)**

3:30 P.M. – 6:00 P.M.

Grand Ballroom West, 3rd Floor

SESSION 33 (Grand Ballroom East, 3rd Floor)

MORE ON TEVAR, TAAAs AND PARARENAL ANEURYSMS, THEIR TREATMENT AND THE MULTILAYER STENT (5-MINUTE TALKS)

Moderators: *Ronald M. Fairman, MD*

*Mark A. Adelman, MD*

**1:00 – 1:05** Fenestrated And Branched Grafts To Repair Visceral Patch Aneurysms After Open TAAA Repair  
*James H. Black III, MD*

**1:06 – 1:11** Risk Stratification And Prediction Of Long-Term Success After TEVAR For Thoracic Aneurysm Based On The MOTHER Registry  
*Ian Loftus, MD*  
*Matt M. Thompson, MD*

**Topics Related To The Multilayer Flow Modulating Stent**

**1:12 – 1:17** Value Of The Cardiatis Multilayer Flow Modulating Stent For The Treatment Of Non-Aortic Aneurysms  
*Antonella Ruffino, MD*  
*Claudio Rabbia, MD, PhD*

**1:18 – 1:23** Does The Multilayer Stent Exclude And Fix Aortic Aneurysms: Summary Of The French Experience  
*Claude D. Vaislic, MD*

**1:24 – 1:29** Results Of Treatment Of Complex TAAAs With The Multilayer Uncovered Stent: The Moroccan Experience  
*Amira Benjelloun, MD*

**1:30 – 1:35** With TAAAs, Does The Multilayer Stent Promote Aneurysm Sac Shrinkage And Prevent Rupture: What Is The Evidence  
*Sherif Sultan, MD*  
*Niamh Hynes, MD*

**1:36 – 1:41** Chinese Experience With The Multilayer Stent For Treatment Of Complex Aortic Aneurysms  
*Qingsheng Lu, MD*  
*Zaiping Jing, MD*

**1:42 – 1:47** Is The Multilayer Stent An Effective Treatment For Arch Aneurysms And TAAAs: What Happens To Sac Pressure And Aneurysm Size After Treatment: Is Rupture Prevented  
*Thomas Larzon, MD*

**1:48 – 1:53** **DEBATE:** The Multilayer Stent Is Going To Work For The Treatment Of Complex Aortic Aneurysms: Theoretical Considerations And Clinical Experience  
*Edward B. Diethrich, MD*

**1:54 – 1:59** **DEBATE:** The Multilayer Stent Is Not Going To Work For The Treatment Of Complex Aneurysms: Theoretical Considerations  
*Luigi Inglese, MD*

**2:00 – 2:05** Another Skeptical View On The Value Of The Multilayer Stent For The Treatment Of Complex Aortic Aneurysms  
*Piergiorgio Cao, MD*

**2:06 – 2:12** Panel Discussion

SESSION 34 (Grand Ballroom East, 3rd Floor)

PROGRESS IN VASCULAR IMAGING AND  
GUIDANCE (5-MINUTE TALKS)

Moderators: *Brian R. Hopkinson, ChM*  
*John H. Furtek, BS, RT(r)*

- 2:12 – 2:17** Can Noninvasive Imaging Keep Up With Evolving Technology  
*Allan W. Reid, FRCR*
- 2:18 – 2:23** All The Things You Can Learn From Transcranial Doppler (TCD) That Most Of Us Don't Know About: A New Look At TCD  
*Zsolt Garami, MD*
- 2:24 – 2:29** The Value Of Hansen Magellen Robotic Assisted Catheter Manipulation For Complex Aortic Endografting  
*Nicholas J.W. Cheshire, MD*
- 2:30 – 2:35** Little Known Tips And Tricks For Making CO<sub>2</sub> Angiography Work Better Than Commonly Thought  
*Kyung Cho, MD*
- 2:36 – 2:41** What Is The Best Prophylaxis For Contrast Induced Nephropathy (CIN) In Patients Undergoing Angiography: Does Saline Beat Bicarbonate And Mucomist: What Is The Best Regimen  
*Barry T. Katzen, MD*
- 2:42 – 2:47** IVUS Guided EVAR And TEVAR Is Feasible And Effective: Tips And Tricks  
*Martin R. Back, MD*
- 2:48 – 2:53** Vascular Imaging Strategies For Patients With Renal Insufficiency Requiring MR Imaging  
*Barry Stein, MD*
- 2:54 – 2:59** Noninvasive Quantification Of Pressure Gradients And Flow With 4D Flow Sensitive MRI: What Unique Information Can This Technique Tell Us In Aortic Dissection  
*Jon S. Matsumura, MD*  
*Chris Francois, FRCS*
- 3:00 – 3:05** Encouraging 1-Year Clinical Results With A Spiral Flow Prosthetic Graft In Lower Extremity Bypasses  
*Nick Shaper, FRCS*
- 3:06 – 3:30** Panel Discussion And Break  
Visit Exhibits and Pavilions (2nd and 3rd Floors)

PROGRAM H (SESSIONS 35 – 36)  
(GRAND BALLROOM WEST, 3RD FLOOR)

SESSION 35 (Grand Ballroom West, 3rd Floor)

MORE NEW CONCEPTS ABOUT AAAs, EVAR  
AND OTHER TREATMENTS OF AORTIC DISEASE  
(5-MINUTE TALKS)

Moderators: *Timur P. Sarac, MD*  
*Palma M. Shaw, MD*

- 1:00 – 1:05** Fenestrated Cuff-Extender For Treatment Of Migrated Infrarenal Endografts: Midterm Results  
*Krassi Ivancev, MD, PhD*
- 1:06 – 1:11** Do Most AAA Patients Survive Long Enough To Benefit From Aneurysm Repair  
*Jack L. Cronenwett, MD*
- 1:12 – 1:17** New Findings Regarding Treatment Of Infection Following AAA Repair By EVAR Or Open Surgery  
*Laura Capoccia, MD, PhD*

- 1:18 – 1:23** Strategies To Minimize Blood Loss During EVAR Procedures And Why It Is Important  
*Claude Mialhe, MD*
- 1:24 – 1:29** Off-The-Shelf Device For Pararenal Aneurysms  
*Mark A. Farber, MD*
- 1:30 – 1:35** How To Place Bifurcated Devices In Patients With Iliac Occlusions  
*David J. Minion, MD*  
*Mark A. Farber, MD*  
*William D. Jordan, Jr., MD*
- 1:36 – 1:41** When Should Thoracic Endografts Be Ballooned: How Can Ballooning Be Harmful  
*Jean Bismuth, MD*
- 1:42 – 1:47** Endovascular Treatment Of Various Pathologic Lesions Involving The Aortic Arch  
*Dittmar Boeckler, MD*
- 1:48 – 1:53** Endovascular Treatment Of Aortic Arch Lesions: What Device Can Be Used To Treat Which Lesions  
*Nicola Mangialardi, MD*
- 1:54 – 1:59** Use Of Motor Evoked Potential And Leaving A Side Branch Open With Delayed Closure To Prevent Spinal Cord Ischemia During Endovascular TAAA Repair  
*Geert W.H. Schurink, MD, PhD*  
*Michael J. Jacobs, MD*
- 2:00 – 2:05** Experience With Endostapling (Aptus HeliFX) For Endograft Fixation: It Really Works With Short Necks In The Abdominal And Thoracic Aorta  
*Burkhardt Zipfel, MD*
- 2:06 – 2:12** Panel Discussion And Break

SESSION 36 (Grand Ballroom West, 3rd Floor)

**MORE NEW CONCEPTS AND DATA RELATED TO THORACOABDOMINAL AND PARARENAL ANEURYSMS AND CHIMPS (5-MINUTE TALKS)**

**Moderators:** *Timothy A.M. Chuter, DM*

*Keith D. Calligaro, MD*

- 2:12 – 2:17** Intrasac Flow Characteristics Of An Enlarging AAA With A Type II Endoleak After EVAR: What To Do To Fix It  
*Julio A. Rodriguez-Lopez, MD*
- 2:18 – 2:23** How To Eliminate Gutter Leakage After Chimney And Periscope Grafts: Based On An In Vitro Measurement Study  
*Jan D. Blankensteijn, MD*
- 2:24 – 2:29** Endograft Type And Sizing For Successful Parallel Endografts Or CHIMPS  
*David J. Minion, MD*
- 2:30 – 2:35** I Have Been Converted: For Some TAAAs Open Surgery Should Be Replaced By Endovascular Treatments: When Should It Not Be  
*Joseph S. Coselli, MD*
- 2:36 – 2:41** Is There A Difference In Outcome Between Double And Triple Or Quadruple Fenestrated Grafts: Findings Of The GLOBALSTAR Registry  
*Peter L. Harris, MD*  
*S. Rao Vallabhaneni, MD*
- 2:42 – 2:47** CHIMPS: How And When Do They Work And When Don't They  
*Ralf R. Kolvenbach, MD*

- 2:48 – 2:53** **DEBATE:** CHIMPS Will Have A Major Role Even When Fenestrated And Branched Grafts Are Widely Available  
*Frank J. Criado, MD*
- 2:54 – 2:59** **DEBATE:** The Current State-Of-The-Art In Fenestrated And Branched Endografts: When Widely Available They Will And Should Eliminate The Need For CHIMPS  
*Roy K. Greenberg, MD*  
*Tara M. Mastracci, MD*
- 3:00 – 3:05** What Can Be Expected From Chimney Grafts In Para And Juxtarenal AAAs: Are They As Good As Some Say  
*Jean-Pierre Becquemini, MD*
- 3:06 – 3:11** Tips And Tricks To Make Chimney Grafts Work For Juxta And Pararenal AAAs  
*Alan M. Graham, MD*
- 3:12 – 3:17** A Simple Technique Of Limb Perfusion To Prevent Limb Ischemia From Complex Lengthy EVARs  
*Timothy A. Resch, MD, PhD*
- 3:18 – 3:30** Panel Discussion And Break  
Visit Exhibits and Pavilions (2nd and 3rd Floors)

PROGRAM I (SESSIONS 37 – 38: ARTERIAL)  
(GRAND BALLROOM EAST, 3RD FLOOR)

SESSION 37 (Grand Ballroom East, 3rd Floor)

UPDATES, CONTROVERSIES AND NEW CONCEPTS  
IN THE TREATMENT OF RUPTURED AAAs  
(5-MINUTES TALKS)

**Moderators:** *Nicholas J.W. Cheshire, MD*  
*Frank J. Veith, MD*

- 3:30 – 3:35** Update On Dutch Ruptured AAA RCT Of EVAR vs. Open Repair  
*Willem Wisselink, MD*
- 3:36 – 3:41** **DEBATE:** We Still Need Level I Evidence To Support Use Of EVAR With Ruptured AAAs: Update On The Findings Of The UK IMPROVE Trial  
*Janet T. Powell, MD, PhD*
- 3:42 – 3:47** **DEBATE:** We Don't Need A RCT: All Ruptured AAAs Can Be Treated Endovascularly And The Results Are Excellent  
*Dieter O. Mayer, MD*  
*Thomas Larzon, MD*
- 3:48 – 3:53** EVAR Must Be Part Of Any Ruptured AAA Program: Based On A Consensus Panel Finding  
*Marc R.H.M. van Sambeek, MD, PhD*
- 3:54 – 3:59** Why Open Repair Is Still The Gold Standard For Treatment Of Ruptured AAA  
*Jürg Schmidli, MD*
- 4:00 – 4:05** **DEBATE:** With Ruptured AAAs The Turn-Down Rate For Treatment Is Key  
*Ian Loftus, MD*  
*Matt M. Thompson, MD*
- 4:06 – 4:11** **DEBATE:** Technique Not Turn-Down Rate Is Important: Tips And Tricks To Get Good Outcomes From EVAR For AAAs Short-Term And Long-Term  
*Mario Lachat, MD*  
*Dieter O. Mayer, MD*  
*Frank J. Veith, MD*



- 4:12 – 4:17 Are Outcomes Of Treatment For Ruptured AAAs Better If A Specialist Vascular Surgeon Is Caring For The Patient Than Some Other Specialist (General Surgeon Or Cardiac Surgeon)  
*Florian Dick, MD*
- 4:18 – 4:23 Prophylactic Use Of Polypropylene Mesh Overlay In Open Repair For AAAs Decreases The 30% Incisional Hernia Rate  
*Sebastian E. Debus, MD, PhD*
- 4:24 – 4:29 Is The Transfer Of RAAA Patients To Specialized Centers From Smaller Hospitals Worthwhile: A UK Delphi Consensus Study Shows It Is Under Certain Conditions  
*Robert J. Hinchliffe, MD*
- 4:30 – 4:35 Estimating AAA Rupture Risk: It Is Not Just Diameter: Quantitation Of Other Easily Determinable Factors  
*Jesper Swedenborg, MD, PhD*
- 4:36 – 4:41 Degree Of Calcification As A Prognostic Factor For Rupture With AAAs  
*Clark J. Zeebregts, MD, PhD*
- 4:42 – 4:52 Panel Discussion

SESSION 38 (Grand Ballroom East, 3rd Floor)

## NEW LATE BREAKING CONCEPTS AND RESULTS IN AORTIC TRAUMATIC TRANSECTION AND TYPE B AORTIC DISSECTIONS (5-MINUTE TALKS)

**Moderators:** *Edward B. Diethrich, MD*  
*Keith D. Calligaro, MD*

- 4:53 – 4:58 Endovascular Treatment Of Traumatic Aortic Transection In Young Patients: Problems Encountered And How To Solve Them  
*Giorgio M. Biasi, MD*
- 4:59 – 5:04 Impact Of Proper Device Sizing In Traumatic Aortic Injuries: How Should Graft Size Be Determined  
*Mark A. Farber, MD*
- 5:05 – 5:10 10-Year Follow-up Of TEVAR For Traumatic Aortic Transection: How Durable Is The Procedure And The Endograft  
*Karl H. Orend, MD*
- 5:11 – 5:16 What Happens After TEVAR For Traumatic Aortic Transection  
*Mark Conrad, MD*  
*Richard P. Cambria, MD*
- 5:17 – 5:22 A New More Accurate Method For Measuring False Lumen Thrombosis (FLT<sub>x</sub>) In Type B Aortic Dissections: 3D MRI With Blood Pool Contrast Agent Obviates Overestimation Of FLT<sub>x</sub>  
*Rachel Clough, MD, PhD*  
*Peter R. Taylor, MA, MChir*
- 5:23 – 5:28 Computational Flow Analysis In Type B Aortic Dissections: Lessons Learned  
*Zhuo Cheng, PhD*
- 5:29 – 5:34 Volumetric Assessment Of Type B Aortic Dissections On CT Imaging: Can We Predict Which Patients Will Have False Lumen Thrombosis  
*Frank R. Arko, MD*

- 5:35 – 5:40** **DEBATE:** Fenestrated And Branched Endograft Solutions Are Better Than A Petticoat Graft (Proximal Covered Stent And Distal Bare Stent) For Complicated Type B Aortic Dissections  
*Eric L.G. Verhoeven, MD, PhD*
- 5:41 – 5:46** **DEBATE:** Fenestrated And Branched Endografts Are Not Better Than A Petticoat Graft For Complicated Type B Dissections – Even If Chronic  
*Germano Melissano, MD*  
*Roberto Chiesa, MD*
- 5:47 – 5:52** Update From The STABLE Trial: The Petticoat Concept Of A Proximal Covered Stent And A Distal Bare Stent Is Supported By Follow-up To 2 Years: When Is The Distal Bare Stent Indicated  
*Joseph V. Lombardi, MD*
- 5:52 – 6:00** Panel Discussion

PROGRAM J (SESSIONS 39 – 40: VENOUS)  
(GRAND BALLROOM WEST, 3RD FLOOR)

SESSION 39 (Grand Ballroom West, 3rd Floor)

MORE PROGRESS IN THE TREATMENT OF  
VENOUS DISEASE - PART IIA (5-MINUTE TALKS)

**Moderators:** *Joann Lohr, MD*

*J. Leonel Villavicencio, MD*

- 3:30 – 3:35** Neurological Complications Of Sclerotherapy For Varicose Veins: Incidence And Prevention  
*Alun H. Davies, MA, DM*
- 3:36 – 3:41** Radiofrequency Treatment Of Perforating Veins For Recalcitrant Venous Ulcers: How To Do It And Does It Help  
*Peter F. Lawrence, MD*
- 3:42 – 3:47** Local Hyperbaric O<sub>2</sub> To Heal Refractory Venous Ulcers  
*Sherif Sultan, MD*  
*Niamh Hynes, MD*
- 3:48 – 3:53** Update And Clinical Experience With Biodegradable IVC Filter  
*David Rosenthal, MD*
- 3:54 – 3:59** Why Routine IVC Filters Should Be Placed In Patients With Massive And Submassive PEs  
*Gary M. Ansel, MD*
- 4:00 – 4:05** Novel Technique For Removing Retrievable IVC Filter When Its Hook Cannot Be Snared  
*Benjamin M. Jackson, MD*  
*Ronald M. Fairman, MD*
- 4:06 – 4:11** Non-Lipid Lowering Effects Of Crestor On DVT  
*Thomas W. Wakefield, MD*
- 4:12 – 4:17** Improved Bioprosthetic Valve For Treatment Of Deep Venous Insufficiency: Value Of Autologous Endothelial Cells  
*Dusan Pavcnik, MD, PhD*
- 4:18 – 4:23** Superficial Vein Thrombophlebitis: To Treat Or Not To Treat  
*Joseph D. Raffetto, MD*
- 4:24 – 4:29** How To Decrease The Risk Of Anastomotic Stenosis And Occlusion In Bypasses For Takayasu's Disease  
*Byung-Boong Lee, MD*
- 4:30 – 4:40** Panel Discussion

SESSION 40 (Grand Ballroom West, 3rd Floor)  
PROGRESS IN ENDOVASCULAR TREATMENT  
OF MASSIVE AND SUBMASSIVE PULMONARY  
EMBOLI AND OTHER HOT VENOUS TOPICS –  
PART IIB (5-MINUTE TALKS)

**Moderators:** *Bo G. Eklof, MD, PhD*  
*Nicholas J. Morrissey, MD*

- 4:40 – 4:45** Ultrasound-Assisted Thrombolysis For Massive And Submassive PE  
*Nils Kucher, MD*  
*Iris Baumgartner, MD*
- 4:46 – 4:51** New Findings In The Use Of Ultrasound Accelerated Thrombolysis In The Treatment Of Submassive PEs  
*Tod E. Engelhardt, MD*
- 4:52 – 4:57** Endovascular Treatment Of Massive PE: How And When Should It Be Done  
*David L. Gillespie, MD*
- 4:58 – 5:03** Update On VORTEX Suction Thrombectomy Catheter To Treat PEs And IVC Thrombi: Clinical Experience, Safety And Precautions  
*Christopher J. Kwolek, MD*
- 5:04 – 5:09** Does Treatment With The Trellis Mechanical Thrombectomy Device Decrease The Postthrombotic Syndrome After 2 Years: Results Of The ISOL-8 Multicenter Trial  
*Paul J. Gagne, MD*
- 5:10 – 5:15** Value Of Ultrasound Accelerated Thrombolysis In DVT: When Is It Indicated  
*Cees H.A. Wittens, MD, PhD*
- 5:16 – 5:21** Update On New Anticoagulants For Venous Thromboembolism Prophylaxis And Treatment  
*Thomas W. Wakefield, MD*
- 5:22 – 5:27** Should Venous IVUS Be Used In All Serious Leg Swelling Patients To Detect Lymphedema From Venous Disease So It Can Be Treated By Stenting  
*Seshadri Raju, MD*
- 5:28 – 5:33** New Technique For Deep Venous Valve Reconstruction  
*Ramesh K. Tripathi, MD*
- 5:34 – 5:39** The Relationship Between Venous And Arterial Disease: Is Venous Disease Really An Arterial Problem  
*Seshadri Raju, MD*
- 5:40 – 5:45** How Should We Manage The Unretrievable Retrievable IVC Filter  
*Werner Lang, MD*
- 5:46 – 6:00** Panel Discussion

## SATURDAY, NOVEMBER 17, 2012

6:00 A.M. General Registration – 2nd Floor Promenade  
Faculty Registration – Morgan Suite – 2nd Floor  
Continental Breakfast – Sutton Complex, 2nd Floor

SESSION 41 (Grand Ballroom East, 3rd Floor)

NEW DEVELOPMENTS IN AAAs AND THEIR  
TREATMENT (5-MINUTE TALKS)

Moderators: *K. Wayne Johnston, MD*  
*Dhiraj M. Shah, MD*

- 6:40 – 6:45 Impact Of A Redeployable AAA Stent-Graft (Gore Excluder C-3) To Improve Proximal Seal In Difficult Anatomy: Does It Make A Difference  
*Eric L.G. Verhoeven, MD, PhD*
- 6:46 – 6:51 Is A Thick Layer Of Neck Thrombus A Contraindication For EVAR  
*Hence J.M. Verhagen, MD, PhD*
- 6:52 – 6:57 Final Result Of The PEVAR Trial: A RCT Comparing Percutaneous With Open Access For EVAR  
*Zvonimir Krajcer, MD*
- 6:58 – 7:03 Open And Endovascular Repair Of Para-Anastomotic Aneurysms  
*Germano Melissano, MD*  
*Roberto Chiesa, MD*
- 7:04 – 7:09 Transecting The Left Renal Vein For Aortic Surgery: Why, How, When, Where And Why Not  
*Afshin Assadian, MD*
- 7:10 – 7:15 **DEBATE:** Laparoscopic Vascular Surgery Should Be Growing And Vascular Surgeons Should Learn It And Do It  
*Joseph S. Giglia, MD*
- 7:16 – 7:21 **DEBATE:** Why Laparoscopic And Robotic Aortic Surgery Are Losing Their Appeal And Will Not Become Widespread  
*Willem Wisselink, MD*
- 7:22 – 7:27 The Rise And Fall Of AAAs: The Decreasing Incidence Of AAAs: What Is The Cause  
*Frank A. Lederle, MD*
- 7:28 – 7:33 Is EVAR Indicated And Justified For Inflammatory AAAs: When Is It Not  
*Samuel R. Money, MD, MBA*
- 7:34 – 7:39 Is There A Role For AUI Endografts For EVAR In 2012: Should One Be In Your Endovascular Tool Box For Emergency Use  
*Thomas L. Forbes, MD*
- 7:40 – 7:45 Feasibility Of EVAR For Infected AAAs: When Does It Work And When Doesn't It  
*Chung-Dann Kan, MD, PhD*
- 7:46 – 7:51 How To Manage Infected Aortic Endografts  
*Edward Y. Woo, MD*  
*Ronald M. Fairman, MD*
- 7:52 – 7:57 Long-Term Quality Of Life Data After EVAR And Open Repair: From The DREAM Trial: Open Repair Wins And Why  
*Jan D. Blankensteijn, MD*

**7:58 – 8:03** The Vital Focus On EVAR vs. Open Repair At 15 Years: Is The Game Changing  
*Roger M. Greenhalgh, MD*

**8:04 – 8:12** Panel Discussion

SESSION 42 (Grand Ballroom East, 3rd Floor)

## NEW DEVELOPMENTS IN TREATMENT OF THE AORTA AND ITS BRANCHES (5-MINUTE TALKS)

*Moderators: Ross Milner, MD*

*Jean-Pierre Becquemin, MD*

**8:13 – 8:18** How Does Transcatheter Intra-arterial Denervation Work: Who Should Be Treated And Who Should Not: Why Is the Artery Not Injured And Are There Dangers From The Treatment  
*Dierk Scheinert, MD*

**8:19 – 8:24** What Are The Secondary Benefits – Other Than Reducing Blood Pressure – To Renal Denervation: When Will This Treatment Be Available In The US And How Long Will All Benefits Last  
*Michael R. Jaff, DO*  
*Ido Weinberg, MD, MSc*

**8:25 – 8:30** Status Of Renal PTA And Stenting After ASTRAL And CORAL: What's New In The Field  
*Thomas A. Sos, MD*

**8:31 – 8:36** Frontiers In Renal Artery Stenting: What Does The Future Hold: Better Stents, Better Balloons, Etc.  
*Max Amor, MD*

**8:37 – 8:42** Long-Term Outcomes Of PTA And/Or Stenting For Renal Fibromuscular Hyperplasia: What Is The Best Treatment  
*Albeir Y. Mousa, MD*  
*Ali F. AbuRahma, MD*

**8:43 – 8:48** Best Method To Assess SMA Stents: How Does Duplex Correlate With Pressure Measurements, CTA And Clinical Outcomes  
*Timothy A. Resch, MD, PhD*

**8:49 – 8:54** Early And Late Outcomes Of PTA And Stenting Of Celiac And SMA Occlusive Disease: Advantages, Limitations And Results Up To 10 Years  
*Ali F. AbuRahma, MD*

**8:55 – 9:00** Can The Results Of Mesenteric Revascularization Improve With Covered Stents And Distal Protection Devices  
*Gustavo S. Oderich, MD*

**9:01 – 9:06** How To Treat Isolated SMA Dissections: When Medical vs. Interventional vs. Surgical Therapy  
*Young Wook Kim, MD*

**9:07 – 9:13** Panel Discussion

*Moderators: Michael B. Silva, Jr., MD*

*James C. Stanley, MD*

**9:14 – 9:19** **DEBATE:** Treatment Of Mid-Aortic Syndrome In Young Adults: Interventional Treatment Is Indicated In Some  
*Ramesh K. Tripathi, MD*

**9:20 – 9:25** **DEBATE:** Interventional Therapy Is Never Indicated For Mid-Aortic Syndrome At Any Age: Open Surgery Is Best  
*Wilhelm Sandmann, MD*

- 9:26 – 9:31** When Are Reentry Devices And Covered Stents Needed For Iliac Occlusive Lesions  
*Jörn O. Balzer, MD, PhD*
- 9:32 – 9:37** **DEBATE:** Open Surgery Is Still Needed For Some Aortoiliac Occlusive Lesions: Which Ones  
*Michel S. Makaroun, MD*
- 9:38 – 9:43** **DEBATE:** Endovascular Treatment Is Best For All Aortoiliac Occlusive Lesions  
*Martin Malina, MD, PhD*
- 9:44 – 9:49** Endovascular Treatment Of Juxtarenal Aortic Occlusions Should Always Be Possible Using Chimneys And Other Adjuncts  
*Sonia Ronchey, MD*  
*Nicola Mangialardi, MD*
- 9:50 – 9:55** Use Of Advanta V12 Covered Stents For Endovascular Reconstruction Of The Aortoiliac Bifurcation To Treat Complex Occlusive Lesions  
*Michel M.P. Reijnen, MD, PhD*  
*Peter C.J. Goverde, MD*
- 9:56 –10:20** Panel Discussion And Break  
Visit Exhibits and Pavilions (2nd and 3rd Floors)

SESSION 43 (Grand Ballroom East, 3rd Floor)

**FUTURE ISSUES REGARDING HEALTH CARE;  
CONFLICT OF INTEREST; GOVERNMENT;  
INDUSTRY RELATIONS; BUSINESS OF MEDICINE;  
PRACTICE COSTS; AND REIMBURSEMENTS  
(5-MINUTE TALKS)**

**Moderators:** *Julius H. Jacobson II, MD*  
*Kenneth Ouriel, MD, MBA*

- 10:20–10:25** How To Succeed With A Physician Founded Medical Device Company: The Embrella Device As An Example  
*Jeffrey P. Carpenter, MD*
- 10:26 – 10:31** Physician Focused Tort Reform By Limiting Expert MD Testimony Fees And Taking Other Accountability Measures: We Physicians Can Stop Medical Malpractice Abuses No Matter What The Damned Lawyers Do  
*O. William Brown, MD, JD*
- 10:32 –10:37** What Will Health Care Reform Mean To Practicing Vascular Surgeons, Hospitals And Surgical Services  
*Robert M. Zwolak, MD, PhD*
- 10:38 –10:43** What's Happening With Vascular Reimbursement  
*Sean P. Roddy, MD*
- 10:44 –10:49** What Is A Vascular Surgeon Worth To A Health Care System: A Look At The Finances Surrounding Vascular Care  
*Michael C. Stoner, MD*
- 10:50 –10:55** Disclosure And Conflict Of Interest: Have We Gone Too Far Or Not Far Enough  
*Timothy M. Sullivan, MD*
- 10:56 –11:01** Current Status Of The Physician-Industry Relationship: Update On What The Government, Our Medical Schools And Our Hospitals Are Doing To Separate Doctors From Industry  
*Barry T. Katzen, MD*
- 11:02 – 11:07** Physician-Industry Relationships And Conflict Of Interest: No Conflict – No Interest – No Success: How To Deal With The Pitfalls And Problems – Legally And Ethically  
*Scott L. Stevens, MD*

- 11:08 – 11:13** What Is Happening With The Physician-Industry Relationship In Community Practice  
*Russell H. Samson, MD, RVT*
- 11:14 – 11:19** Cost Analysis Of Carotid Interventions In Asymptomatic Patients  
*Alun H. Davies, MA, DM*
- 11:20 – 11:25** Do Outcomes Of CEA Differ Among Different Specialties – Vascular Surgeons, General Surgeons And Neurosurgeons: Who Does The Best  
*Carlos H. Timaran, MD*  
*Ali F. AbuRahma, MD*
- 11:26 – 11:31** What Has And Will The FDA Do To Medical Innovation In The US: An Innovator's Perspective: Will Things Improve  
*Edward B. Diethrich, MD*
- 11:32 – 11:37** Panel Discussion
- 11:38 – 11:43** Poster Award Presentation

SESSION 44 (Grand Ballroom East, 3rd Floor)

### TRIBUTE TO OUR MILITARY (5-MINUTE TALKS)

**Moderators:** *Norman M. Rich, MD*

*Todd E. Rasmussen, MD*

- 11:43 – 11:48** From The Front Lines To The Ivory Tower And Back: How Advances At Walter Reed National Military Medical Center Are Used At The Front  
*Robert Craig, DO*
- 11:49 – 11:54** A Brief History Of The Tourniquet In Battle  
*Norman M. Rich, MD*
- 11:55 – 12:00** Vascular Surgery Lessons Learned After A Decade Of War In Iraq And Afghanistan  
*Todd E. Rasmussen, MD*

SESSION 45 (Grand Ballroom East, 3rd Floor)

### LUNCHEON SESSION: NEW OR IMPROVED ENDOVASCULAR DEVICES (5-MINUTE TALKS)

**Moderators:** *Eric L.G. Verhoeven, MD, PhD*

*Juan C. Parodi, MD*

- 12:01 – 12:06** Recent Improvements In The Cook Zenith AAA Endograft: How Do They Make A Difference  
*Tara M. Mastracci, MD*
- 12:07 – 12:12** Update On Advantages And Limitations Of The Lombard AORFIX Graft: When Will It Be Approved In The US  
*Brian R. Hopkinson, ChM*  
*Mark F. Fillinger, MD*
- 12:13 – 12:18** Worldwide Experience With The Aptus HELIFX Endostaples: Can They Fix Endoleaks And Prevent Aortic Neck Enlargement And Migration  
*David H. Deaton, MD*
- 12:19 – 12:24** Update On The NELLIX Device For EVAR: Advantages And Limitations  
*Jeffrey P. Carpenter, MD*
- 12:25 – 12:30** Off-The-Shelf Fenestrated VENTANA Device For Renal Revascularization With Juxta And Pararenal AAAs: Clinical Update And Will In Situ Fenestration Be Possible With Newer Multilayer Stretchable PTFE Endograft Coverings  
*Daniel G. Clair, MD*

- 12:31 – 12:36** Advantages And Limitations Of The INCRAFT From Cordis: 1-Year Clinical Data From The INNOVATION Trial  
*Dierk Scheinert, MD*
- 12:37 – 12:42** Description And Clinical Experience With The Anaconda Fenestrated Endograft For Juxta And Pararenal AAAs  
*Clark J. Zeebregts, MD, PhD*
- 12:43 – 12:48** Worldwide Mid-Term Results (2-Year) Of The Endurant Endograft For AAAs: Does It Expand The Proportion Of Patients Who Can Undergo EVAR Safely And Effectively  
*Dittmar Boeckler, MD*  
*Michel S. Makaroun, MD*
- 12:49 – 12:54** Current Status Of The Bolton TREOVANCE AAA Endograft: Advantages And Limitations  
*Edward Y. Woo, MD*  
*Ronald M. Fairman, MD*
- 12:55 – 1:00** Panel Discussion

SESSION 46 (Grand Ballroom East, 3rd Floor)

**ISSUES RELATED TO TRAINING, CERTIFICATION, SIMULATION, SPECIALTIES, GUIDELINES AND RANDOMIZED CONTROLLED TRIALS (5-MINUTE TALKS)**

**Moderators:** *Mario Lachat, MD*  
*Karl A. Illig, MD*

- 1:00 – 1:05** What's New With Maintenance Of Certification (MOC) Requirements For Vascular Surgeons  
*Anton N. Sidawy, MD, MPH*
- 1:06 – 1:11** Recent Developments In The Evolution Of Vascular Training And Training Programs: Current Status Of The 0:5 Programs And Number Of Vascular Surgery Applicants And Spots  
*Karl A. Illig, MD*
- 1:12 – 1:17** How To Redesign Workflow To Improve Patient Care And Resident Training  
*Richard J. Powell, MD*
- 1:18 – 1:23** Advantages Of Case Specific Simulator Rehearsal With Endovascular Procedures  
*Isabelle Van Herzeele, MD, PhD*
- 1:24 – 1:29** What's New And Better With The Pontresina Vascular Surgery Simulator Course For Trainees  
*Hans-Henning Eckstein, MD, PhD*
- 1:30 – 1:35** Guidelines Are Outdated By The Time They Are Published: Some Examples  
*Janet T. Powell, MD, PhD*
- 1:36 – 1:41** Randomized Controlled Trials Can Be Misleading Even When Reported In Leading Journals: Guidelines Based On These Trials Can Also Be Misleading  
*Frank J. Veith, MD*
- 1:42 – 1:47** Advantages And Limitations Of The OVATION Endograft (TriVascular) For AAA Repair: Based On The 1-Year Global Experience  
*Manish Mehta, MD, MPH*
- 1:48 – 1:53** Cost Effectiveness Of Different Treatment Strategies For CLI With Gangrene Or Necrosis  
*Michael Belkin, MD*
- 1:54 – 2:00** Panel Discussion



SESSION 47 (Grand Ballroom East, 3rd Floor)

**MORE ABOUT HEALTH CARE REFORM, FDA,  
ETHICS, COSTS, STANDARDS AND GUIDELINES  
(5-MINUTE TALKS)**

*Moderators: Kim J. Hodgson, MD*

*Thomas F. O'Donnell, Jr., MD*

- 2:00 – 2:05** Impact Of Obamacare On Medicine In The US  
*Clifford J. Buckley, MD*  
*Shirley Buckley, RN*
- 2:06 – 2:11** Why The Canadian Health Care System Works Better Than Obamacare Will  
*Dheeraj Rajan, MD*
- 2:12 – 2:17** How Should Aviation Training Serve As A Model For Educating Vascular Surgeons  
*John F. Eidt, MD*
- 2:18 – 2:23** What Has And Will The FDA Do To Medical Innovation In The US: An FDA Consultant's Perspective: Will Things Improve  
*Thomas J. Fogarty, MD*
- 2:24 – 2:29** What Is The FDA Doing To Help The US Device Industry Be More Competitive: Is It Working  
*Dorothy B. Abel, BSBME*  
*Kenneth J. Cavanaugh, Jr., PhD*
- 2:30 – 2:35** How To Get A Physician-Sponsored IDE: Tips And Tricks  
*Benjamin W. Starnes, MD*
- 2:36 – 2:41** Advantages Of The ESVS (European Society for Vascular Surgery) Guidelines For Vascular Surgery: Some Examples As To Why They Are Better Than US Guidelines  
*Jean-Baptiste Ricco, MD, PhD*
- 2:42 – 2:47** Current State Of The SVS Vascular Quality Initiative: Is It Growing And Is It Working  
*Jack L. Cronenwett, MD*
- 2:48 – 2:53** Vascular Quality Initiatives: A Dark Cloud Behind A Silver Lining: What Are Some Of The Problems And How Can They Be Resolved  
*Scott L. Stevens, MD*
- 2:54 – 3:10** Panel Discussion And Break  
Visit Pavilions and Exhibits (2nd and 3rd Floors)

**CONCURRENT SATURDAY AFTERNOON PROGRAMS**

PROGRAM K (SESSIONS 48 – 49)

3:10 P.M. – 6:10 P.M.

**Vascular Disease; Medical Treatment; Complications, New Techniques And Concepts**

Grand Ballroom East, 3rd Floor

PROGRAM L (SESSIONS 50 – 51)

3:10 P.M. – 6:10 P.M.

**Updates, New Technology And Concepts; More New Concepts, Updates And Techniques**

Grand Ballroom West, 3rd Floor

PROGRAM K (SESSIONS 48 – 49)  
(GRAND BALLROOM EAST, 3RD FLOOR)

SESSION 48 (Grand Ballroom East, 3rd Floor)

VASCULAR DISEASE NATURAL HISTORY; MEDICAL  
TREATMENT; PREVENTION AND TREATMENT OF  
COMPLICATIONS (5-MINUTE TALKS)

*Moderators: Vivian Gahtan, MD*

*Peter F. Lawrence, MD*

- 3:10 – 3:15** New Developments In Anticoagulant Drugs For Vascular Patients  
*Anthony J. Comerota, MD*
- 3:16 – 3:21** Decision Making Tool For Determining Which CLI Treatment Is Best: Open vs. Endovascular  
*Darren B. Schneider, MD*
- 3:22 – 3:27** Ongoing Developments In Drug Treatment Of Vascular Disease: Do HDL Raising Drugs Show Promise For Preventing Strokes And MIs  
*Michael R. Jaff, DO*  
*Ron Waksman, MD*  
*Ido Weinberg, MD, MSc*
- 3:28 – 3:33** Role Of Optimal Medical Treatment In Stroke Prevention: Does It Really Work  
*Michael R. Jaff, DO*  
*Ido Weinberg, MD, MSc*
- 3:34 – 3:39** **DEBATE:** The Truth About Statin Toxicity: Has It Been Overplayed By The FDA And By The Media  
*Bruce A. Perler, MD, MBA*
- 3:40 – 3:45** **DEBATE:** Statins May Be Harmful And Should Be Used Less  
*Sherif Sultan, MD*
- 3:46 – 3:51** How Should We Interpret The JUPITER Trial Showing The Value Of Statins: Has JUPITER Gotten A Bum Rap  
*Russell H. Samson, MD, RVT*
- 3:52 – 3:57** Do L-Arginine Supplements Help Vascular Patients: When And How Should They Be Given  
*Vikram S. Kashyap, MD*
- 3:58 – 4:03** Carotid Glomectomy Is A Good Treatment For Syncopal Vasophlegia: How To Do It  
*Erik E. Debing, MD, PhD*
- 4:04 – 4:09** Interactive Telephone Program To Allow Daily Monitoring Of Vascular Patients  
*John (Jeb) W. Hallett, MD*
- 4:10 – 4:15** Comparative Performance Of Rotorex And Angiojet For Clot Removal From Lower Extremity Arteries: Advantages And Limitations Of Each  
*Hermann Steinkamp, MD*
- 4:16 – 4:21** A New Device To Treat Resistant Hypertension By Carotid Baroreceptor Stimulation: The BAROSTIM Trial  
*Fred A. Weaver, MD*
- 4:22 – 4:29** Routine Use Of Ultrasound Guidance And Micropuncture Makes Endovascular Access Safer: How To Do It  
*Peter A. Schneider, MD*
- 4:30 – 4:37** Panel Discussion

SESSION 49 (Grand Ballroom East, 3rd Floor)

**NEW TECHNIQUES; NEW CONCEPTS**  
**(5-MINUTE TALKS)**

**Moderators: Michael B. Silva, Jr., MD**  
**John J. Ricotta, MD**

- 4:38 – 4:43** Laparoscopic Treatment Of The Arcuate Ligament Syndrome: Technique, Indications And Results  
*Yves Alimi, MD*
- 4:44 – 4:49** Is There Still A Place For Unilateral And Even Bilateral Hypogastric Embolization In 2012: How Safe Is It  
*Dieter Raithel, MD, PhD*
- 4:50 – 4:55** Hypogastric Preservation In Patients With Common Iliac Aneurysms Using Off-The-Shelf Devices  
*Karthikeshwar Kasirajan, MD*
- 4:56 – 5:01** Unusual Causes Of Upper Extremity Arterial Occlusive Disease  
*Kenneth J. Cherry, MD*
- 5:02 – 5:07** Catheter Directed Prostaglandins Are An Effective Treatment For CLI: As The Sole Treatment Or As An Adjunct To Other Endovascular Therapy  
*Oscar L. Ojeda, MD*  
*Marcelo Patero, MD*
- 5:08 – 5:13** Carotid Interventions For Acute Stroke: When Are They Worthwhile And When Are They Not  
*R. Clement Darling III, MD*
- 5:14 – 5:19** How Do Pericardial Patches Heal And Why Are They Likely To Resist Infection  
*Alan Dardik, MD, PhD*
- 5:20 – 5:25** Imaging And Endovascular Techniques In The Removal Of Transvenous Pacer And ICD Leads  
*Ali Khojenezhad, MD, PhD*
- 5:26 – 5:31** Update On Treatment Of Infected Abdominal And Thoracic Endografts: Is It A Solvable Or Hopeless Problem And Is Non-Excisional Treatment Ever Successful  
*Peter R. Taylor, MA, MChir*
- 5:32 – 5:37** Non-Atherosclerotic Aortic Thrombosis: Causes, Diagnosis And Treatment  
*Cynthia K. Shortell, MD*
- 5:38 – 5:43** The SoloPath Expandable Introducer Sheath: How Does It Work And How Can It Be Helpful In EVAR Procedures  
*Jeffrey P. Carpenter, MD*
- 5:44 – 5:49** Management Of Infected CEA Patches: A 10-Year Experience  
*Ali F. AbuRahma, MD*
- 5:50 – 5:55** In Situ Fenestration For Left Subclavian Revascularization During TEVAR Is Safer And Better Than Carotid Subclavian Bypass: How To Do It  
*Frank R. Arko, MD*
- 5:56 – 6:01** Bell Bottom Iliac Limbs Have A Downside  
*Gustavo S. Oderich, MD*
- 6:02 – 6:10** Panel Discussion

PROGRAM L (SESSIONS 50 – 51)  
(GRAND BALLROOM WEST, 3RD FLOOR)

SESSION 50 (Grand Ballroom West, 3rd Floor)  
UPDATES, NEW TECHNOLOGY, NEW CONCEPTS  
(5-MINUTE TALKS)

**Moderators:** *Herbert Dardik, MD*  
*Dhiraj M. Shah, MD*

- 3:10 – 3:15** Current Optimal Treatment Of Atrial Fibrillation In Vascular Patients  
*Jeffrey S. Berger, MD, MS*
- 3:16 – 3:21** Prevalence Of Carotid Stenosis Varies According To Race: Highest In Caucasians And Native Americans  
*Caron B. Rockman, MD*
- 3:22 – 3:27** Ehrlos-Danlos Patients Can Have Endovascular Procedures Performed Safely: What Precautions Are Needed  
*James H. Black III, MD*
- 3:28 – 3:33** Bioabsorbable Scaffolds (REMEDY Stent), DEBs And DESs, In The SFA: What Is Their Future  
*Sumaira Macdonald, MBChB, PhD*
- 3:34 – 3:39** Can The Achilles Tendon Be Excised Safely And With Minimal Disability To Treat Bad Heel Wounds And Plantar Pedal Ulcers  
*Wayne Caputo, DPM*  
*Clifford M. Sales, MD, MBA*
- 3:40 – 3:45** Drug Eluting Balloon Evaluation For Lower Limb Multilevel Treatment – DEBELLUM Trial: 1-Year Results  
*Fabrizio Fanelli, MD*  
*Plinio Rossi, MD*
- 3:46 – 3:51** Bypasses For Hand Digital Ischemia: What Is Their Role And Their Results  
*R. Clement Darling III, MD*
- 3:52 – 3:57** Retrohepatic Balloon Occlusion Of The IVC For Trauma And Renal Cell Cancer: How To Do It With Current Technology  
*Joseph S. Giglia, MD*
- 3:58 – 4:03** Carotid-To-Axillary Bypass Is Useful As A Debranching Technique And Easier And Less Risky Than Carotid-To-Subclavian Bypass  
*Frank J. Criado, MD*
- 4:04 – 4:09** VIATORR Covered Stent For Early TIPS And Its Effect On Hepatic Encephalopathy And Ascites: Other New Horizons In TIPS  
*Ziv J. Haskal, MD*
- 4:10 – 4:15** Which Post EVAR Patients Need Minimal Follow-up Surveillance: What Should That Consist Of  
*Hence J.M. Verhagen, MD, PhD*
- 4:16 – 4:21** Angioslide Angioplasty Balloon With Embolic Capture (Proteus Device): When To Use It And Evidence Of Effectiveness  
*Peter C.J. Goverde, MD*
- 4:22 – 4:27** Outcomes Of Endovascular Treatment Of Lower Extremity Lesions Are Worse In Young Patients (<50)  
*Rabih A. Chaer, MD*
- 4:28 – 4:34** Panel Discussion

SESSION 51 (Grand Ballroom West, 3rd Floor)

**MORE NEW CONCEPTS, UPDATES AND NEW  
TECHNIQUES (5-MINUTE TALKS)**

*Moderators: Enrico Ascher, MD*

*Palma M. Shaw, MD*

- 4:34 – 4:39** Limitations Of A Large Palmaz Stent For Treating Type I Endoleaks  
*Tilo Koelbel, MD, PhD*
- 4:40 – 4:45** Recent Volumetric Analyses Of Post EVAR AAA Sac Behavior: Is Sac Enlargement Still A Concern  
*Mark F. Fillinger, MD*
- 4:46 – 4:51** 2-Stage Treatment For Aorto-Enteric Fistulas Following Aortic Reconstruction: A New Better Way  
*Gioacchino Coppi, MD*
- 4:52 – 4:57** Siena Score For Evaluating AAAs Suitability For EVAR: What Is It And How Does It Help  
*Francesco Setacci, MD*
- 4:58 – 5:03** Advantages And Early Results Of The ALTURA Ultra Low Profile AAA Endograft  
*Albrecht H. Krämer, MD*
- 5:04 – 5:09** Fascial Suture To Close Large Percutaneous Sheath Insertion Sites Cheaply And Effectively (The Larzon Technique): Tips And Tricks  
*Timothy A. Resch, MD, PhD*
- 5:10 – 5:15** Cost Per Day Of Patency In Endo vs. Open Lower Extremity Revascularization Procedures  
*Manish Mehta, MD, MPH*
- 5:16 – 5:21** Current Status Of Silver Impregnated Grafts To Treat Aortic Infection: Are We In The US Being Denied A Valuable Treatment Adjunct  
*Max Zegelman, MD, PhD*
- 5:22 – 5:27** Antibiotic Drug Delivery Implants Facilitates Treatment Of Some Infected Vascular Prosthetic Grafts  
*Dennis F. Bandyk, MD*
- 5:28 – 5:33** DW-MRI Based Evidence That Interruption Of Flow Embolic Protection With The MoMa Device Is Effective During CAS (The DESERVE Trial)  
*Giancarlo Biamino, MD, PhD*
- 5:34 – 5:39** Optimal Current Use Of Anticoagulants And Antiplatelet Drugs In Patients Undergoing CEA  
*Timothy M. Sullivan, MD*
- 5:40 – 5:45** Causes And Implications Of 30-Day Readmissions After AAA Repair: Endo And Open  
*K. Craig Kent, MD*
- 5:46 – 5:51** BASIL Survival Prediction Model In Patients With CLI: Validation And Comparison With PREVENT And FINNUVASC Scores  
*Robert J. Hinchliffe, MD*
- 5:52 – 5:57** Importance Of Pressure Gradients In Assessing Hemodynamic Significant Vascular Lesions: A Simple Method To Measure Them  
*Ali Amin, MD, RVT*
- 5:58 – 6:05** Panel Discussion

**SUNDAY, NOVEMBER 18, 2012**

**6:30 A.M. Continental Breakfast**  
**Grand Ballroom Foyer, 3rd Floor**

SESSION 52 (Grand Ballroom East, 3rd Floor)

**NEW DEVELOPMENTS AND UPDATES: EARLY CAROTID TREATMENT, TAKAYASU'S DISEASE AND TECHNIQUES FOR EVALUATING CAROTID PLAQUES NONINVASIVELY (5-MINUTE TALKS)**

*Moderators: Frans L. Moll, MD, PhD*

*Lucien D. Castellani, MD*

- 6:40 – 6:45** Techniques For Crossing Over Difficult Aortic Bifurcations To Deliver Contralateral Interventions  
*Scott L. Stevens, MD*
- 6:46 – 6:51** Outcomes Of Urgent CEA In Symptomatic Patients: Are They Acceptable  
*Gabriel Szendro, MD*
- 6:52 – 6:57** Can The 14-Day Treatment Target For Symptomatic Carotid Disease Patients Be Met: Are The Outcomes Acceptable  
*A. Ross Naylor, MD*
- 6:58 – 7:03** Results Of Urgent CEA In Symptomatic Patients: Can CAS Results Equal Them  
*Laura Capoccia, MD, PhD*
- 7:04 – 7:09** Is Early Intervention For Symptomatic Carotid Stenosis As Good For CAS As CEA  
*Sumaira Macdonald, MBChB, PhD*
- 7:10 – 7:15** How To Treat Cerebral Ischemia From Takayasu's Disease  
*Zhong Gao Wang, MD*
- 7:16 – 7:21** When Is Endovascular Treatment Of Takayasu's With PTA, Stent Or Stent-Graft Indicated And Justified By The Results  
*Xiaoyun Luo, MD*
- 7:22 – 7:27** Pros And Cons Of Open Bypass Surgery And Endovascular Procedures With Supra-aortic Lesions Due To Takayasu's Disease  
*Young Wook Kim, MD*
- 7:28 – 7:33** Panel Discussion

*Moderators: Thomas S. Riles, MD*

*Allan L. Brook, MD*

- 7:34 – 7:39** **DEBATE:** Key Findings In The SAMMPRIS Trial Showing Intracranial Stents To Be Less Effective Than Best Medical Treatment In Preventing Strokes  
*Colin P. Derdeyn, MD*
- 7:40 – 7:45** **DEBATE:** SAMMPRIS Had Major Flaws And Reached Misleading Conclusions  
*L. Nelson Hopkins, MD*
- 7:46 – 7:51** How To Make Endovascular Treatment Of Acute Strokes Work Best In 2012: Why Have Some Of The Trials To Date Been Negative  
*Don Frei, MD*
- 7:52 – 7:57** Relationship Between IVUS-Characterized Plaque Morphology And Embolic Potential – Spontaneously And During CAS  
*Wei Zhou, MD*

- 7:58 – 8:03** Dynamic Contrast Ultrasonography To Stratify Risk In Asymptomatic Carotid Stenosis Patients: How Does It Work  
*Alun H. Davies, MA, DM*
- 8:04 – 8:09** 3-D Ultrasound And MRI Assessment Of Carotid Plaques: Do Statins Result In Plaque Shrinkage And Other Beneficial Changes  
*Henrik Sillesen, MD, DMSc*
- 8:10 – 8:15** How To Identify Asymptomatic Carotid Stenoses At High Risk For Causing A Stroke: Searching For The Holy Grail  
*Jose Fernandes e Fernandes, MD, PhD*
- 8:16 – 8:21** Impact Of Contralateral Carotid Occlusion (CCO) On The Comparative Results Of CEA And CAS For Treatment Of Carotid Stenosis: CAS Is Equivalent To CEA With CCO  
*Joseph J. Ricotta II, MD, MS*  
*Gilbert R. Upchurch, MD*  
*Gregg S. Landis, MD*
- 8:22 – 8:28** Panel Discussion

SESSION 53 (Grand Ballroom East, 3rd Floor)

**MORE ABOUT THORACIC AND ABDOMINAL ANEURYSMS: MANAGEMENT OF COMPLICATIONS (5-MINUTE TALKS)**

**Moderators:** *K. Wayne Johnston, MD*  
*Larry H. Hollier, MD*

- 8:28 – 8:33** Current Treatment Of Para-Anastomotic Aneurysms After Open Surgery: They Are Easily Fixed Endovascularly  
*Arno von Ristow, MD*
- 8:34 – 8:39** Endovascular Treatment Of Late Complications From Open AAA Surgery  
*Giancarlo Mansueto, MD*
- 8:40 – 8:45** MRI Is Better Than CTA For Finding Endoleaks And Identifying Their Type: Why  
*Frans L. Moll, MD, PhD*
- 8:46 – 8:51** EVAR Of Primary Infected (Mycotic) AAAs: Results Are Surprisingly Good But Not Universally So  
*Anders Wanhainen, MD, PhD*  
*Martin Björck, MD, PhD*
- 8:52 – 8:57** Techniques For Safe Open Conversion After Failed EVAR And TEVAR  
*Germano Melissano, MD*  
*Roberto Chiesa, MD*
- 8:58 – 9:03** Complications Of TEVAR For Treatment Of Traumatic Aortic Injury And How They Can Be Prevented And Treated  
*Ali Azizzadeh, MD*
- 9:04 – 9:09** How To Treat AAAs With <14 mm Distal Necks Safely With Bifurcated Endografts  
*Gustavo S. Oderich, MD*
- 9:10 – 9:15** Cost Effectiveness Of EVAR And Open Repair In The OVER Trial After 2 Years  
*Frank A. Lederle, MD*
- 9:16 – 9:21** Thoracic Aortic Aneurysm In Patients With AAAs: How Common Are They And When Should They Be Looked For With Chest CT  
*Rabih A. Chaer, MD*  
*Michel S. Makaroun, MD*

- 9:22 – 9:27** When Are Custom Made Endografts Needed To Treat Thoracic Aneurysm Pathology  
*Vicente Riambau, MD, PhD*
- 9:28 – 9:33** Limb Component Issues With Newer Lower Profile EVAR Devices: Will They Be A Problem  
*Jean-Pierre Becquemin, MD*
- 9:34 – 9:39** Are There Still Indications For Hybrid Procedures For TAAA Repair  
*Ian Loftus, MD*
- 9:40 – 9:45** Present Status Of Intrasac Pressure Measurements With The CardioMEMS Device In The Management Of Endoleaks: Is It Worthwhile And Worth The Cost  
*Ross Milner, MD*
- 9:46 – 10:00** Panel Discussion And Break  
Coffee available in the Grand Ballroom Foyer, 3rd Floor.

SESSION 54 (Grand Ballroom East, 3rd Floor)

**NEW DEVELOPMENTS IN CAROTID DISEASE TREATMENT AND ASSOCIATED ISSUES (5-MINUTE TALKS)**

**Moderators:** *Hans-Henning Eckstein, MD, PhD*  
*John B. Chang, MD*

- 10:00–10:05** A Postop MI With Only A Rise In Troponin Is A Bad Thing But No Worse A Predictor Of Late Mortality Than Any Stroke: Based On CREST And Other Data  
*Wesley S. Moore, MD*
- 10:06 – 10:11** When Do Clot Retrieval Devices Work In Acute Stroke: Which Device Is Best – Merci, Penumbra, Solitaire: The SWIFT Trial  
*L. Nelson Hopkins, MD*
- 10:12 – 10:17** CAS Or CEA For Carotid Disease Associated With Neck Radiation: Which Treatment Is Best  
*Frans L. Moll, MD, PhD*
- 10:18 – 10:23** Value And Limitation Of Optical Coherence Tomography To Evaluate Carotid Plaques And Luminal Anatomy Before And After CAS  
*Carlo Setacci, MD*
- 10:24 – 10:29** Simplified Safe Technique For Carotid Subclavian Bypass  
*Ramon Berguer, MD, PhD*  
*Mark D. Morasch, MD*
- 10:30 – 10:35** **DEBATE:** When Should A Shunt Be Used During CEA: From The VSGNE  
*Philip P. Goodney, MD, MS*  
*Jack L. Cronenwett, MD*
- 10:36 – 10:41** **DEBATE:** A Shunt Should Never Be Used During CEA: What Is Required To Use The No-Shunt Technique Safely  
*Russell H. Samson, MD, RVT*
- 10:42 – 10:47** Panel Discussion

**Moderators:** *Daniel G. Clair, MD*  
*Thomas S. Riles, MD*

- 10:48 – 10:53** Technical Tricks And Devices Make CAS Easier And Safer With The MoMa Flow Cessation Device And The 2 Wire PITON Catheter  
*Gioacchino Coppi, MD*



- 10:54 – 10:59** How To Risk Adjust Symptomatic And Asymptomatic Patients For CAS And CEA: A View Of A Vascular Specialist Who Does Both  
*Jon S. Matsumura, MD*
- 11:00 – 11:05** The Case Against Routine Carotid Patching Despite All The Level I Evidence And Hype: How And When To Avoid Patches  
*Glenn M. LaMuraglia, MD*
- 11:06 – 11:11** Endovascular Treatment And Bailout Of Complications From Carotid Surgery: A Simpler Better Solution Than Redo Surgery  
*Franco Grego, MD*  
*Giovanni P. Deriu, MD*
- 11:12 – 11:17** A New Better Monitoring Technique For CEA: Light General/Endotracheal Anesthesia Which Allows Patients To Demonstrate Motor Function: It Really Works And Decreases Patient And Surgeon Stress  
*Giancarlo G.C. Accarino, MD*
- 11:18 – 11:23** PTFE Interposition Grafts For CEA Gone Wrong: An Effective And Durable Bailout Procedure  
*Dieter Raitzel, MD, PhD*
- 11:24 – 11:29** **DEBATE:** AHA And European Cardiology Guidelines For CAS Have It Right: CAS Is An Alternative To CEA For Symptomatic Patients With Carotid Stenosis  
*Alberto Cremonesi, MD*
- 11:30 – 11:35** **DEBATE:** Nonsense: The SVS Guidelines Have It Right: CAS Is Not An Alternative To CEA For Most Symptomatic Patients With Carotid Stenosis  
*Michel S. Makaroun, MD*
- 11:36 – 11:42** Panel Discussion

SESSION 55 (Grand Ballroom East, 3rd Floor)

**NEW DEVELOPMENTS AND CONTROVERSIAL ISSUES RELATED TO CAS AND CEA (5-MINUTE TALKS)**

**Moderators:** *Peter A. Schneider, MD*  
*Frank J. Veith, MD*

- 11:42 – 11:47** Comparison Of 5 Different Guidelines For Treating Carotid Stenosis: How Can Such Differing Interpretations Be Drawn From The Same Data  
*Kosmas I. Paraskevas, MD*  
*Dimitri P. Mikhailidis, MD*  
*Frank J. Veith, MD*
- 11:48 – 11:53** CREST Cost Comparisons Between CAS And CEA: Possible Flaws In The CREST Cost Data That Make Its Conclusions Misleading  
*W. Charles Sternbergh III, MD*
- 11:54 – 11:59** Impact Of Cranial Nerve Defects (CRI) In CREST At One Year: These CRIs Were Minor And Not Equivalent To Strokes  
*Thomas G. Brott, MD*
- 12:00 – 12:05** **DEBATE:** CEA vs. CAS In Symptomatic Patients: The Heart Should Not Rule The Head When Deciding Treatment Strategies  
*A. Ross Naylor, MD*
- 12:06 – 12:11** **DEBATE:** CEA vs. CAS In Symptomatic Patients: The Heart Should Rule The Head When Deciding Treatment Strategies  
*Peter A. Schneider, MD*

- 12:12 – 12:17** Which Carotid Patients Needing Invasive Treatment Do I Currently Send For CEA  
*Klaus D. Mathias, MD*
- 12:18 – 12:23** Are CAS vs. CEA Trials Inherently Biased: Critical Appraisal Of Endpoints  
*Timothy M. Sullivan, MD*
- 12:24 – 12:29** **DEBATE:** Many Selected Asymptomatic Carotid Stenosis Patients Benefit From CEA: How Should They Be Picked  
*Bruce A. Perler, MD, MBA*
- 12:30 – 12:35** **DEBATE:** Not So: With Asymptomatic Carotid Stenosis Patients Any Benefit Of Invasive Treatment Is Outweighed By The Risks  
*Anne L. Abbott, MD, PhD*
- 12:36 – 12:41** Predictors Of Early Adverse Outcomes After CEA: Are They An Indication For CAS  
*Erik E. Debing, MD, PhD*
- 12:42 – 12:47** Current Strategies For Treating Carotid And Vertebral Dissections  
*L. Nelson Hopkins, MD*
- 12:48 – 12:53** Is A Postop MI With Only A Rise In Troponin A Bad Thing And Predictive Of Late Increased Mortality Risk  
*Andres Schanzer, MD*
- 12:54 – 12:59** Current Stent Design For CAS Procedures Is Inadequate: What Is On The Horizon To Remedy This  
*Sumaira Macdonald, MBChB, PhD*
- 1:00 – 1:20** Panel Discussion  
Lunch available in the Grand Ballroom.

SESSION 56 (Grand Ballroom East, 3rd Floor)

**NEW HORIZONS, NEW CONCEPTS AND LATE BREAKING DEVELOPMENTS (5-MINUTE TALKS)**

**Moderators:** *John E. Connolly, MD*  
*Enrico Ascher, MD*

- 1:20 – 1:25** Endovascular Conversion Of Open Surgical Failures And Complications: Tips And Tricks  
*Jos C. van den Berg, MD, PhD*
- 1:26 – 1:31** Technique Of Balloon Common Iliac Occlusion To Facilitate Antegrade Wire Passage Through Flush Iliac Occlusions: A Cheaper Safer Way  
*Peter H. Lin, MD*
- 1:32 – 1:37** Proportion Of CLI Patients Requiring Open Surgery When Endo Is The First And Favored Option: A Totally Endo First Strategy May Not Be Cost Effective  
*Firas F. Mussa, MD*
- 1:38 – 1:43** What Happens When SFA And Popliteal Stents Fail  
*Vincent L. Rowe, MD*  
*Steven G. Katz, MD*
- 1:44 – 1:49** CFA Stenting Can Be Done Safely And Effectively In An Outpatient Setting: Tips And Tricks  
*Sam S. Ahn, MD, MBA*
- 1:50 – 1:55** Results Of The DUET Trial: A RCT Comparing Ultrasound Enhanced vs. Standard Thrombolysis For Arterial Occlusions  
*Jean-Paul de Vries, MD, PhD*
- 1:56 – 2:01** Xenograft Pericardial Tubes And Radical Debridement Of Surrounding Tissues: A New Concept For Treating Prosthetic Graft Infections  
*Jürg Schmidli, MD*

- 2:02 – 2:07** Current Optimal Treatment Of Carotid And Vertebral Spontaneous And Traumatic Dissections  
*Irwin V. Mohan, MD*
- 2:08 – 2:13** Update On The SETA Balloon Expandable AAA Endograft: Mid-Term Clinical Experience  
*Hernan G. Bertoni, MD*
- 2:14 – 2:19** Panel Discussion
- 2:20 – 2:25** Open Aortic Repair After Failed EVAR: Tips And Tricks To Lower Morbidity And Mortality  
*R. Clement Darling III, MD*

**Moderators:** *James F. McKinsey, MD*  
*Lucien D. Castellani, MD*

- 2:26 – 2:31** Crossing Lower Extremity CTOs Using The VIANCE And ENTEER Devices: Final Results Of The PFAST Trial  
*Subhash Banerjee, MD*
- 2:32 – 2:37** Endovascular Techniques For Carotid And Cerebral Artery Thrombectomy For Acute Stroke: Experience In >130 Patients  
*Klaus D. Mathias, MD*
- 2:38 – 2:43** Interventions Performed Within 1 Week Of A Neurological Event: Outcomes Of CEA Are Better Than CAS (Data From The EVA-3S, The SPACE And The ICSS Trials)  
*Gustav Fraedrich, MD*  
*Barbara Rantner, MD*  
*Georg Goebel, MD and Leo H. Bonati, MD*  
*On behalf of the CSTC*
- 2:44 – 2:49** How Was CREST Data Presented In The FDA Application For Low Risk Carotid Stenting In A Way That Renders Them Misleading  
*Thomas G. Brott, MD*
- 2:50 – 2:55** Filters vs. Flow Reversal And Occlusion: Advantages And Disadvantages Of Both  
*Claudio J. Schonholz, MD*
- 2:56 – 3:01** SVS Registry Results Show CEA To Have Superior Outcomes To Those Of CAS In Symptomatic And Asymptomatic Patients Over 65  
*Brian G. Rubin, MD*
- 3:02 – 3:07** Can Medical Treatments Decrease AAA Growth Rates: Prospects For The Future  
*Russell H. Samson, MD, RVT*
- 3:08 – 3:14** Panel Discussion
- 3:15 – 3:20** Comparative Outcomes Of Bell Bottom Technique And Hypogastric Exclusion For Common Iliac Aneurysms Treated By EVAR: Bell Bottom Wins  
*Mark K. Eskandari, MD*

SESSION 57 (Grand Ballroom East, 3rd Floor)

**LATE BREAKING TOPICS OF PARTICULAR INTEREST (5-MINUTE TALKS)**

**Moderators:** *Kenneth Ouriel, MD, MBA*  
*Frank J. Veith, MD*

- 3:21 – 3:26** 4-Year Results With Sandwich Technique For Treating Common And Internal Iliac Aneurysms  
*Armando C. Lobato, MD, PhD*
- 3:27 – 3:32** Iliac Branched Devices Work Well In Worldwide Experience: The PRESERVE Trial  
*W. Anthony Lee, MD*

- 3:33 – 3:38** Infected AAAs: Endovascular Therapy Should Be The First Choice: How To Make It Work With 2-6 Years Follow-up  
*Boonprasit Kritpracha, MD*
- 3:39 – 3:44** Novel Technique For Treating Type II Endoleaks By Accessing AAA Sac And Nidus Via Distal Endograft Attachment Site  
*Giocchino Coppi, MD*
- 3:45 – 3:50** Flow Control To Prevent Embolic Complications During Endovascular Treatment Of Aortoiliac Occlusive Disease  
*Claudio J. Schonholz, MD*
- 3:51 – 3:56** Treatment Of Refractory Postthrombotic Syndrome By Cutting Balloon Angioplasty Of The Popliteal Vein  
*Thomas O. McNamara, MD*
- 3:57 – 4:02** Military Translational Research To Develop A New Fluoroscopy-Free Endovascular Balloon Occlusion System To Treat End-Stage Shock  
*Todd E. Rasmussen, MD*
- 4:03 – 4:08** Double Chimney Technique To Treat Arch Aneurysms: How To Make Them Work  
*Jan S. Brunkwall, MD, PhD*
- 4:09 – 4:14** Endovascular Graft Treatment Of Popliteal Aneurysms Is As Effective As Open Surgery In Terms Of Long-Term Patency  
*Michel S. Makaroun, MD*  
*Rabih A. Chaer, MD*
- 4:15 – 4:20** Panel Discussion
- 4:20 – 4:25** Raffle Drawing – You Must Be Present To Win
- 4:25** Symposium Ends

**Save The Date: November 20-24, 2013**  
**Hilton New York**



35<sup>th</sup>

International Symposium

CHARING

CROSS

CONTROVERSIES

CHALLENGES

CONSENSUS

6 - 9 APRIL 2013

REGISTER NOW

NATIONAL HALL, OLYMPIA  
LONDON, UK  
[WWW.CXSYMPOSIUM.COM](http://WWW.CXSYMPOSIUM.COM)

EDUCATION INNOVATION EVIDENCE  
VASCULAR & ENDOVASCULAR  
**CHALLENGES** UPDATE  
Incorporating  
ADVANCED IMAGING FOR INTERVENTIONS



Download the CX App  
[www.bibamedical.com/apps](http://www.bibamedical.com/apps)



To join the conversation search  
[@cxsymposium](https://twitter.com/cxsymposium) on twitter



Follow CX Symposium  
on facebook

email: [info@cxsymposium.com](mailto:info@cxsymposium.com)

symposium hotline: +44 (0) 20 7736 8788

fax: +44 (0) 20 7736 8283

# FACULTY

## A

**Anne L. Abbott, MD, PhD, FRACP, FRACP**

*Melbourne, Australia*

**Dorothy B. Abel, BSBME**

*Silver Spring, Maryland*

**Apolonia E. Abramowicz, MD**

*Bronx, New York*

**Kenneth D. Abreo, MD**

*Shreveport, Louisiana*

**Ali F. AbuRahma, MD**

*Charleston, West Virginia*

**Giancarlo G.C. Accarino, MD**

*Salerno, Italy*

**Charles W. Acher, MD**

*Madison, Wisconsin*

**Mark A. Adelman, MD**

*New York, New York*

**Sam S. Ahn, MD, MBA, FACS**

*Los Angeles, California and*

*Dallas, Texas*

**Afsaneh Alavi, MD, FRCPC**

*Toronto, Ontario, Canada*

**Yves Alimi, MD**

*Marseille, France*

**Jose I. Almeida, MD, RVT, FACS**

*Miami, Florida*

**Ali Amin, MD, RVT, FACS, FACC**

*Reading, Pennsylvania*

**Max Amor, MD**

*Essey-Lès-Nancy, France*

**Gary M. Ansel, MD**

*Columbus, Ohio*

**Frank R. Arko, MD**

*Charlotte, North Carolina*

**John E. Aruny, MD**

*New Haven, Connecticut*

**Enrico Ascher, MD**

*Brooklyn, New York*

**Afshin Assadian, MD**

*Vienna, Austria*

**Ali Azizzadeh, MD**

*Houston, Texas*

**Nobuyoshi Azuma, MD**

*Asahikawa, Hokkaido, Japan*

## B

**Martin R. Back, MD**

*Tampa, Florida*

**Jörn O. Balzer, MD, PhD**

*Mainz, Germany*

**Dennis F. Bandyk, MD**

*La Jolla, California*

**Subhash Banerjee, MD**

*Dallas, Texas*

**Richard A. Baum, MD, MPA, MBA**

*Boston, Massachusetts*

**Jonathan D. Beard, MD**

*Sheffield, United Kingdom*

**Jean-Pierre Becquemin, MD, FRCS**

*Creteil, France*

**Michael Belkin, MD**

*Boston, Massachusetts*

**Amira Benjelloun, MD**

*Rabat, Morocco*

**Jeffrey S. Berger, MD, MS, FAHA, FACC**

*New York, New York*

**Patrice F. Bergeron, MD**

*Marseille, France*

**Ramon Berguer, MD, PhD**

*Ann Arbor, Michigan*

**Todd Berland, MD**

*New York, New York*

**Hernan G. Bertoni, MD**

*Buenos Aires, Argentina*

**Giancarlo Biamino, MD, PhD**

*Mercogliano (AV), Italy*

**Giorgio M. Biasi, MD**

*Milan, Italy*

**Jean Bismuth, MD**

*Houston, Texas*

**James H. Black III, MD**

*Baltimore, Maryland*

**Jan D. Blankensteijn, MD**

*Amsterdam, The Netherlands*

**John Blebea, MD, MBA**

*Tulsa, Oklahoma*

**Dittmar Boeckler, MD**

*Heidelberg, Germany*

**Thomas Boeni, MD**

*Zurich, Switzerland*

**Amman Bolia, MD**

*Leicester, United Kingdom*

**Marc Bosiers, MD**

*Dendermonde, Belgium*

**Bruce J. Brener, MD**

*Livingston and Newark, New Jersey*

**Marc A. Brenner, DPM**

*Glendale and Manhasset, New York*

**Fleur E. Brolmann, MD**

*Amsterdam, The Netherlands*

**Allan L. Brook, MD**

*Bronx, New York*

**Thomas G. Brott, MD**

*Jacksonville, Florida*

**O. William Brown, MD, JD**

*Royal Oak, Michigan*

**Elchanan Bruckheimer, MBBS**

*Petah-Tikva, Israel*

**Jan S. Brunkwall, MD, PhD**

*Cologne, Germany*

**Clifford J. Buckley, MD**

*Temple, Texas*

**Nick J. Burfitt, BSc, MB, BChir,**

**MRCS, FRCR**

*London, United Kingdom*

**Ronald G. Bush, MD**

*Dayton, Ohio*

**Jacques Busquet, MD**

*Paris, France*

## C

**Keith D. Calligaro, MD**

*Philadelphia, Pennsylvania*

**Richard P. Cambria, MD**

*Boston, Massachusetts*

**Piergiorgio Cao, MD, FRCS**

*Rome, Italy*

**Lou Caplan, MD**

*Boston, Massachusetts*

**Laura Capoccia, MD, PhD**

*Rome, Italy*

**Wayne Caputo, DPM**

*Belleville, New Jersey and*

*New York, New York*

**Jeffrey P. Carpenter, MD**

*Camden, New Jersey*

**Lucien D. Castellani, MD**

*Tours, France*

# FACULTY

**Neal S. Cayne, MD**

*New York, New York*

**Rabih A. Chaer, MD**

*Pittsburgh, Pennsylvania*

**Elliot L. Chaikof, MD, PhD**

*Boston, Massachusetts*

**John B. Chang, MD**

*Roslyn, New York*

**Stephen W.K. Cheng, MBBS**

*Hong Kong, China*

**Zhuo Cheng, PhD**

*London, United Kingdom*

**Kenneth J. Cherry, MD**

*Charlottesville, Virginia*

**Nicholas J.W. Cheshire, MD**

*London, United Kingdom*

**Roberto Chiesa, MD**

*Milano, Italy*

**Marc Chimowitz, MD**

*Charleston, South Carolina*

**Larry Chinitz, MD**

*New York, New York*

**Kyung Cho, MD**

*Ann Arbor, Michigan*

**Timothy A.M. Chuter, DM**

*San Francisco, California*

**Daniel G. Clair, MD**

*Cleveland, Ohio*

**Giacomo Clerici, MD**

*Milan, Italy*

**Rachel Clough, MD, PhD**

*London, United Kingdom*

**Anthony J. Comerota, MD, FACS,  
FACC**

*Toledo, Ohio*

**John E. Connolly, MD**

*Orange, California*

**Mark Conrad, MD**

*Boston, Massachusetts*

**Michael S. Conte, MD**

*San Francisco, California*

**Gioacchino Coppi, MD**

*Modena, Italy*

**Joseph S. Coselli, MD**

*Houston, Texas*

**Robert Craig, DO**

*Bethesda, Maryland*

**Alberto Cremonesi, MD, FESC**

*Cotignola, Italy*

**Enrique Criado, MD, FACS**

*Ann Arbor, Michigan*

**Frank J. Criado, MD, FACS, FSVM**

*Baltimore, Maryland*

**Jack L. Cronenwett, MD**

*Lebanon, New Hampshire*

**David L. Cull, MD, FACS**

*Greenville, South Carolina*

**Jacob Cynamon, MD**

*New York, New York*

## D

**Michael D. Dake, MD**

*Stanford, California*

**Ronald L. Dalman, MD**

*Stanford, California*

**Michael C. Dalsing, MD**

*Indianapolis, Indiana*

**Alan Dardik, MD, PhD**

*New Haven, Connecticut*

**Herbert Dardik, MD**

*Englewood, New Jersey*

**R. Clement Darling III, MD**

*Albany, New York*

**Tony S. Das, MD**

*Dallas, Texas*

**Alun H. Davies, MA, DM, FRCS,**

**FHEA, FEBVS, FACPh**

*London, United Kingdom*

**Jean-Paul de Vries, MD, PhD**

*Nieuwegein, The Netherlands*

**David H. Deaton, MD**

*Washington, District of Columbia*

**Erik E. Debing, MD, PhD**

*Brussels, Belgium*

**Sebastian E. Debus, MD, PhD**

*Hamburg, Germany*

**Koen Deloose, MD**

*Dendermonde, Belgium*

**Ralph G. DePalma, MD**

*Washington, District of Columbia*

**Colin P. Derdeyn, MD**

*St. Louis, Missouri*

**Florian Dick, MD**

*Bern, Switzerland*

**Nicolas A. Diehm, MD**

*Bern, Switzerland*

**Edward B. Diethrich, MD**

*Phoenix, Arizona*

**Alan M. Dietzek, MD, RPVI, FACS**

*Danbury, Connecticut*

**Leonard Dimitri DaSilva, MD**

*Tallahassee, Florida*

**Aaron S. Dumont, MD**

*Philadelphia, Pennsylvania*

## E

**Hans-Henning Eckstein, MD, PhD**

*Münich, Germany*

**Michael E. Edmonds, MD**

*London, United Kingdom*

**John F. Eidt, MD**

*Little Rock, Arkansas*

**Bo G. Eklof, MD, PhD**

*Helsingborg, Sweden*

**Steve Elias, MD**

*New York, New York*

**Tod C. Engelhardt, MD**

*New Orleans, Louisiana*

**Mark K. Eskandari, MD**

*Chicago, Illinois*

**Anne M. Eskes, RN, MSc**

*Amsterdam, The Netherlands*

## F

**Ronald M. Fairman, MD**

*Philadelphia, Pennsylvania*

**Fabrizio Fanelli, MD**

*Rome, Italy*

**Mark A. Farber, MD**

*Chapel Hill, North Carolina*

**Peter L. Faries, MD, FACS**

*New York, New York*

**Ted Feldman, MD**

*Evanston, Illinois*

**Jose Fernandes e Fernandes, MD,**

**PhD, FRCS (Eng), FACS**

*Lisbon, Portugal*

**Hector Ferral, MD**

*Chicago, Illinois*

**Roberto Ferraresi, MD**

*Milano, Italy*

# FACULTY

**Marcelo Ferreira, MD**  
*Rio de Janeiro, Brazil*

**Mark F. Fillinger, MD**  
*Lebanon, New Hampshire*

**David Fiorella, MD**  
*Stony Brook, New York*

**Eugene S. Flamm, MD**  
*Bronx, New York*

**Thomas J. Fogarty, MD**  
*Portola Valley, California*

**Thomas L. Forbes, MD**  
*London, Ontario, Canada*

**Gustav Fraedrich, MD**  
*Innsbruck, Austria*

**Don Frei, MD**  
*Denver, Colorado*

**Wei Guo Fu, MD**  
*Shanghai, China*

**John H. Furtek, BS, RT(r)**  
*Charleston, South Carolina*

## G

**Paul J. Gagne, MD**  
*New York, New York*

**Vivian Gahtan, MD**  
*Syracuse, New York*

**Zsolt Garami, MD**  
*Houston, Texas*

**Lawrence A. Garcia, MD**  
*Boston, Massachusetts*

**Mark J. Garcia, MD**  
*Newark, Delaware*

**Antonios P. Gasparis, MD**  
*Stony Brook, New York*

**Gary A. Gelbfish, MD**  
*New York, New York*

**Jean Luc Gerard, MD**  
*Creteil, France*

**Gary Giangola, MD**  
*New Hyde Park, New York*

**Joseph S. Giglia, MD**  
*Cincinnati, Ohio*

**David L. Gillespie, MD**  
*Rochester, New York*

**Marc H. Glickman, MD**  
*Norfolk, Virginia*

**Peter Glociczki, MD**  
*Rochester, Minnesota*

**Jerry Goldstone, MD, FACS,  
FRCSEd**  
*Cleveland, Ohio*

**Philip P. Goodney, MD, MS**  
*Lebanon, New Hampshire*

**David Gordon, MD**  
*Bronx, New York*

**Peter C.J. Goverde, MD**  
*Antwerp, Belgium*

**Alan M. Graham, MD**  
*New Brunswick, New Jersey*

**Richard J. Gray, MD, FSIR**  
*Philadelphia, Pennsylvania*

**William A. Gray, MD**  
*New York, New York*

**Richard M. Green, MD**  
*New York, New York*

**Roy K. Greenberg, MD**  
*Cleveland, Ohio*

**Roger M. Greenhalgh, MD**  
*London, United Kingdom*

**Franco Grego, MD**  
*Padua, Italy*

**Marcelo S. Guimaraes, MD**  
*Charleston, South Carolina*

## H

**Neil J. Halin, DO**  
*Boston, Massachusetts*

**John (Jeb) W. Hallett, MD**  
*Charleston, South Carolina*

**Alison Halliday, MS, FRCS**  
*Oxford, United Kingdom*

**Peter L. Harris, MD, FRCS**  
*London, United Kingdom*

**Ziv J. Haskal, MD, FACR, FAHA,  
FSIR**

*Baltimore, Maryland*

**Stephan Haulon, MD**  
*Lille, France*

**Don Heck, MD**  
*Winston-Salem, North Carolina*

**Jennifer A. Heller, MD**  
*Baltimore, Maryland*

**Peter Henke, MD**  
*Ann Arbor, Michigan*

**Mitchell L. Henry, MD**  
*Columbus, Ohio*

**Robert J. Hinchliffe, MD**  
*London, United Kingdom*

**Anil P. Hingorani, MD**  
*Brooklyn, New York*

**Joshua A. Hirsch, MD**  
*Boston, Massachusetts*

**Kim J. Hodgson, MD**  
*Springfield, Illinois*

**Judy M. Holdstock, DMU, DCR**  
*Guildford and London,  
United Kingdom*

**Larry H. Hollier, MD**  
*New Orleans, Louisiana*

**L. Nelson Hopkins, MD**  
*Buffalo, New York*

**Brian R. Hopkinson, ChM, FRCS**  
*Nottingham, United Kingdom*

**Emmanuel M. Houdart, MD**  
*Paris, France*

**Jeffrey E. Hull, MD**  
*Richmond, Virginia*

## I

**Karl A. Illig, MD**  
*Tampa, Florida*

**Luigi Inglese, MD**  
*Milan, Italy*

**Krassi Ivancev, MD, PhD**  
*London, United Kingdom*

## J

**Benjamin M. Jackson, MD**  
*Philadelphia, Pennsylvania*

**Glenn Jacobowitz, MD**  
*New York, New York*

**Michael J. Jacobs, MD**  
*Maastricht, The Netherlands*

**Julius H. Jacobson II, MD**  
*New York, New York*

**Michael R. Jaff, DO**  
*Boston, Massachusetts*

**Edward C. Jauch, MD, MS**  
*Charleston, South Carolina*

**Zaiping Jing, MD**  
*Shanghai, China*



# FACULTY

**K. Wayne Johnston, MD, FRCS**

*Toronto, Ontario, Canada*

**William D. Jordan, Jr., MD**

*Birmingham, Alabama*

## K

**Lowell S. Kabnick, MD, FACS,  
FACPh**

*New York, New York*

**Chung-Dann Kan, PhD**

*Tainan, Taiwan*

**Paul H.L. Kao, MD**

*Taipei, Taiwan*

**Christof Karmonik, PhD**

*Houston, Texas*

**Vikram S. Kashyap, MD**

*Cleveland, Ohio*

**Karthikeshwar Kasirajan, MD**

*Blackhawk, California*

**Piotr M. Kasprzak, MD**

*Regensburg, Germany*

**Konstantinos Katsanos, MSc, MD,  
PhD, EBIR**

*Patras, Greece*

**Barry T. Katzen, MD**

*Miami, Florida*

**K. Craig Kent, MD**

*Madison, Wisconsin*

**Ali Khoynezhad, MD, PhD**

*Los Angeles, California*

**Young Wook Kim, MD**

*Seoul, Korea*

**Ted King, MD**

*Oakbrook Terrace, Illinois*

**Tilo Koelbel, MD, PhD**

*Hamburg, Germany*

**Raghu Kolluri, MD**

*Springfield, Illinois*

**Ralf R. Kolvenbach, MD**

*Duesseldorf, Germany*

**Dietmar H. Koschyk, MD**

*Hamburg, Germany*

**Zvonimir Krajcer, MD, FACC**

*Houston, Texas*

**Albrecht H. Krämer, MD**

*Santiago, Chile*

**Boonprasit Kritpracha, MD**

*Hat Yai, Songkhla, Thailand*

**Nils Kucher, MD**

*Bern, Switzerland*

**Toru Kuratani, MD, PhD**

*Osaka, Japan*

**Christopher J. Kwolek, MD**

*Boston, Massachusetts*

## L

**Daniel L. Labovitz, MD**

*New York, New York*

**Nicos Labropoulos, BSc (Med),  
PhD, DIC, RVT**

*Stony Brook, New York*

**Mario Lachat, MD**

*Zurich, Switzerland*

**John R. Laird, MD**

*Sacramento, California*

**Brian LaMendola, RN, MBA**

*Pittsburgh, Pennsylvania*

**Johannes Lammer, MD**

*Vienna, Austria*

**Patrick J. Lamparello, MD**

*New York, New York*

**Glenn M. LaMuraglia, MD**

*Boston, Massachusetts*

**Gregg S. Landis, MD**

*Queens, New York*

**Werner Lang, MD**

*Erlangen, Germany*

**David J. Langer, MD**

*Manhasset, New York*

**Kamphol Laohapensang, MD**

*Chiang Mai, Thailand*

**Thomas Larzon, MD**

*Örebro, Sweden*

**Peter F. Lawrence, MD**

*Los Angeles, California*

**Frank A. Lederle, MD**

*Minneapolis, Minnesota*

**Byung-Boong Lee, MD**

*Washington, District of Columbia*

**Jason T. Lee, MD**

*Stanford, California*

**Timmy Lee, MD, MSPH, FACP,  
FASN**

*Cincinnati, Ohio*

**W. Anthony Lee, MD**

*Boca Raton, Florida*

**Martin B. Leon, MD**

*New York, New York*

**Oleg Leontiev, MD**

*Philadelphia, Pennsylvania*

**Mauri J.A. Lepantalo, MD**

*Helsinki, Finland*

**Christos D. Liapis, MD**

*Athens, Greece*

**David S. Liebeskind, MD**

*Los Angeles, California*

**Timothy K. Liem, MD**

*Portland, Oregon*

**Francesco Liistro, MD**

*Arezzo, Italy*

**Peter H. Lin, MD**

*Houston, Texas*

**Jes S. Lindholt, MD**

*Odense, Denmark*

**Evan C. Lipsitz, MD**

*New York, New York*

**Armando C. Lobato, MD, PhD**

*São Paulo, Brazil*

**Ian Loftus, MD**

*London, United Kingdom*

**Joann Lohr, MD**

*Cincinnati, Ohio*

**Charmaine Lok, MD**

*Toronto, Canada*

**Joseph V. Lombardi, MD**

*Camden, New Jersey*

**Lars Lonn, MD, PhD**

*Copenhagen, Denmark*

**Robert A. Lookstein, MD, FSIR,  
FAHA**

*New York, New York*

**Qingsheng Lu, MD**

*Shanghai, China*

**Marzia Lugli, MD**

*Modena, Italy*

**Alan B. Lumsden, MD, FACS**

*Houston, Texas*

**Xiaoyun Luo, MD**

*Beijing, People's Republic of China*

**Fedor Lurie, MD, PhD**

*Honolulu, Hawaii*

# FACULTY

## M

**Sumaira Macdonald, MBChB (Comm), FRCP, FRCR, PhD**  
*Newcastle-upon-Tyne, United Kingdom*

**Edward G. Mackay, MD**  
*St. Petersburg, Florida*

**Michel S. Makaroun, MD**  
*Pittsburgh, Pennsylvania*

**Thomas S. Maldonado, MD**  
*New York, New York*

**Martin Malina, MD, PhD**  
*Malmö, Sweden*

**Nicola Mangialardi, MD**  
*Rome, Italy*

**Giancarlo Mansueto, MD**  
*Verona, Italy*

**Marco G. Manzi, MD**  
*Vicenza, Italy*

**Michael L. Marin, MD**  
*New York, New York*

**William A. Marston, MD**  
*Chapel Hill, North Carolina*

**Tara M. Mastracci, MD**  
*Cleveland, Ohio*

**Elna M. Masuda, MD**  
*Honolulu, Hawaii*

**Klaus D. Mathias, MD**  
*Dortmund, Germany*

**Jon S. Matsumura, MD**  
*Madison, Wisconsin*

**Jerry Matteo, MD**  
*Jacksonville, Florida*

**James May, MD, MS, FRACS, FACS**  
*Sydney, Australia*

**Dieter O. Mayer, MD**  
*Zurich, Switzerland*

**James F. McKinsey, MD**  
*New York, New York*

**Robert B. McLafferty, MD**  
*Springfield, Illinois*

**Thomas O. McNamara, MD**  
*Los Angeles, California*

**Manish Mehta, MD, MPH**  
*Albany, New York*

**George H. Meier III, MD**  
*Cincinnati, Ohio*

**Mark H. Meissner, MD**  
*Seattle, Washington*

**Germano Melissano, MD**  
*Milano, Italy*

**Philip M. Meyers, MD**  
*New York, New York*

**Claude Mialhe, MD**  
*Monaco*

**Joseph L. Mills, MD**  
*Tucson, Arizona*

**Ross Milner, MD**  
*Maywood, Illinois*

**Erich Minar, MD**  
*Vienna, Austria*

**David J. Minion, MD**  
*Lexington, Kentucky*

**J. Mocco, MD, MS**  
*Nashville, Tennessee*

**Irwin V. Mohan, MD, FRCS, FEBVS, FRACS**  
*Sydney, Australia*

**Louise Moist, MD, MSc**  
*London, Canada*

**Frans L. Moll, MD, PhD**  
*Utrecht, The Netherlands*

**Gregory L. Moneta, MD**  
*Portland, Oregon*

**Samuel R. Money, MD, MBA**  
*Scottsdale, Arizona*

**Wesley S. Moore, MD**  
*Los Angeles, California*

**Robert A. Morgan, MD**  
*London, United Kingdom*

**Nicholas J. Morrissey, MD**  
*New York, New York*

**Albeir Y. Mousa, MD**  
*Charleston, West Virginia*

**Patrick E. Muck, MD, FACS**  
*Cincinnati, Ohio*

**Bart E. Muhs, MD, PhD**  
*New Haven, Connecticut*

**Firas F. Mussa, MD**  
*New York, New York*

**Jihad A. Mustapha, MD**  
*Wyoming, Michigan*

**Pramook Mutirangura, FRCS (Edinburgh)**  
*Bangkok, Thailand*

## N

**Gregory J. Nadolski, MD**  
*Philadelphia, Pennsylvania*

**A. Ross Naylor, MD, FRCS**  
*Leicester, United Kingdom*

**Peter K. Nelson, MD**  
*New York, New York*

**Richard F. Neville, MD**  
*Washington, District of Columbia*

**Andrew N. Nicolaidis, MS, FRCS**  
*Nicosia, Cyprus*

**Christoph A. Nienaber, MD, PhD**  
*Rostock, Germany*

**Furuzan Numan, MD**  
*Istanbul, Turkey*

## O

**Thomas F. O'Donnell, Jr., MD**  
*Boston, Massachusetts*

**Gustavo S. Oderich, MD, FACS**  
*Rochester, Minnesota*

**Oscar L. Ojeda, MD**  
*Buenos Aires, Argentina*

**Karl H. Orend, MD**  
*Ulm, Germany*

**Kenneth Ouriel, MD, MBA, FACS, FACC**  
*New York, New York*

## P

**Peter J. Pappas, MD**  
*Brooklyn, New York*

**Kosmas I. Paraskevas, MD**  
*Athens, Greece*

**Juan C. Parodi, MD**  
*Buenos Aires, Argentina*

**Aman B. Patel, MD**  
*New York, New York*

**William D. Paulson, MD**  
*Augusta, Georgia*

**Dusan Pavcnik, MD, PhD**  
*Portland, Oregon*

**Eric K. Peden, MD**  
*Houston, Texas*

**Patrick Peeters, MD**  
*Bonheiden, Belgium*

# FACULTY

**Bruce A. Perler, MD, MBA**  
*Baltimore, Maryland*

**Ivo Petrov, MD, PhD**  
*Sofia, Bulgaria*

**Timothy A. Pflederer, MD**  
*Peoria, Illinois*

**Paul Pittaluga, MD**  
*Nice, France*

**Don Poldermans, MD**  
*Spijkensisse, The Netherlands*

**Janet T. Powell, MD, PhD**  
*London, United Kingdom*

**Richard J. Powell, MD**  
*Lebanon, New Hampshire*

## R

**Joseph D. Raffetto, MD**  
*West Roxbury, Massachusetts*

**Dieter Raithel, MD, PhD**  
*Nuremberg, Germany*

**Dheeraj Rajan, MD, FRCPC**  
*Toronto, Canada*

**Seshadri Raju, MD**  
*Flowood, Mississippi*

**Zoran Rancic, MD, PhD**  
*Zurich, Switzerland*

**Hisham Rashid, MSc, FRCS,  
FRCS(Gen)**  
*London, United Kingdom*

**Peter A. Rasmussen, MD**  
*Cleveland, Ohio*

**Todd E. Rasmussen, MD, FACS**  
*Fort Sam Houston (San Antonio),  
Texas*

**Allan W. Reid, FRCR**  
*Glasgow, United Kingdom*

**Donald B. Reid, MD**  
*Wishaw, Scotland*

**Michel M.P. Reijnen, MD, PhD**  
*Arnhem, The Netherlands*

**Timothy A. Resch, MD, PhD**  
*Malmö, Sweden*

**Vicente Riambau, MD, PhD**  
*Barcelona, Spain*

**Jean-Baptiste Ricco, MD, PhD**  
*Poitiers, France*

**Norman M. Rich, MD, FACS,  
DMCC**  
*Bethesda, Maryland*

**Götz M. Richter, MD, PhD**  
*Stuttgart, Germany*

**John J. Ricotta, MD**  
*Washington, District of Columbia*

**Joseph J. Ricotta II, MD, MS**  
*Atlanta, Georgia*

**Thomas S. Riles, MD**  
*New York, New York*

**Krishna J. Rocha-Singh, MD**  
*Springfield, Illinois*

**Caron B. Rockman, MD**  
*New York, New York*

**Sean P. Roddy, MD**  
*Albany, New York*

**Julio A. Rodriguez-Lopez, MD**  
*Phoenix, Arizona*

**Marco Romanelli, MD, PhD**  
*Pisa, Italy*

**Sonia Ronchey, MD**  
*Rome, Italy*

**Eric E. Roselli, MD**  
*Cleveland, Ohio*

**Kenneth Rosenfield, MD**  
*Boston, Massachusetts*

**David Rosenthal, MD**  
*Atlanta, Georgia*

**Plinio Rossi, MD**  
*Rome, Italy*

**Vincent L. Rowe, MD**  
*Los Angeles, California*

**Howard A. Rowley, MD**  
*Madison, Wisconsin*

**Prabir Roy-Chaudhury, MD, PhD**  
*Cincinnati, Ohio*

**Brian G. Rubin, MD**  
*St. Louis, Missouri*

**Steven H. Rudolph, MD**  
*Brooklyn, New York*

**Maria Antonella Ruffino, MD**  
*Torino, Italy*

## S

**Theodore F. Saad, MD**  
*Newark, Delaware*

**Nirvana Sadaghianloo, MD**  
*Nice, France*

**Mikel Sadek, MD**  
*New York, New York*

**Hazim J. Safi, MD**  
*Houston, Texas*

**Clifford M. Sales, MD, MBA**  
*Summit, New Jersey*

**Russell H. Samson, MD, RVT, FACS**  
*Sarasota, Florida*

**Luis A. Sanchez, MD**  
*St. Louis, Missouri*

**Wilhelm Sandmann, MD**  
*Kamp-Lintfort, Germany*

**Timur P. Sarac, MD**  
*Cleveland, Ohio*

**Richard R. Saxon, MD**  
*San Diego, California*

**Pamela W. Schaefer, MD**  
*Boston, Massachusetts*

**Andres Schanzer, MD**  
*Worcester, Massachusetts*

**Dierk Scheinert, MD**  
*Leipzig, Germany*

**Larry A. Scher, MD**  
*Bronx, New York*

**Marc L. Schermerhorn, MD**  
*Boston, Massachusetts*

**A. Frederick Schild, MD**  
*Miami, Florida*

**Jürg Schmidli, MD**  
*Bern, Switzerland*

**Andrej Schmidt, MD**  
*Leipzig, Germany*

**Darren B. Schneider, MD**  
*New York, New York*

**Peter A. Schneider, MD**  
*Honolulu, Hawaii*

**Claudio J. Schonholz, MD**  
*Charleston, South Carolina*

**Geert Willem H. Schurink, MD, PhD**  
*Maastricht, The Netherlands*

**Lewis B. Schwartz, MD**  
*Abbott Park, Illinois*

**Francesco Serino, MD**  
*Rome, Italy*

**Carlo Setacci, MD**  
*Siena, Italy*

**Francesco Setacci, MD**  
*Siena, Italy*

# FACULTY

**Stephen Settle, MD**

*Austin, Texas*

**Dhiraj M. Shah, MD**

*Albany, New York*

**Joseph N. Shams, MD**

*New York, New York*

**Nick Shaper, FRCS**

*Bradford, England*

**Palma M. Shaw, MD**

*Boston, Massachusetts*

**Cynthia K. Shortell, MD**

*Durham, North Carolina*

**Chang Shu, MD**

*Chang Sha, Hunan Province, China*

**R. Gary Sibbald, MD**

*Toronto, Canada*

**Anton N. Sidawy, MD, MPH**

*Washington, District of Columbia*

**Henrik Sillesen, MD, DMSc**

*Copenhagen, Denmark*

**Michael B. Silva, Jr., MD**

*Galveston, Texas*

**Tony P. Smith, MD**

*Durham, North Carolina*

**Björn Sonesson, MD, PhD**

*Malmö, Sweden*

**Thomas A. Sos, MD**

*New York, New York*

**Francesco Spinelli, MD**

*Messina, Italy*

**James C. Stanley, MD**

*Ann Arbor, Michigan*

**Benjamin W. Starnes, MD**

*Seattle, Washington*

**Barry Stein, MD, FSIR, FACR**

*Hartford, Connecticut*

**Hermann Steinkamp, MD**

*Berlin, Germany*

**W. Charles Sternbergh III, MD**

*New Orleans, Louisiana*

**Scott L. Stevens, MD**

*Knoxville, Tennessee*

**Gregg W. Stone, MD**

*New York, New York*

**Michael C. Stoner, MD**

*Greenville, North Carolina*

**Timothy M. Sullivan, MD**

*Minneapolis, Minnesota*

**Sherif Sultan, MD, FRCS,**

**EBQS-VASC**

*Galway, Ireland*

**Bauer E. Sumpio, MD, PhD**

*New Haven, Connecticut*

**Jesper Swedenborg, MD, PhD**

*Stockholm, Sweden*

**Gabriel Szendro, MD**

*Beer Sheva, Israel*

## T

**Victor F. Tapon, MD**

*Durham, North Carolina*

**Apostolos K. Tassiopoulos, MD**

*Stony Brook, New York*

**Peter R. Taylor, MA, MChir, FRCS,**

**ARCM**

*London, United Kingdom*

**Gunnar Tepe, MD**

*Rosenheim, Germany*

**Lucie G. Thibault, Pharm.D**

*Tustin, California*

**Robert W. Thompson, MD**

*St. Louis, Missouri*

**Carlos H. Timaran, MD**

*Dallas, Texas*

**Giovanni Torsello, MD**

*Münster, Germany*

**Magdiel Trinidad-Vazquez, MD**

*Guadalajara Jalisco, Mexico*

**Ramesh K. Tripathi, MD, FRCS,**

**FRACS**

*Bangalore, India*

**Aquilla S. Turk, DO**

*Charleston, South Carolina*

## V

**Claude D. Vaislic, MD**

*Le Chesnay, France*

**S. Rao Vallabhaneni, MD, FRCS**

*Liverpool, United Kingdom*

**Jos C. van den Berg, MD, PhD**

*Lugano, Switzerland*

**Renate R. van den Bos, MD, PhD**

*Rotterdam, The Netherlands*

**Isabelle Van Herzeele, MD, PhD**

*Ghent, Belgium*

**Marc R.H.M. van Sambeek, MD,**

**PhD**

*Eindhoven, The Netherlands*

**Michael A. Vasquez, MD, RVT**

*Buffalo, New York*

**Joseph A. Vassalotti, MD**

*New York, New York*

**Frank J. Veith, MD**

*Cleveland, Ohio and*

*New York, New York*

**Hence J.M. Verhagen, MD, PhD**

*Rotterdam, The Netherlands*

**Eric L.G. Verhoeven, MD, PhD**

*Nürnberg, Germany*

**Hester Vermeulen, PhD**

*Amsterdam, The Netherlands*

**Thomas M. Vesely, MD**

*St. Louis, Missouri*

**J. Leonel Villavicencio, MD**

*Bethesda, Maryland, and*

*Washington, District of Columbia*

**Arno von Ristow, MD**

*Rio de Janeiro, Brazil*

## W

**Thomas W. Wakefield, MD**

*Ann Arbor, Michigan*

**Ron Waksman, MD**

*Washington, District of Columbia*

**Craig M. Walker, MD**

*Houma, Louisiana*

**Jeffrey Y. Wang, MD**

*Rockville, Maryland*

**Zhong Gao Wang, MD**

*Beijing, China*

**Anders Wanhainen, MD, PhD**

*Uppsala, Sweden*

**Haimanot (Monnie) Wasse, MD,**

**MPH, FASN**

*Atlanta, Georgia*

**Fred A. Weaver, MD**

*Los Angeles, California*

**Lawrence Wechsler, MD**

*Pittsburgh, Pennsylvania*

**Ido Weinberg, MD, MSc**

*Boston, Massachusetts*

# FACULTY

**Michael I. Weintraub, MD**

*Valhalla, New York and  
New York, New York*

**Rodney A. White, MD**

*Los Angeles, California*

**Mark S. Whiteley, MS, FRCS**

*Guildford, United Kingdom*

**Mark H. Wholey, MD**

*Pittsburgh, Pennsylvania*

**Chumpon Wilasrusmee, MD, MSc**

*Bangkok, Thailand*

**Willem Wisselink, MD**

*Amsterdam, The Netherlands*

**Cees H.A. Wittens, MD, PhD**

*Maastricht, The Netherlands*

**Edward Y. Woo, MD**

*Philadelphia, Pennsylvania*

**Jack Work, MD**

*Atlanta, Georgia*

## Y

**Yoshihiko Yokoi, MD**

*Tokyo, Japan*

**Albert J. Yoo, MD**

*Boston, Massachusetts*

## Z

**Osama O. Zaidat, MD**

*Milwaukee, Wisconsin*

**Paolo Zamboni, MD**

*Ferrara, Italy*

**Christopher K. Zarins, MD**

*Stanford, California*

**Clark J. Zeebregts, MD, PhD**

*Groningen, The Netherlands*

**Max Zegelman, MD, PhD**

*Frankfurt, Germany*

**Thomas Zeller, MD**

*Bad Krozingen, Germany*

**Wei Zhou, MD**

*Stanford, California*

**Burkhardt Zipfel, MD**

*Berlin, Germany*

**Gregg H. Zoarski, MD**

*Newark, Delaware*

**Robert M. Zwolak, MD, PhD**

*Lebanon, New Hampshire*

## VEITHSYMPOSIUM ON DEMAND

[www.veithondemand.com](http://www.veithondemand.com)

**VEITH** SYMPOSIUM™

Connecting The **Vascular** Community

VIEW THE  
ENTIRE 2012  
VEITHSYMPOSIUM  
ONLINE

Purchase all the Talks, Slides, and Videos - fully  
synchronized - and all the Panels.

This Library or Components thereof can be used as an  
Educational Resource or Teaching Tool.

For more information on how to obtain the  
VEITHsymposium Online Library, please call  
800-987-9314, ext. 300.

This activity has been approved for *AMA PRA Category 1 Credits*™.

# REGISTRATION



Wednesday, November 14 – Sunday, November 18, 2012

HILTON NEW YORK  
1335 Avenue Of The Americas  
New York, NY 10019

## Meeting Registration

(See Registration Form on reverse side)

Full Registration	Tuition
<input type="checkbox"/> Practicing Physicians .....	\$1395
<input type="checkbox"/> Practicing Physicians Combination Rate VEITHsymposium and AVIDsymposium .....	\$1895
<input type="checkbox"/> US and Canadian Vascular Surgery Fellows In Training* .....	Complimentary
<input type="checkbox"/> Non-U.S. Fellows <input type="checkbox"/> Nurse Practitioners	
<input type="checkbox"/> Physician Assistants .....	\$695
<input type="checkbox"/> Residents <input type="checkbox"/> Nurses <input type="checkbox"/> Technologists.....	\$650
<input type="checkbox"/> Allied Health Care Professionals .....	\$950

\*Tuition is provided through an Educational Grant by W.L. Gore & Associates, Inc.  
Letter of verification from Chief of Service must be faxed to 888-418-7043.

### Component Meetings (Tuition includes access to any Wednesday Only meeting.)

- Wednesday Only - Endovenous Management  
of Varicose Veins ..... \$345
- Wednesday Only - Hemodialysis Access..... \$345
- Wednesday Only - WOUNDS..... \$345
- Wednesday Only - WOUNDS (nurses only)..... \$145
- Wednesday Only - Emerging Management Options for  
Pulmonary Embolism ..... Included in all tuition categories
- Wednesday Only - Management of Proximal Venous  
Obstruction..... Included in all tuition categories

**Refund:** There is a \$95 cancellation fee if canceled by October 19, 2012. No refunds will be made thereafter.

**Online:** <http://www.VEITHsymposium.org>

**Phone:** 800-987-9314, Ext. 200 or 718-549-3140 with your payment information.

**Fax:** the reverse form with your credit card payment to 888-418-7043

**Mail:** this form with your payment to:  
The Cleveland Clinic Educational Foundation  
Attn: VEITH 020892  
P.O. Box 931653  
Cleveland, OH 44193-1082

### Additional Information

VEITHsymposium  
4455 Douglas Avenue, Suite 11E  
Riverdale, New York 10471

**Phone:** 800-987-9314 or 718-549-3140

**E-mail:** [registrar@veithsymposium.org](mailto:registrar@veithsymposium.org) or  
[admin@veithsymposium.org](mailto:admin@veithsymposium.org)

# REGISTRATION



## Full Registration

## Tuition

- Practicing Physicians ..... \$1395
- Practicing Physicians Combination Rate  
VEITHsymposium and AVIDsymposium ..... \$1895
- US and Canadian Vascular Surgery Fellows  
In Training\* ..... Complimentary
- Non-U.S. Fellows     Nurse Practitioners
- Physician Assistants ..... \$695
- Residents     Nurses     Technologists..... \$650
- Allied Health Care Professionals ..... \$950

\*Tuition is provided through an Educational Grant by W.L. Gore & Associates, Inc.  
Letter of verification from Chief of Service must be faxed to 888-418-7043.

## Component Meetings (Tuition includes access to any Wednesday Only meeting.)

- Wednesday Only - Endovenous Management  
of Varicose Veins ..... \$345
- Wednesday Only - Hemodialysis Access..... \$345
- Wednesday Only - WOUNDS..... \$345
- Wednesday Only - WOUNDS (nurses only)..... \$145
- Wednesday Only - Emerging Management Options for  
Pulmonary Embolism ..... Included in all tuition categories
- Wednesday Only - Management of Proximal Venous  
Obstruction..... Included in all tuition categories

First Name: \_\_\_\_\_

Last Name (Surname) \_\_\_\_\_

Degree: \_\_\_\_\_

Specialty: \_\_\_\_\_

Physician     Non-Physician    Cleveland Clinic Employee?     Yes     No

Affiliation: \_\_\_\_\_

Address Type:     Home     Other

Address: \_\_\_\_\_

City: \_\_\_\_\_ State/Province \_\_\_\_\_

Zip Code: \_\_\_\_\_ Country \_\_\_\_\_

E-mail: \_\_\_\_\_

*(A valid registrant's e-mail address is required for confirmation and CME certificate.)*

Phone: \_\_\_\_\_ Fax \_\_\_\_\_

## Payment Method

**Check:** Please make checks payable to the Cleveland Clinic Educational Foundation and mail to:  
The Cleveland Clinic Educational Foundation  
Attn: VEITH 020892  
P.O. Box 931653  
Cleveland, OH 44193-1082

Name on Card: \_\_\_\_\_

Credit Card Number: \_\_\_\_\_

Verification Code: \_\_\_\_\_ Expiration Date \_\_\_\_\_  
(3-4 Digit Code on Credit Card)

Zip Code: \_\_\_\_\_ Country \_\_\_\_\_

Signature: \_\_\_\_\_



**VEITH** SYMPOSIUM™  
Connecting The **Vascular** Community

**SAVE THE DATE**

Wednesday – Sunday, November 20–24, 2013

**V**ascular  
**E**ndovascular  
**I**ssues  
**T**echniques  
**H**orizons

Symposium Chairman  
**Frank J. Veith, MD**

Symposium Co-Chairmen  
**Enrico Ascher, MD**  
**Kenneth Ouriel, MD, MBA**  
**Daniel G. Clair, MD**

Sponsored by

 **Cleveland Clinic**



**Hilton**

[www.VEITHsymposium.org](http://www.VEITHsymposium.org)





**THE CLEVELAND CLINIC EDUCATIONAL FOUNDATION**

PO BOX 931653

CLEVELAND, OH 44193-1082



**Hilton**  
Hilton New York

Wednesday - Sunday,  
November 14 – 18, 2012

Translation to Spanish, Portuguese,  
Russian and Mandarin Chinese will  
be available Thursday to Sunday.

**WEDNESDAY, NOVEMBER 14, 2012**

- Hemodialysis Access • Emerging Management Options for Pulmonary Embolism
- Management of Proximal Venous Obstruction
- Endovenous Management of Varicose Veins • WOUNDS
- Multidisciplinary Acute Stroke Management

**AGAIN THIS YEAR**

6th Annual Poster Session, Wednesday – Friday, November 14 – 16, 2012



Connecting The **Vascular** Community  
[www.veithsymposium.org](http://www.veithsymposium.org)



Non-profit Org  
US Postage

**PAID**

White Plains, NY  
Permit No. 7033